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Summary 
PIM1 (Proviral Integration site for Murine leukemia virus site 1) is a 
constitutively active serine/threonine protein kinase that is induced 
physiologically by the JAK-STAT and NF-κB pathways. PIM1 mediates 
survival signalling in cells, and contributes to the development of resistance 
towards chemotherapy and radiotherapy. It is also overexpressed in a wide 
range of haematological malignancies, and in solid tumours of the prostate, 
colon, breast and lung among others, which makes it an attractive drug 
target. However, the mechanisms regulating PIM1 kinase activity and protein 
levels have remained largely unexplored. 
Based on PIM1 protein sequence analysis, I identified the presence of 
a conserved motif (IK169DE171) in the active site of PIM1 that is recognised by 
the Small ubiquitin-like modifier (SUMO). By site-directed mutagenesis of 
individual lysine residues in PIM1, I showed that PIM1 is covalently modified 
by SUMO at the consensus K169 site, and also at a second promiscuous 
site. However, the K169R mutant only abolished SUMOylation at one site, 
but the E171A mutant abolished SUMOylation at both sites. I also showed 
that members of the Protein inactivator of activated STATs (PIAS) family 
could act as E3 SUMO ligases for PIM1. SUMOylated PIM1 showed higher 
protein kinase activity in vitro when Histone H3.3 was used a substrate, 
indicating that SUMOylation might enhance PIM1 kinase activity. 
Interestingly, both K169R and E171A displayed substrate specificity in vitro 
and when expressed in cells, suggesting that SUMOylation might govern 
PIM1 substrate specificity under certain contexts.  
Cycloheximide chase analysis revealed that both K169R and K67M 
(catalytically inactive) mutants of PIM1 were less stable. This can be 
attributed to the observation that the K169R mutant is incapable of 
undergoing autophosphorylation similar to the K67M mutant of PIM1. This 
indicates that both K169 and K67 residues are critical for the intrinsic kinase 
activity, and may not represent SUMO-specific effects. On the other hand, 
autophosphorylation of E171A was unaffected, which makes it a better 
mutant to study effect of SUMOylation on PIM1. The E171A mutant was 
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more stable than wild-type PIM1 in the cycloheximide assay suggesting that 
SUMOylation destabilises PIM1. In support of this result, the E171A mutant 
also showed reduced levels of ubiquitination. Furthermore, expression of 
RNF4 (a polySUMO targeted E3 ubiquitin ligase) led to degradation of 
SUMOylated PIM1, and siRNA knockdown of RNF4 increased endogenous 
levels of PIM1 in cells. Taken together, the data presented here identify a 
novel mechanism of PIM1 degradation that is, in part, dependent on 
SUMOylation. SUMOylation of PIM1 also increased PIM1 activity in vitro and 
appears to dictate substrate specificity. Hence, further analysis of this 
pathway might open avenues for therapeutic intervention.  
 
 
 
 
 
 
 
Chapter 1 
 
Introduction 
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1.1 The PIM family of oncogenes 
Tumorigenesis is a complex multi-step process, which involves activation 
of oncogenes, and suppression or inactivation of protective tumour suppressor 
genes, thereby leading to initiation of transformation programme in a cell. The 
PIM family of proto-oncogenes comprises three members named PIM1, PIM2 
and PIM3 encoding serine/threonine protein kinases of approximately 34 kDa of 
the same name with a broad range of cellular targets. The founding member of 
this family i.e. Pim1 was first identified in Moloney Murine leukemia virus (MuLV) 
induced T-cell lymphomas as a small chromosomal region that frequently 
displayed proviral insertions associated with transcriptional activation of this 
gene, hence the name Proviral Integration site for MuLV (Theo Cuypers et al., 
1984; Selten et al., 1985). Subsequently Pim2 was identified as a common 
proviral integration site in transplanted murine T-cell lymphoma (Breuer et al., 
1989). In contrast, Pim3 was originally identified as Kinase Induced by 
Depolarisation (Kid1) in rat brain cells (Feldman et al., 1998), and later 
established as a Pim1 and 2 related kinase overexpressed in lymphomas.  
The generation of Pim transgenic and knockout mouse models provided 
interesting information about their oncogenic functions. Pim1 transgenic mice 
carrying an upstream immunoglobulin enhancer element (Eµ) and downstream 
proviral long terminal repeat (LTR) causing increased Pim1 protein expression 
showed spontaneous development of T-cell lymphomas at low frequency and 
with long latency showing that Pim1 is a weak oncogene by itself (van Lohuizen 
et al., 1989). Interestingly, it was observed that a large number of MuLV-induced 
lymphomas with proviral integrations near Myc also showed integration in Pim1 
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locus leading to a speculation that Pim1 might cooperate with Myc in the 
transformation process (Theo Cuypers et al., 1984). Transgenic mice 
coexpressing both Eµ-Pim1 and Eµ-Myc succumbed to lymphomas prenatally 
confirming their strong oncogenic partnership (Verbeek et al., 1991). As second 
evidence, transgenic mice carrying Eµ-Myc but deficient in either Pim1 or all 
three Pim showed delayed development of lymphomas suggesting that levels of 
Pim expression might be rate-limiting for Myc-driven tumours. Furthermore, the 
dependency of Myc on Pim expression was demonstrated in transgenic Eµ-Myc 
mice deficient in Pim1 where almost 90% tumours showed proviral integrations 
near Pim2 locus, and in Eµ-Myc Pim1:Pim2 double knockout mice where Pim3 
was activated by insertional mutagenesis (van der Lugt et al., 1995; Mikkers et 
al., 2002). This also indicates that members of Pim family have overlapping 
functions and can compensate for each other in tumorigenesis.  
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1.2 Structural features of PIM kinases 
The human PIM genes are located at different chromosomal locations 
(PIM1 on chr.6p21.2, PIM2 on chr.Xp11.23 and PIM3 on chr.22q13.33) each 
containing six exons and five introns with large 5’ and 3’ untranslated regions 
(UTRs). PIM mRNAs are particularly unique in that the 3’UTR contains five 
copies of the RNA destabilising AUUUA motif, leading to a short half-time in the 
cells (Saris et al., 1991; Wingett et al., 1991). A stem-loop pair sequence called 
eIF4E sensitivity element is also present in the 3’ UTR for specific binding of 
eukaryotic translation initiation factor (eIF4E), which allows nuclear export of 
Pim transcripts for enhanced translation. The 5’ UTR, on the other hand, 
contains long GC-rich regions making PIM mRNAs weak transcripts requiring 
cap-dependent translation (Hoover et al., 1997; Culjkovic et al., 2006). 
PIM1 in both mice and humans encodes two protein isoforms of 34 kDa 
and 44 kDa arising from two alternate translation initiation sites (Saris, Domen 
and Berns, 1991). Interestingly, only the 34 kDa PIM1 (or PIM1S) is widely 
reported and studied. Figure 1.1 shows a general representation of PIM1 gene 
products. The human 44 kDa PIM1 (or PIM1L) was identified in prostate cancer 
cells where it was shown to contribute towards resistance to drugs and 
chemotherapy (Xie et al., 2006, 2008). Both isoforms show comparable kinase 
activity, but exhibit differences in localisation and protein stability. The 44 kDa 
isoform is relatively more stable and is specifically localised to the cell 
membrane, whereas the 34 kDa isoform is nucleo-cytoplasmic. PIM2 encodes 
three protein isoforms while no isoforms are reported for PIM3. Pim kinases are 
highly evolutionarily conserved showing >90% sequence similarity across 
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different species. For example humans, cows, dogs, cats, rats, mice, zebrafish 
and C. elegans all contain the 313 amino acid long PIM1. Multiple sequence 
alignment of human Pim kinases suggest that PIM1 is 67.2% and 79.9% similar 
to PIM2 and PIM3 respectively, whereas Pim2 and Pim3 are 64.4% similar to 
each other at the protein level (Figure 1.2).  
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Figure 1.1 PIM1 gene, transcript and protein 
The PIM1 gene contains 6 exons (blue boxes) and 5 introns with large 5’ and 3’ untranslated 
regions (UTRs). The mRNA transcript contains a GC-rich 5’ UTR (lariat) and five copies of 
destabilising AUUUA motif (orange circles) at 3’ UTR. ATG is the common or predominant 
translation site, giving rise to a 34 kDa PIM1 protein. An alternative translation initiation site CTG 
gives rise to a 44 kDa PIM1 isoform with 90 extra amino acids, which is localised to the cell 
membrane. 
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PIM1 MLLSKINSLAHLRAAPCNDLH-ATKLAP-GKEKEPLESQYQVGPLLGSGGFGSVYSGIRV 
PIM2 MLTK------PLQGPPAPPG--TPTPPPGGKDREAFEAEYRLGPLLGKGGFGTVFAGHRL 
PIM3 MLLSKFGSLAHLCGPGGVDHLPVKILQPAKADKESFEKAYQVGAVLGSGGFGTVYAGSRI 
 
PIM1 SDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVS--SGFSGVIRLLDWFERPDSF 
      PIM2 TDRLQVAIKVIPRNRVLGWSPLSDSVTCPLEVALLWKVGAGGGHPGVIRLLDWFETQEGF 
PIM3 ADGLPVAVKHVVKERVTEWGSLG-GATVPLEVVLLRKVGAAGGARGVIRLLDWFERPDGF 
 
PIM1 VLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILID 
PIM2 MLVLERPLPAQDLFDYITEKGPLGEGPSRCFFGQVVAAIQHCHSRGVVHRDIKDENILID 
PIM3 LLVLERPEPAQDLFDFITERGALDEPLARRFFAQVLAAVRHCHSCGVVHRDIKDENLLVD 
 
PIM1 LNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMV 
PIM2 LRRGCAKLIDFGSGALLHDEPYTDFDGTRVYSPPEWISRHQYHALPATVWSLGILLYDMV 
PIM3 LRSGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSATVWSLGVLLYDMV 
 
PIM1 CGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLP 
PIM2 CGDIPFERDQEILEAELHFPAHVSPDCCALIRRCLAPKPSSRPSLEEILLDPWMQTPAED 
PIM3 CGDIPFEQDEEILRGRLLFRRRVSPECQQLIRWCLSLRPSERPSLDQIAAHPWMLGADGG 
 
PIM1 -QETAEIHLHSLSPGPSK--------- 313 
Pim2 VPLNPS----KGGPAPLAWSLLP---- 311 
Pim3 VPESCDLRLCTLDPDDVASTTSSSESL 326 
 
 
Figure 1.2 Protein sequence alignment of PIM kinase family members 
Multiple sequence alignment of PIM kinases was performed using Clustal Omega software. The 
sequences for alignment were retrieved from Ensembl genome browser. The accession 
numbers for PIM1, PIM2 and PIM3 proteins are ENST00000373509, ENST00000376509 and 
ENST00000360612 respectively. Identical residues are shown in red and the hinge region is 
highlighted in grey. 
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Several groups have crystallised PIM1 in complex with nucleotide 
analogs or small molecule ATP-competitive inhibitors revealing distinctive 
conformational features of PIM proteins (Bullock et al., 2005; Jacobs et al., 
2005; Kumar et al., 2005; Qian et al., 2005). Unlike most protein kinases, PIM 
kinases are constitutively active and do not require any phosphorylation events 
for the activation of their kinase activity. Structurally, they adopt the typical two-
lobe kinase fold structure with a hinge region (residues 121-126) joining the N- 
and C-terminal lobular domains. The PIM kinases also share the consensus 
hinge region sequence of ERPXPX consisting of proline-123 and proline-125 
(non-hydrogen bond donor) residues (Figure 1.2), which is not seen in any other 
kinases known so far. The presence of two proline residues in the hinge region 
is rather surprising since a proline residue is incapable of forming the 
conventional hydrogen bonds with the adenine of ATP, which is crucial for 
maintaining kinases in their active conformation. They also lack the salt bridge 
between Lys169, a conserved residue in kinases, and the nucleotide phosphate 
group of ATP. Most notably, the conformation of hinge region in PIM1 produces 
a wider and larger ATP binding pocket than other kinases. The active 
conformation of PIM kinases is suggested to be stabilised by two main forces 
i.e. the salt bridge and hydrogen bond between Arg166 and Asp200, and 
hydrophobic clusters between the activation loop and catalytic loop of the 
protein (Qian et al., 2005). The unique structure of PIM1 (Figure 1.3) thus allows 
us to design highly specific and potent inhibitors of PIM kinases for the treatment 
of malignancies.    
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Figure 1.3 Crystal structure of PIM1 with Staurosporine   
The structure is shown with β-sheets as arrows and α-helices as cylinders. The N-
terminal domain (dark blue) is shown with the glycine rich loop drawn in green. The 
hinge connecting the two domains is shown in orange. The C-terminal domain is shown 
in light blue and the activation loop in yellow. The salt-bridge stabilising the active 
conformation of the activation loop is formed by residues Asp200 and Arg166 drawn as 
grey carbon-atoms. The autophosphorylation site (S261) was suggested to be an 
artefact of expression in E. coli. The inhibitor staurosporine in red, is shown in the active 
site of PIM1 (Jacobs et al., 2005). 
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1.3 Regulation of PIM1 
PIM kinases are broadly expressed, although at varying levels, in 
haematopoietic, neuronal, vascular smooth muscle, cardiomyocyte, endothelial 
and epithelial cell lineages and in embryonic stem cells (Nawijn et al., 2011). 
Given that PIM kinases are constitutively active and lack regulatory domains, it 
is conceivable that their enzymatic activity is regulated by their overall protein 
level in a cell (Shay et al., 2005). PIM kinase activity is largely regulated at the 
transcriptional level and via protein stabilisation. PIM genes display features of 
early response genes that are induced primarily, although not exclusively, by 
activation of transcription factors downstream of growth factor signalling 
pathways such as the Janus kinase-signal transducer and activator of 
transcription (JAK-STAT) pathway and nuclear factor-κB (NF-κB) pathways. 
Because PIM kinases show high structural similarity and exhibit overlapping 
functions (as discussed later), the regulation of only PIM1 has been studied in 
great detail.  
 
1.3.1 Transcriptional regulation 
 The JAK-STAT pathway is activated following cytokine receptor 
stimulation by interleukins (IL-2, 3, 5, 6, 9 7, 11, 12, 15), interferons (IFN-α, γ) 
and growth factors such as granulocyte colony-stimulating factor (G-CSF), 
granulocyte-macrophage (GM)-CSF, prolactin, erythropoietin among others 
(Blanco-Aparicio et al., 2014). Upon ligand-receptor binding, JAK kinases are 
activated and catalyse trans-autophosphorylation of their cytoplasmic receptor 
domain. This generates binding sites for STATs and other signalling proteins. 
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Phosphorylation of STATs (STAT3, 5) through JAK leads to dimerisation of 
STAT molecules and subsequent translocation to the nucleus, where they bind 
directly to PIM1 promoter and activate its transcription. In addition, PIM1 can 
negatively regulate the JAK-STAT pathway by interacting with suppressor of 
cytokine signalling (SOCS1, SOCS3) proteins, which inhibits STAT5 activity 
(Chen et al., 2002; Peltola et al., 2004). 
 There are a few noticeable examples where cytokines do not appear to 
be involved in the upregulation of PIM1. For instance, the BCR-ABL fusion 
protein in chronic myelogenous leukemia (CML) activates STAT5 leading to 
expression of PIM1 (Nieborowska-Skorska et al., 2002). Also, the constitutively 
active Fms-like tyrosine kinase 3 (FLT3) oncoprotein expressed in acute myeloid 
leukemia leads to strong upregulation of PIM1 in cells via STAT5 (Kim et al., 
2005). Interestingly, PIM1 appears to maintain the activation of mutant FLT3 by 
phosphorylating only the mutant receptor protein, and enhancing its binding to 
chaperones such as Hsp90, thus protecting it from proteasomal degradation 
(Natarajan et al., 2013a).   
 CD40 receptor, a member of tumour necrosis factor receptor (TNFR) 
superfamily, upon activation by CD40 ligand leads to upregulation of PIM1 
protein levels, and also kinase activity via the NF-κB pathway in B-cells (Zhu et 
al., 2002). Other receptors like B-cell receptors that activate NF-κB can also 
upregulate PIM1 levels in B-cells. Conversely, PIM1 also regulates NF-κB 
signalling by phosphorylating or stabilising a key component of this pathway - 
RelA/p65 (Nihira et al., 2010). 
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 A transcription factor called Kruppel-like factor 5 (KLF5) was also shown 
to induce PIM1 expression in response to DNA damage independently of p53 in 
HCT116 colon cancer cells. KLF5 is recruited to a Sp1 consensus site on the 
PIM1 promoter which activates expression of PIM1, and protects the cells from 
apoptosis (Zhao et al., 2008). The oncogenic K-Ras signalling also upregulates 
the expression of PIM1, probably through transcription in pancreatic cancer 
cells. PIM1 expression in this model served as a marker for K-RAS activity 
conferring anchorage-independent growth and resistance to radiotherapy (Xu et 
al., 2011). 
  A recently published report identified PIM1 as a target of estrogen-
receptor-α (ERα) in MCF7 breast cancer cells (Malinen et al., 2013). PIM1 
expression can also be induced by ERα regulated enhancers located distally 
from PIM1 gene in response to estrogen. This highlights the involvement of 
additional pathways converging to induce PIM expression other than JAK-STAT 
or NF-κB pathways. Similarly HOXA9, a homeodomain transcription factor with 
roles in embryonic development and haematopoiesis, directly targets PIM1 at 
the transcriptional level. HOXA9 binds to a distal region of the PIM1 promoter 
such that transcription of PIM1 is upregulated by its overexpression (Hu et al., 
2007). Since a previous study identified that HOXA9 interacts with eIF4E, it was 
also suggested that HOXA9 might also regulate PIM1 via the eIF4E pathway. 
However, this idea is still not established. But it is now known that PIM2 can 
directly phosphorylate eIF4E to increase cap-dependent of itself and other 
oncogenic proteins (Hammerman et al., 2005). 
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 The role of two large 5’ and 3’ UTRs in PIM mRNA, mentioned earlier, is 
now becoming clear in post-transcriptional control. The 3’ UTR contains two 
AUUUA-rich elements (ARE1 and ARE2), which enhance the decay of the PIM1 
transcript. Tristetraprolin (TTP) is an ARE-binding protein that can recognise 
AREs and promote the decay of transcripts. Overexpression of TTP in LNCaP 
prostate cancer cell was shown to significantly reduce PIM1 expression levels 
and growth of cancer cells (Kim et al., 2012). Surprisingly, it was also found that 
TTP-mediated reduction in p21 (target of PIM1) phosphorylation increased p21 
levels, which explains the effect of TTP on cell growth. In another study, the 
induction of TTP was shown to occur rapidly following mitogenic stimulation of 
PIM1 by agents such as 12-O-tetradecanoyl-phorbol-13-acetate (TPA) in 
various non-haematopoietic cells (Mahat et al., 2012).  
HuR (Hu antigen R) is another mRNA-binding protein that binds to the 3’-
UTR of PIM1 during hypoxia, resulting in stabilisation of the transcript in 
pancreatic cancer cells (Blanco et al., 2015). Finally, various microRNAs (miR) 
miR1 (Nasser et al., 2008), miR33a (Thomas et al., 2012), miR206 (Zhang et al., 
2016), miR328 (Eiring et al., 2010) and miR486-5p (Pang et al., 2014) have 
been shown to bind PIM1 3’UTR, resulting in decreased PIM1 mRNA levels. 
Figure 1.4 summarises the transcriptional regulation mechanisms of PIM1. 
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Figure 1.4 Overview of transcriptional regulation of PIM1 
Stimulation of membrane receptors by cytokines and growth factors stimulates the JAK-STAT 
and NF-κB pathway, which activates transcription of PIM1. Other factors like K-RAS, BCR-ABL, 
ERα, KLF5 and HOXA9 also stimulate expression of PIM1 in various tumours. eIF4E leads to 
enhanced translation of PIM1 mRNA, while Tristetrasporin (TTP) leads to mRNA decay. 
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1.3.2 Post-translational regulation 
 The half-life of PIM1 varies between 5 to 15 minutes in primary cells 
(Amson et al., 1989) and can be increased up to 100 minutes in certain tumour 
cells like chronic myelogenous leukemia (CML) cells K562 and BV173 
expressing the BCR-ABL fusion protein (Shay et al., 2005). In these cells, heat 
shock protein HSP90 interacts with and stabilises PIM1 (Mizuno et al., 2001) by 
protecting it from ubiquitylation and subsequent degradation by the proteasome 
(Shay et al., 2005). In contrast, binding of ubiquitinated PIM1 with HSP70 
favours its degradation via the proteasome (Shay et al., 2005). Treatment with 
Geldanamycin (Hsp90 inhibitor) prevented accumulation of PIM1 with increased 
HSP70 binding, while treatment with PS-341 (inhibitor of 26s subunit of the 
proteasome) caused a build-up of PIM1 with increased HSP90 binding. The 
dynamics of how HSP70 and HSP90 might change the conformation or affect 
the shuttling of PIM1 to the proteasome remains a subject of investigation. This 
study delineates the major post-translational regulation of PIM1 and gives 
insights into how PIM1 could be efficiently targeted for degradation in cancer 
therapy. 
Hypoxia was recently shown to induce PIM1 expression in solid tumours, 
but in a hypoxia-inducible factor 1α (HIF1α)-independent manner. Interestingly, 
inhibition of PIM1 in hypoxic cells resensitised them to chemotherapy, whereas 
forced expression of PIM1 contributed to resistance to cisplatin, even under 
normoxia (Chen et al., 2009b). Hypoxia leads to nuclear accumulation of HSP90 
and decrease in PP2A levels, which prevents degradation of PIM1 by the 
ubiquitin-proteasome system. Hypoxia was also suggested to promote nuclear 
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translocation of PIM1, the mechanism and function of which is still not clear 
(Chen et al., 2009a).  
 Like MYC, all three PIM kinases can be destabilised by the 
serine/threonine protein phosphatase 2A (PP2A) by dephosphorylation or partial 
inactivation of kinase activity (Losman et al., 2003; Ma et al., 2007). PP2A can 
interact with PIM1 substrate through its B56β subunit, as evident by co-
immunoprecipitation experiments, and promote its ubiquitination. Knockdown of 
PP2A or B56β was shown to increase PIM1 stability, and consequently cell 
viability. On the other hand, overexpression of PP2A led to a decrease in PIM1 
protein expression. In one study, it was suggested that PP2A dephosphorylates 
SOCS1 first to form a complex, which then binds to PIM1 and targets it for 
degradation (Losman et al., 2003). In another study, it was suggested that the 
prolyl-isomerise PIN1 binds phosphorylated PIM1 and enhances the ability of 
PP2A holoenzyme to bind to the complex through the B56β protein (Ma et al., 
2007). Figure 1.5 summarises the discussed post-translational regulatory 
mechanisms of PIM1. 
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Figure 1.5 Post-translational regulation of PIM1 
The PIM1 protein is degraded by the ubiquitin-proteasome system. Binding of PIM1 to HSP90 
protects it from proteasomal degradation, while binding to HSP70 promotes degradation. PP2A 
can directly or indirectly promote destabilisation of PIM1. 
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1.4 Targets and functions of PIM1 kinase 
The serine/threonine kinase PIM mediates its effects by phosphorylating 
various substrates involved in regulation of important physiological activities 
such as cell proliferation and cell survival. PIM kinases are largely redundant in 
function (exceptions exist) with strong affinity for substrates containing the 
(K/R)3-X-S/T-X consensus motif, where K-lysine, R –arginine, X- is neither a 
basic nor a large hydrophobic residue, S-serine and T-threonine (Friedmann et 
al., 1992). However, the sequence K/R-X-R-H-X-S/T, present in Insulin receptor 
substrate 1 (IRS1) is phosphorylated 20-fold times more efficiently by PIM 
kinases (Song et al., 2016). Interestingly, the PIM substrate sequence is similar 
to that of other kinases like AKT, protein kinase A and protein kinase C leading 
them to share some substrates. Some noteworthy targets of PIM1 and their 
functions are described below. 
 
1.4.1 Transcriptional regulation  
PIM1 regulates the activity of transcriptional co-activator p100 and factors 
such as c-MYB, RUNX1, RUNX3 and nuclear factor of activated T cell 
cytoplasmic 1 (NFATc1) by direct phosphorylation (Brault et al., 2010). PIM1 has 
recently been shown to phosphorylate androgen receptor (AR) at Ser213 
leading to transcription of AR-regulated genes in absence of androgen in 
prostate cancer cell model (Ha et al., 2013).  
Both PIM1 and PIM2 increase c-MYC protein stability and transcriptional 
activity by phosphorylating Ser62 (main site) and Ser329 residues (Zhang et al., 
2008a). The dependency of the E-box (CACGTG) transcription factor, c-MYC, 
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on PIM1 or vice versa in mediating gene transcription and cellular transformation 
is well known. c-MYC interacts with and recruits PIM1 to E-box located in the 
enhancer region of c-MYC-target genes FOSL1 and ID2 leading to 
phosphorylation of histone H3 at Ser10 (H3S10) (Zippo et al., 2007). This is 
followed by the recruitment of 14-3-3 and histone acetyltransferase MOF leading 
to acetylation (Ac) of Histone 4 at Lys16, which creates a H3K9AcS10P-
H4K16Ac nucleosome platform for BRD4 binding. This is ensued by binding of 
Positive Transcription Elongation Factor b (P-TEFb), which promotes looping of 
the enhancer towards the promoter causing phosphorylation of RNA POL II on 
Ser2, and releases the stalled POL II to drive transcription (Zippo et al., 2009). 
Figure 1.6 illustrates the role of PIM1 in transcription. 
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Figure 1.6 Transcriptional regulation by PIM1 
(A) PIM1 phosphorylates various transcription factors (TF) and co-factors (CF) on the target 
gene promoter, and enhances their transcriptional activity. (B) PIM1 is recruited to enhancer 
regions by MYC, where it phosphorylates H3 at S10 and induces concomitant H4K16 acetylation 
(Ac) by MOF. This is followed by binding of BRD4 and P-TEFb, initiating looping of enhancer 
towards the promoter (dashed line), phosphorylation of RNA POL II at S2, and release of stalled 
POL II (Adapted from Nawijn et al., 2011). 
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1.4.2 Cell Survival  
In human malignancies, PIM promotes cell survival as well as 
chemoresistance through BAD phosphorylation (Figure 1.7). The BCL2-
associated death promoter (BAD), a pro-apoptotic member of B-cell lymphoma 2 
(BCL2) family, is a target of all PIM kinases (Yan et al., 2003; Aho et al., 2004; 
Macdonald et al., 2006). Both PIM1 and 2 phosphorylate BAD at Ser112 
(predominant site), Ser136 and Ser155, while PIM3 mostly phosphorylates at 
Ser136 and Ser155. Phosphorylation of Ser112  (a known gate-keeper site for 
BAD inactivation) by PIM1 disrupts its association with BCL-XL, which promotes 
anti-apoptotic activity. Furthermore, Ser112 phosphorylated BAD binds to 14-3-3 
proteins, and is retained in the cytosol instead of the mitochondria. Interestingly, 
phosphorylation of BAD at Ser155 has been shown to increase glycolysis in 
hepatocytes, pancreatic β-cells and B-lymphocytes (Nawijn et al., 2011). This 
suggests a novel role for PIM kinases in glycolysis as they can also 
phosphorylate BAD at Ser155, however there is no direct evidence to support 
this hypothesis so far. 
PIM1 has also been reported to phosphorylate Apoptosis signalling 
kinase 1 (ASK1) at Ser83 in H1299 cells upon treatment with hydrogen 
peroxide. Ser83 phosphorylation of ASK1 impairs the activation of the 
downstream substrates, JNK and p38, which is associated with decreased 
Capase3 activation, and reduced cell death (Gu et al., 2009). Other mechanisms 
of cell survival functions of PIM1 maybe mediated indirectly by c-MYC at the 
transcriptional or protein levels.  
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Figure 1.7 Survival signalling through BAD phosphorylation 
The pro-apoptotic protein BAD promotes apoptosis by binding and inhibiting BCL-2 family of 
anti-apoptotic proteins. Growth factors activate a number of downstream kinases such as PIM1, 
which can then phosphorylate BAD at three sites (S112, S136 and S155) leading to dissociation 
of BAD from BCL-XL. Phosphorylated BAD is then recognised by 14-3-3 proteins, which 
sequesters it in the cytoplasm, thereby inhibiting apoptosis. 
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1.4.3 Cellular senescence  
PIM1 can have a tumour suppressive role in certain contexts. Activation 
of PIM1 has also been shown to induce cellular senescence through the p53 
pathway. Our lab previously showed that PIM1 can stabilise MDM2 by 
phosphorylating it at Ser166 and Ser186 (predominant) residues, (Hogan et al., 
2008). Furthermore, co-expression of MDM2 and PIM1 induced expression of 
p14 (or ARF) in early passage mouse embryonic fibroblasts (MEFs) leading to 
cellular senescence, as evidenced by an increase in β-galactosidase staining. 
Consistent with our report, another study showed that PIM1 overexpression 
inhibited cell growth by inducing senescence in prostate cancer cells (22Rv1) 
with an intact p53-p21 pathway (Zemskova et al., 2010). Induction of PIM1 by 
IL6 in human diploid fibroblasts has also been suggested to induce senescence, 
by direct phosphorylation of heterochromatin protein 1 (HP1γ) at Ser93. PIM1 
phosphorylated HP1γ promoted the formation of heterochromatin foci and 
silencing of proliferative genes (Jin et al., 2014). 
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1.4.4 Cell Cycle regulation  
PIM1 phosphorylates various proteins involved in the regulation of the cell 
cycle such as CDC25A, p21 and p27 during G1/S, and CDC25C, c-TAK1 during 
G2/M phase (figure. 6). Phosphorylation by PIM1 enhances the phosphatase 
activity of CDC25A, a positive G1-specific cell cycle regulator, allowing cells to 
transit through the G1 and S phases (Mochizuki et al., 1999). Similarly, PIM1 
can also enhance CDC25C phosphatase activity by two ways i.e. by direct 
phosphorylation of CDC25C (Bachmann et al., 2006), and by inactivation of 
CDC25C-associated kinase 1 (c-Tak1), which is a negative regulator of 
CDC25C, ensuring cell cycle progression (Bachmann et al., 2004).   
PIM mediated phosphorylation of p21 (CDKN1A) at Thr145 was shown to 
stabilise p21, and result in nuclear to cytoplasmic relocalisation (Wang et al., 
2002). Cells expressing p21 in the cytoplasm exhibit increased rate of 
proliferation, which is most likely due to the dissociation of nuclear p21 from the 
proliferating cell nuclear antigen (PCNA) (Zhang et al., 2007). 
PIM1 regulates the expression of p27 at both the transcriptional and 
protein levels (Morishita et al., 2008). Firstly, phosphorylation of p27 (CDKN1B) 
at Thr157/Thr198 by PIM1 creates binding sites for 14-3-3 proteins, resulting in 
the cytoplasmic localisation and subsequent degradation of p27. Secondly, 
PIM1 also inactivates the forkhead transcription factors FOXO1 and FOXO3, 
which upregulate the expression of p27 mRNA. Interestingly, PIM1 has also 
been shown to phosphorylate SKP2 at Thr417, the putative E3 ubiquitin ligase 
for p27, which stabilises SKP2, enhancing proteasomal degradation of p27 (Cen 
et al., 2010).  
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During mitosis, PIM1 has been shown to phosphorylate the nuclear 
mitotic apparatus (NuMA) protein, and associate in a complex with motor 
proteins dynein, dynactin and heterochromatin protein 1β (HP1β) maintaining 
the mitotic apparatus (Bhattacharya et al., 2002). A recent study suggested that 
both PIM1 and Polo-like kinase 1 (PLK1) colocalise in the centrosome and 
midbody during mitosis, where they might phosphorylate each other (Van Der 
Meer et al., 2014). However, the precise role played by PIM1 in the mitotic 
complex is still unknown. Figure 1.8 illustrates the role of PIM1 in regulating cell 
cycle. 
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Figure 1.8 Regulation of the cell cycle by PIM1 
PIM1 phosphorylates various proteins involved in the regulation of the cell cycle. 
Phosphorylation of p21, p27 and c-TAK1 by PIM1 (shown in red) inhibits their activity, while 
phosphorylation of CDC25A and CDC25C by PIM1 (shown in green) promotes their activity to 
drive the cell cycle. 
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1.4.5 Translation  
PIM kinases have been shown to regulate protein translation by controlling the 
activity of both upstream and downstream regulators of the mTOR (mammlian 
target of rapamycin) pathway (Figure 1.9). The mTOR complex 1 (mTORC1) 
comprises five proteins namely the kinase mTOR, and the regulatory subunits 
RAPTOR, DEPTOR, mLST8 and PRAS40 (Laplante and Sabatini, 2009). 
PRAS40 is a negative regulator of mTORC1 kinase activity, and upon 
phosphorylation at Thr246 by PIM1, dissociates from the mTORC1 complex 
(Zhang et al., 2009). This increases mTORC1 activity leading to phosphorylation 
of downstream proteins 4E-BP1 and p70 S6K. Phosphorylation of 4E-BP1 and 
p70 S6K activates downstream proteins eIF-4E (eukaryotic initiation factor 4E) 
and eIF-4B (eukaryotic initiation factor 4B) respectively, which initiates cap-
dependent translation of weak mRNA transcripts such as c-MYC, CYCLIN D 
and PIM itself (Schatz et al., 2011). Interestingly, PIM2 can promote protein 
translation even in the presence of rapamycin (mTOR inhibitor) or growth factor 
withdrawal by directly phosphorylating 4E-BP1 and eIF-4E (Hammerman et al., 
2005). Moreover, PIM1 can also directly phosphorylate eIF-4B on Ser406 which 
contributes to the increase in protein levels of the receptor tyrosine kinases such 
as MET, suggesting that PIM kinases can control protein translation in an 
mTOR-independent manner (Cen et al., 2014). The mTORC1 complex activity is 
negatively regulated by the upstream tuberous sclerosis complex (TSC), 
comprising TSC1 and TSC2. In multiple myeloma cells, PIM2 was shown to 
directly phosphorylate TSC2 at Ser1798, relieving suppression of mTORC1 
signalling and promoting cell proliferation (Lu et al., 2013) 
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Figure 1.9 Regulation of mTOR pathway by PIM kinases 
The mTORC1 complex integrates growth and stress signals, and accordingly activates or 
inhibits protein synthesis in cells. PIM kinases promote protein synthesis required for cell growth 
and proliferation by phosphorylating various substrates of the mTOR pathway. Phosphorylations 
that inhibit activity of a protein are shown in red, whereas activating phosphorylations are shown 
in green. PIM kinases inhibit the activity of TSC1/2, the upstream negative regulator of mTORC1 
complex, in addition to PRAS40. Both of these phosphorylations promote the kinase activity of 
mTOR. Activated mTOR activates p70 S6K, which further activates eIF4B to promote protein 
translation. mTOR also inhibits the negative regulator of protein synthesis 4E-BP1 by direct 
phosphorylation. Inactivation of 4E-BP1 activates eIF4E, which also promote protein translation. 
Interestingly, PIM kinases can also directly phosphorylate 4E-BP1, eIF4E and eIF4B 
independently of the mTOR pathway, and upregulate protein translation in cells. 
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1.4.6 Cellular metabolism 
The master sensor of intracellular energy status, AMP-activated kinase 
(AMPK), is an indirect target of Pim kinases. Under energy stress, AMPK 
becomes activated, which then phosphorylates RAPTOR and TSC2 in such a 
way that inhibits the activity of mTORC1, resulting in the inhibition of translation 
and proliferation (Hardie, 2007). Deletion of all three Pim kinases in mouse 
embryonic fibroblasts (MEF) was shown to cause energy deficiency, reduced 
cap-dependent translation and persistent AMPK activation. Interestingly, 
expression of Pim3 alone rescued the phenotype, most likely due to an increase 
in c-Myc and peroxisome proliferator-activated receptor gamma coactivator 1α 
(Pgc1α) protein levels (Beharry et al., 2010). 
Furthermore, PIM kinases also play a crucial role in K-Ras mediated 
cellular transformation, as Pim triple knockout MEF (TKO MEF) undergo cell 
death in response to activated K-RasG12V (Song et al., 2014). Activated K-Ras is 
known to increase the cellular levels of reactive oxygen species (ROS) 
(Weinberg et al., 2010), and Pim kinases appear to be required for the 
transcription of genes such as superoxide dismutase (Sod1, 2, 3), glutathione 
peroxidase 4 (Gpx4), and peroxiredoxin 3 (Prdx3) involved in scavenging ROS. 
Deletion of all three Pim kinases also altered the intracellular concentration of 
178 metabolites involved in glycolysis and mitochondrial oxidative 
phosphorylation. Interestingly, forced expression of c-Myc overcame the defects 
associated with the deletion of Pim kinases, suggesting an important role for 
Pim kinases in regulating cellular metabolism, in part through c-Myc.  
! 29!
The transcription factor, nuclear factor erythroid 2 p45-related factor 2 
(NRF2), is a master regulator of cellular redox homeostasis, and is required for 
the induction of a battery of cytoprotective genes, in response to environmental 
stress conditions such as ROS (DeNicola et al., 2011). A recent study indicated 
that under hypoxic conditions, Pim kinases promote nuclear localisation and 
activity of NRF2 to induce expression of antioxidant genes (Warfel et al., 2016). 
Inhibition of PIM kinase in hypoxic cells by small molecular inhibitors prevented 
nuclear localisation of NRF2 and an increase in intracellular ROS 
concentrations, which induced cell death. Since there is no direct evidence of 
PIM kinases phosphorylating NRF2, these effects are most likely mediated by 
another PIM interacting oncogene. 
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1.4.7 Some unique functions of PIM2 and PIM3 
The regulation of cap-dependent protein translation is one of the 
important functions of PIM2, as mentioned earlier. In addition, PIM2 activates 
NF-κB by inducing phosphorylation of COT (Hammerman et al., 2004) which 
was proposed to be crucial for anti-apoptotic function of PIM2. Interestingly, 
functions of PIM2 seem to be context-dependent as the 34 kDa isoform 
promotes G1 arrest by elevating levels of Thr14/Tyr15 phosphorylation of 
Cyclin-dependent kinase 2 (CDK2), and increases apoptosis in HeLa cells by a 
pathway involving p73 (Levy et al., 2012).  
PIM3 is a positive-regulator of β-catenin dependent transcription and is 
suggested to regulate β-catenin mRNA, hence a regulator of WNT-pathway 
(Isaac et al., 2011). Only PIM3 was shown to phosphorylate STAT3 at Tyr705 in 
prostate cancer (DU145) and pancreatic cancer (MiaPaCa2) cell lines. These 
cells exhibit constitutive expression of the survival protein pSTAT3 via PIM3 
contributing to drug resistance (Chang et al., 2010). Interestingly, c-MYC directly 
induces expression of PIM3 in B-cell lymphomas, and induces survival signalling 
through phosphorylation of BAD (Forshell et al., 2011). PIM3 was recently found 
to promote endothelial cell sprouting and migration in response to TNFα. Hence 
PIM3 plays an important role in TNFα-induced angiogenesis (Yang et al., 2011).  
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1.5 PIM kinases in cancer and their inhibition 
Elevation of PIM1 found in tumours is generally considered not to be due 
to genetic rearrangement, but a result of dysregulated transcriptional regulation 
and protein stability, to some extent associated with MYC expression. Mutations 
in PIM1 are rare, but point mutations have been reported in 43% of B-cell diffuse 
large cell lymphomas (Pasqualucci et al., 2001). PIM kinases are overexpressed 
in a significant proportion of haematological malignancies such as acute myeloid 
leukemia (AML), chronic myelogenous leukemia (CML), mixed-lineage 
lymphoma (MLL), chronic lymphocytic leukemia (CLL), Mantle-cell lymphoma 
(MCL) and Burkitt’s lymphoma where its expression level correlates with poor 
prognosis. In case of solid tumours of epithelial origin, PIM is overexpressed in 
prostate cancer (almost 50%), squamous cell carcinoma, pancreatic cancer, 
gastric cancer, colorectal cancers and others where its expression correlates 
with high-tumour grade (Brault et al., 2010; Nawijn et al., 2011). 
 
1.5.1 PIM1 and therapeutic resistance 
PIM kinases confer therapeutic resistance in multiple cancer types 
through several mechanisms. The 44 kDa isoform of PIM1 has been shown to 
negatively affect drug transport into the cells by phosphorylating the P-
glycoprotein ATP-binding cassette G2 (ABCG2) at Thr362, promoting its activity. 
ABC proteins have been shown to function as efflux pumps for 
chemotherapeutic drugs, and their expression is linked to drug resistance (Xie et 
al., 2008). PIM1 also phosphorylates ABCB1 at Ser683 which protects it from 
ubiquitin mediated degradation, as well as enhancing its glycosylation and cell 
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surface expression (Xie et al., 2010). PIM kinase inhibitors have also been 
shown to reduce surface expression of ABCB1 and ABCG2 in breast cancer 
(Natarajan et al., 2013b) suggesting that PIM kinase inhibitors can be used to 
sensitize tumours to chemotherapy.  
PIM kinase inhibitors were shown to sensitise cells towards the BCL-2 
inhibitor ABT-737, by reducing the expression of MCL1 (Song and Kraft, 2012). 
A study showed that inhibition of AKT leads to activation of a compensatory 
survival signalling pathway by upregulating expression of PIM1, and several 
other receptor tyrosine kinases such as MET. Inhibition of PIM1 not only induced 
apoptosis but also reduced expression of RTK by downregulation of cap-
dependent translation in AKT-inhibitor resistant cells (Cen et al., 2013).  
 
1.5.2 PIM kinase inhibitors in development 
PIM kinases are increasingly being considered as targets for new drug 
development because of their important roles in regulating cancer-specific 
pathways, such as cell survival, cell cycle progression and cellular migration. 
The crystal structure of PIM kinases, as discussed earlier, shows the unique 
mode of ATP binding, which indicates that highly specific inhibitors can be 
identified for use in cancer therapy with least off-target effect on other kinases. 
Due to functional redundancy, simultaneous targeting of all three PIM kinases 
can be advantageous in treating cancer. Supporting this view is the fact that the 
PIM kinases are dispensable in normal cells as Pim triple knockout mice are 
viable and fertile with normal life span, although they display reduced body size 
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(Mikkers et al., 2004). This makes PIM kinase a useful target for cancer therapy 
without affecting the normal tissues severely. 
Several small-molecule inhibitors of PIM1/2/3 have been designed, some 
of which have already undergone clinical trials, or are in preclinical stages at the 
moment. Most PIM inhibitors are ATP-competitive compounds that form polar 
interactions with the active site residues in PIM kinases (for example Lys67 in 
PIM1), and appear to display a common mechanism of action. PIM kinase 
inhibitors target translation by reducing levels of phospho 4E-BP1 and phospho 
S6K, and induce apoptosis by reducing phospho BAD, concomitant with a 
G0/G1 cell cycle arrest (Keane et al., 2015). Some clinically relevant PIM kinase 
inhibitors have been described below with clinicaltrial.gov identifier numbers 
(NCT) mentioned in brackets. 
 
a) SGI-1776 (Supergen)   
It was the first ATP-competitive inhibitor of PIM kinases to enter Phase I clinical 
trails for the treatment of refractory prostate cancer, refractory non-Hodgkin’s 
lymphoma and leukemia (NCT00848601 and NCT01239108). Unfortunately, the 
study had to be terminated prematurely because of cardiotoxicity. It is possible 
that this side effect could be associated with the reported cardioprotective role of 
PIM1 (Muraski et al., 2007). The in vitro IC50 values for PIM1, 2 and 3 are 7, 
363 and 69 nM respectively. Although it is highly selective for Pim kinases, it 
also inhibits FLT3 and TRKA (Chen et al., 2009c). 
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b) AZD1208 (Astrazeneca) 
It is a second generation ATP-competitive inhibitor of PIM kinases with IC50 
values in the low nanomolar range, and a more potent inhibitor than SGI-1776. 
The sensitivity of AZD1208 in AML cell lines was reported to correlate with PIM1 
expression and STAT5 activation (Keeton et al., 2014). It was tested in Phase I 
clinical trails for the treatment of acute myeloid leukemia (AML) and advanced 
lymphomas and other solid cancers (NCT01489722 and NCT01588548). 
Unfortunately, the AML trial had to be terminated and the results have not been 
made public. 
 
c) LGH447 (Novartis) 
It was first tested as a single agent for the treatment of refractory/relapsed 
multiple myeloma. The results were promising, and a further Phase I/II clinical 
trial is currently underway as a single agent in AML/high risk myelodysplastic 
syndromes, and in combination with PI3K inhibitor BYL719 in multiple myeloma 
(NCT01456689, NCT02160951, NCT02144038 and NCT02078609). 
 
d) LGB321 (Novartis) 
It is an ATP-competitive inhibitor of PIM kinases, and structurally related to 
LGH447 with IC50 in picomolar range. It is currently being tested in preclinical 
models, where it demonstrated limited activity in solid tumours, but good activity 
in haematological malignancies, especially against those overexpressing PIM2 
(Garcia et al., 2014). 
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e) AZD1897 (Astrazeneca) 
This ATP-competitive pan-PIM kinase inhibitor has not yet reached clinical trials. 
However, published data from in vitro and in vivo settings showed >50% 
synergistic cytotoxicity when combined with AKT inhibitor AZD5363 (Meja et al., 
2014). 
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1.6 The Ubiquitin System 
Ubiquitination (or ubiquitylation) is the process by which the 76 amino 
acid long polypeptide, called ubiquitin, is covalently attached to one or more 
lysine residues in target proteins. This is achieved by an enzymatic cascade 
consisting three main steps namely activation, conjugation and ligation 
respectively (Figure 1.10). In the first step, ubiquitin (Ub) is transferred to an 
Ubiquitin activating enzyme (or E1) in an ATP-dependent manner, to form an 
E1-Ub complex linked by a thioester bond. In the second step, the activated 
ubiquitin is transferred to ubiquitin conjugating enzyme (UBC or E2), again 
forming an E2-Ub thioester bond. In the third step, a Ubiquitin ligase (or E3), 
which binds both E2-Ub and substrate, allows the formation of an isopeptide 
bind between the carboxy terminal of ubiquitin and the amino group of a lysine 
residue on the target protein. Similar to phosphorylation, ubiquitination is also a 
reversible modification, which can be edited and/or erased by a set of enzymes 
called Deubiquitinases (or DUBs). Presently, it is estimated that the human 
proteome contains two E1s (UBA1 and UBA6), about 40 E2s, over 600 E3 
ubiquitin ligases and over 90 DUBs (Heride et al., 2014). The discovery of 
ubiquitin sparked the identification of several ubiquitin-like (Ubl) proteins or 
modifiers such as NEDD8, SUMO, ISG15, FAT10 and others. All members of 
the ubiquitin-like family of proteins contain the conserved ubiquitin β-fold, and 
target the substrate lysine residue by a pathway similar to ubiquitin (Kerscher et 
al., 2006). Since SUMO is the topic of discussion of this thesis, other ubiquitin-
like modifications have not been described here.  
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Figure 1.10 The ubiquitin conjugation cycle 
The enzymatic cascade describing the covalent attachment of ubiquitin (Ub) to lysine residues of 
a target protein are shown in this figure. In the first step, a ubiquitin activating enzyme (E1) forms 
a thioester bond with ubiquitin. In the second step the activated ubiquitin is transferred to a 
ubiquitin conjugating enzyme E2. In the third step, a ubiquitin E3 ligase binds the ubiquitin 
loaded E2 and the substrate, and catalyses transfer of ubiquitin to a lysine residue on the target 
protein. Multiple copies of ubiquitin can be attached to the substrate leading to formation of 
polyubiquitin chains. Enzymes called deubiquitinating enzymes (DUB) can cleave the ubiquitin 
chain from the target freeing the ubiquitin and the substrate. 
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1.6.1 The Ubiquitin code and its functions 
The N-terminal methionine (M1) and the seven lysine residues (K6, K11, 
K27, L29, K33, K48 and K63) present within ubiquitin act as further sites of 
attachment by ubiquitin itself, thereby allowing formation of polymeric chains 
(Kulathu and Komander, 2012). The process of addition of polymeric ubiquitin 
chains to proteins is called polyubiquitination, whereas the addition of a single 
ubiquitin moiety is called monoubiquitination. About 10% of total histone H2A 
population in cells is monoubiquitinated. Monoubiquitination of histones is 
mediated by the Polycomb repressive complex, and is therefore implicated in 
gene silencing (Wang et al., 2004).  
When a ubiquitin chain is formed of the same type of lysine or methionine 
linkages, it is called a homotypic ubiquitin chain. On the other hand, a 
heterotypic ubiquitin chain is a chain that is formed of mixed linkages within the 
same chain. The type of the linked chain formed on a substrate is dictated by a 
specific combination of the E2 and E3 enzymes involved in the process. 
Different linkages are conformationally distinct from each other, and therefore 
serve as binding platforms for other proteins containing ubiquitin binding 
domains (UBD). This interaction mediates downstream events associated with 
protein degradation, trafficking and cellular signalling (Komander and Rape, 
2012).  
The most widely studied and abundant form of homotypic ubiquitin chain 
found in eukaryotic cells is K48-linked chain. Proteins conjugated with K48-
linked ubiquitin chains are specifically recognised and degraded by the 26S 
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proteasome, which is composed of one 20S core and two 19S regulatory 
subunits (Chau et al., 1989; Thrower et al., 2000). However, this does not mean 
that other homotypic linkages are not recognised by the proteasome. For 
example, in addition to K48-linked chains, K11- and K29-linked conjugates also 
accumulate when the proteasome is inhibited. Interestingly, K11-linked chains 
synthesised by the anaphase promoting complex (APC/C) result in the 
proteolysis of substrates, such as Aurora-B, involved in mitosis (Jin et al., 2008; 
Matsumoto et al., 2010; Min et al., 2015).  
Another well-studied homotypic chain, after K48-linked chain, is K63-
linked chain. In contrast to K48-linked chains, K63-linked chains are generally 
involved in non-proteolytic functions such as DNA repair and cell signalling 
pathways (Chen and Sun, 2009). K63-linked chains play a crucial role in 
cytokine (TNFα, IL-1R) induced activation of NF-κB pathway. Binding of 
cytokines to their membrane receptors initiates the recruitment of multi-protein 
complexes inside the cell including the E3 ubiquitin ligase TRAF6, which 
catalyses the formation of K63-linked chains on itself and other substrates. The 
K63-linked chains act as a scaffold for a protein kinase called TGFβ activated 
kinase 1 (TAK1), which can then phosphorylate the downstream kinase, IκB 
kinase (IKK) resulting in its activation (Deng et al., 2000; Wang et al., 2001). 
The functions of M1, K6, K27, K29 and K33-linked chains are still largely 
unknown, but recent discoveries point to a diverse range of functions. In brief, 
K6-linked chains were shown to recruit a cofactor UBXN1, which inhibits the 
activity of BRCA1-BARD1 complex during the DNA damage response (Wu-Baer 
et al., 2010). Polyubiquitination of several mitochondrial proteins by K27-linked 
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chains upon mitochondrial damage was shown to recruit the autophagy adaptor 
protein p62, leading to clearance of damaged mitochondria by a process called 
mitophagy (Geisler et al., 2010). Of note, polyubiquitination of kinases such as 
NUAK1 and MARK4 by K29- and K33-linked chains has been shown to inhibit 
their kinase activity without leading to degradation (Al-Hakim et al., 2008). 
Lastly, similar to K63-linked chains, both M1- and M1/K63-hybrid chains are 
involved in the activation of immune signalling and NF-κB activation (Rahighi et 
al., 2009; Emmerich et al., 2013). Figure 1.11 illustrates the crystal structure of 
ubiquitin with internal site of modification, and their associated functions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 41!
 
 
Figure 1.11 Types and function of different ubiquitin linkages 
Crystal structure of ubiquitin (centre) showing the seven internal lysine residues and methionine 
residue. Ubiquitin can form links with other ubiquitin molecules through these residues, leading 
to formation of different chains. Different conformations of polyubiquitin chains with different 
linkages are illustrated here. (Adapted from Komander 2009; Komander and Rape 2012) 
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1.7 Small Ubiquitin-like Modifier (SUMO)  
The Small Ubiquitin-like Modifier (SUMO) is a member of the ubiquitin-
like family of proteins, which shares similarities with ubiquitin at the structural 
level (Martin et al., 2007). Figure 1.12 shows similarity between SUMO and 
ubiquitin at the protein, structural and mechanistic level. Yeast contains only one 
SUMO isoform called Smt3 (Shen et al., 1996b), while humans express five 
different SUMO isoforms – SUMO1, SUMO2, SUMO3 (Melchior, 2000), SUMO4 
(Owerbach et al., 2005) and SUMO5 (Liang et al., 2016). Only SUMO1, SUMO2 
and SUMO3 have been extensively studied in the literature, and described in 
this thesis. SUMO4 is defective in substrate conjugation as a Pro90 residue in 
its C-terminal domain prevents its maturation and activation (Owerbach et al., 
2005). However, another study showed that SUMO4 is rapidly degraded under 
‘normal’ conditions, but stabilised under stress conditions like starvation. During 
this period, SUMO4 was suggested to be processed by endogenous hydrolases, 
and covalently conjugated to its substrates (Guo et al., 2005; Wei et al., 2008). 
SUMO5 was only recently identified as a regulator of PML nuclear bodies, 
similar to SUMO2/3 (Liang et al., 2016). Other SUMO5 substrates are yet to be 
identified.  
SUMO2 and SUMO3 differ from each other by only 3 amino acids at their 
N-terminus, and are functionally indistinguishable. Moreover, the SUMO2 
antibody also recognises SUMO3, hence in the literature they are commonly 
referred to as SUMO2/3. On the other hand, SUMO1 is only 46% identical to 
SUMO2/3 at the sequence level (Martin et al., 2007). An important feature that 
distinguishes SUMO2/3 from SUMO1 is its ability to form polymeric chains on 
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itself. SUMO2/3 contain an internal consensus SUMO modification site, which 
allows conjugation of other SUMO molecules. SUMO1 does not contain this 
motif but is still able to recognise the site in SUMO2/3 for SUMO modification. 
Attachment of SUMO1 to a chain hence results in termination of the poly-SUMO 
chain (Tatham et al., 2001). A sequence alignment of the protein sequences of 
SUMO1, SUMO2 and SUMO3 is shown in figure 1.12A. 
Although most SUMO targets can be modified by all SUMO isoforms, 
some substrates display SUMO-paralogue specificity i.e. they can only be 
modified by one SUMO isoform (Vertegaal et al., 2006). For instance, the Ran 
GTP-ase Activating Protein 1 (RanGAP1), the first identified SUMO substrate, is 
modified exclusively by SUMO1 (Matunis et al., 1996; Saitoh and Hinchey, 
2000). Although it seems that SUMO2/3 can compensate for the loss of SUMO1 
as mice deficient for SUMO1 are viable (Evdokimov et al., 2008; Zhang et al., 
2008b). Examples of substrates that are preferentially modified by SUMO2/3 in 
cells include Topoisomerase II, BMAL1 and p68 (Jacobs et al., 2007; Agostinho 
et al., 2008; Lee et al., 2008). 
Interestingly, there is a larger pool of unconjugated SUMO2/3 in cells 
than SUMO1, with most of SUMO1 being conjugated to RanGAP1 (Saitoh and 
Hinchey, 2000). Various studies have shown that the levels of SUMO2/3 
modified proteins in a cell increase dramatically in response to stress such as 
heat shock and DNA damage (Enserink, 2015), suggesting that the free pool of 
SUMO2/3 is conjugated under physiological conditions of stress.  
SUMO1 and SUMO2/3 also display differences in their cellular 
localisation. In interphase HeLa cells stably expressing YFP-tagged SUMO 
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isoforms, SUMO1 was found to localise to the nuclear envelope, nucleolus and 
cytoplasmic foci, whereas SUMO2 and 3 were predominantly present in the 
nucleoplasm and nuclear bodies. During mitosis, however, SUMO1 was 
localised to the spindle, and SUMO2/3 to the centromeres and condensed 
chromosomes (Ayaydin and Dasso, 2004).  
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Ub       ---------------------MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKE 
SUMO1    MSDQEAKPSTEDLGDKKEGEYIKLKVIGQDSSEIHFKVKMTTHLKKLKESYCQRQ 
SUMO2    MADEKPKE----GVKTENNDHINLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQ 
SUMO3    MSEEKPKE----GVKTE-NDHINLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQ 
 
 
Ub       GIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG 76 
SUMO1    GVPMNSLRFLFEGQRIADNHTPKELGMEEEDVIEVYQEQTGG 97 
SUMO2    GLSMRQIRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQTGG 93 
SUMO3    GLSMRQIRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQTGG 92 
 
 
 
Figure 1.12 Structural relationship between SUMO and ubiquitin  
(A) Multiple sequence alignment of ubiquitin, SUMO1, 2 and 3 was performed using Clustal 
Omega software. The sequences for alignment were retrieved from 
http://www.ncbi.nlm.nih.gov/protein/. The accession numbers are CAA44911.1 (ubiquitin), 
NP_001005781.1 (SUMO1), AAH716545.1 (SUMO2) and NP_008867.2 (SUMO3). Identical 
residues present in all four proteins are shown in red, and identical residues present in all SUMO 
family members are shown in green. (B) Crystal structures of ubiquitin, SUMO1 and SUMO2/3 
showing structural similarity (Martin et al., 2007). (C) Both ubiquitin and SUMO form a covalent 
isopeptide bond with the lysine on the target protein through their C-terminal diglycine motif 
(Hickey et al., 2012). 
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1.7.1 SUMOylation pathway 
SUMOylation is the process by which SUMO1/2/3 is covalently attached 
to one or more lysine residues on a target protein. The modified lysine residue is 
usually part of a consensus SUMO motif (described in the next section). The 
enzymatic process is similar to that of the ubiquitin pathway, with a few 
exceptions. All SUMO isoforms are synthesised as inactive precursors, which 
are first cleaved at their C-terminus by SUMO specific proteases (or SENP) to 
expose the di-glycine motif. A hetero-dimeric SUMO E1 enzyme (SAE1/2) then 
activates SUMO proteins in an ATP-dependent manner resulting in the 
formation of a thioester bond between SUMO and SAE1/2. The activated SUMO 
is then transferred to an E2 SUMO conjugating enzyme UBC9, again through 
the formation of a thioester bond. Lastly, in the presence of an E3 SUMO ligase, 
UBC9 catalyses the formation of an isopeptide bond between the di-glycine 
motif of SUMO and the substrate lysine residue. SUMOylation can also be 
reversed by the isopeptidase activity of SENP resulting in substrate 
deSUMOylation (Hay, 2005). The process of SUMOylation has been 
summarised in figure 1.13. 
Modification by SUMO is a highly dynamic process where substrates 
undergo rapid SUMOylation and equally rapid deconjugation cycles (Hay, 2005). 
The highly labile nature of this modification is reflected in the co-localisation of 
the proteins involved in SUMO addition or removal. Additionally, requirement of 
ATP for activation of SUMO pathway may be a rate-limiting factor affecting 
steady state levels of SUMOylation. Another long-standing observation in the 
SUMO system is that only a small proportion of a particular substrate is post-
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translationally modified relative to the total pool of the protein in the cell. While 
this is true in most situations, proteins involved in the DNA repair process (such 
as PARP and PCNA) are thought to be SUMOylated to a greater degree. 
Furthermore, almost 100% of all cellular RanGAP1 is modified by SUMO1 in 
cells. Hence, these observations indicate that the concept of only 1% of a 
substrate being SUMOylated at a given point (Johnson, 2004) is probably not 
true, and needs to be validated experimentally. Nevertheless, even a small 
proportion of SUMOylated protein is still important as mutation of the 
SUMOylated lysine in substrates can have large functional defects. For 
example, a small pool of SUMOylated ELK1 is still fully able to repress 
transcription (Yang et al., 2003). In this case, it has been proposed that SUMO 
is required for initiation but not maintenance of repression. Accordingly, SUMO 
conjugation may promote recruitment of factors necessary to form a repressive 
complex. Once the complex is formed and the SUMOylated protein is locked in 
the complex, SUMO is no longer required and is removed by the action of 
SENP. This further raises the possibility that a previously SUMOylated protein 
molecule may have different properties compared to an identical protein 
molecule with no history of SUMOylation. This has been observed in the case of 
Thymine-DNA glycosylase (TDG), where SUMOylated TDG shows increased 
rate of enzymatic activity (Hardeland et al., 2002).  
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Figure 1.13 The SUMOylation pathway 
The mature form of SUMO is first activated by the formation of a thioester bond with the active 
site of the SUMO E1 enzyme, SAE1/2, in the presence of ATP. The activated SUMO is then 
passed to the active site of the SUMO E2 enzyme, Ubc9, which then catalyses transfer of 
SUMO to the target protein, often in the presence of an E3 SUMO ligase. SUMO can be 
conjugated to one or more lysine on the substrate in a number of ways. SUMO monomers or 
polymers can be cleaved by the action of SUMO proteases (SENP), releasing free SUMO which 
can undergo further rounds of conjugation to target proteins. 
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1.7.2 SUMO Recognition Motifs 
Generally, SUMO conjugation of substrates occurs on lysine residues 
present within a core consensus motif ψKxE/D, where ψ (psi) is a hydrophobic 
residue (usually I/V/L/F/M) and x is any amino acid (Rodriguez et al., 2001). 
However, not all proteins containing this motif are SUMOylated, and in some 
cases the modified lysine does not conform to the consensus motif. Therefore, 
additional residues surrounding the SUMO motif and/or other structural features 
guiding SUMO modification of a substrate have also been suggested. For 
example, some proteins such as p53 and IκBα require a nuclear localisation 
signal for efficient SUMO1 modification in cells (Rodriguez et al., 2001). Other 
proposed SUMO recognition motifs are described below.  
1. A patch of acidic residues present immediately downstream of the 
consensus SUMO-motif ψKxE/Dxx(E/D)4xxxx, termed NDSM (negatively 
charged amino acid-dependent SUMOylation motif), was suggested to 
enhance UBC9 binding to ELK1, thus promoting SUMOylation (Yang et al., 
2006).  
2. In some cases, phosphorylation of residues adjacent to the SUMO-motif 
was suggested to be required for SUMOylation. This motif ψKxE/DxxSP 
called PDSM (phosphorylation dependent SUMOylation motif) is present in 
many transcription factors such as heat-shock factor1 (HSF1), GATA1 and 
MEF2 (Hietakangas et al., 2006). 
3. The voltage gated potassium channel Kv 1.5 protein is SUMOylated at a 
Synergy control motif, characterised by the consensus sequence [P/G]-x-(0-
4)-ψKxE/D-x-(0-4)-[P/G] (Benson et al., 2007). 
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4. Recently, a mass-spectrometry-based proteomics study identified substrates 
containing an inverted SUMO-motif E/DxKψ, and another extended SUMO-
motif called hydrophobic cluster SUMOylation motif (HCSM). The HCSM 
motif consists of at least three hydrophobic amino acids preceding the 
SUMOylated lysine residue, and is involved in SUMOylation of proteins such 
as RanGAP1, BRD4 and ZBTB1 (Matic et al., 2010). 
 1.7.3 SAE1/SAE2 
The SUMO activating enzyme (SAE), or the SUMO E1 enzyme, is a 
heterodimer comprising two subunits SAE1 and SAE2 in human (Desterro et al., 
1999), or Aos1 and Ubs2 respectively in yeast (Johnson et al., 1997). 
Structurally, SAE1 resembles the N terminus, and SAE2 the C terminus of a 
ubiquitin E1 enzyme UBA1 (Gong et al., 1999). While both SAE1 and SAE2 
contain a nuclear localisation signal (NLS), only SAE2 contains the ubiquitin-like 
(UbL) domain that interacts with SUMO1 (Lois and Lima, 2005). Mechanistically, 
the SUMO E1 activates SUMO and transfers it to the SUMO E2 enzyme Ubc9. 
This is achieved in three steps. Firstly, SAE1/2 binds ATP and magnesium, and 
catalyses adenylation of the C-terminal di-glycine motif of SUMO1. This 
adenylated glycine in SUMO is then attacked by an active site cysteine (Cys173) 
present in SAE2 resulting in the release of AMP and formation of the SUMO E1-
SUMO thioester bond. Lastly, The charged E1 is then recruited to UBC9, where 
SUMO is transferred to the active cysteine (Cys93) of UBC9 (Olsen et al., 2010). 
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1.7.4 UBC9 or UBE2I 
The SUMO E2 enzyme, Ubc9, was first identified in S. cerevisae based 
on its sequence similarity with other known ubiquitin E2 enzymes, where it was 
shown to be critical for cell cycle progression (Seufert et al., 1995). Human 
UBC9 (or UBE2I) was discovered later in a yeast-two hybrid system using 
human RAD52 protein as “bait”. In the same study, UBC9 was found to interact 
with other proteins such as RAD51, p53 and SUMO1, suggesting a role in the 
DNA damage/repair pathway (Shen et al., 1996a). It was initially thought that 
Ubc9 conjugated ubiquitin, but it was later demonstrated that it was a SUMO 
specific, not ubiquitin, conjugating E2 enzyme (Desterro et al., 1997).  
Unlike the ubiquitin system where specific combinations of E2 and E3 
enzymes are required for substrate specificity and conjugation, the SUMO E2 
alone can recognise and modify substrates with SUMO in the absence of an E3 
SUMO ligase, at least in vitro (Gareau and Lima, 2010). Structural biology has 
provided mechanistic insights into the mechanism of this unique interaction 
between the substrate and the E2. The crystal structure of a charged UBC9 
(UBC9 conjugated to SUMO) in complex with its substrate showed that the 
residues in the SUMO consensus motif are directly recognised by and bound to 
UBC9, and the target lysine fits into a hydrophobic groove on UBC9 (Bernier-
Villamor et al., 2002; Lin et al., 2002). UBC9 also contains a patch of basic 
residues which can interact with the acidic residues present downstream of the 
core SUMO-motif, such as in negatively charged amino acid dependent 
SUMOylation motif (NDSM). Since most validated SUMO motifs are often 
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present in extended loops or unstructured domains of a substrate protein, this 
could be a crucial factor in determining the ability or the extent to which the 
substrate can be modified by SUMO.  
 
1.7.5 SUMO E3 ligases 
The SUMO E3 ligases can be broadly divided into following two classes: 
 
1.7.5.1 SP-RING containing E3 SUMO ligases 
So far, five functional E3 SUMO ligases containing the SP-RING 
(Siz/PIAS-RING) domain have been identified in humans. These include 
members of the Protein Inactivator of Activated STATs (PIAS) family (PIAS1, 
PIAS2/x, PIAS3 and PIAS4/y) and NSE2 (or MMS21). The PIAS family is 
described in detail in the next section. 
NSE2 is a dedicated and essential subunit of the human SMC5-SMC6 
DNA repair complex. Upon DNA damage, NSE2 stimulates SUMOylation of 
SMC6, which protects the cell from apoptosis, most likely by promoting 
homologous recombination (Potts and Yu, 2005). In addition, two novel PIAS-
like proteins containing the SP-RING domain, ZIMP7 and ZIMP10, have also 
been identified, but the SUMO E3 ligase activity of these proteins has not yet 
been explored in detail (Huang et al., 2005; Lee, Beliakoff and Sun, 2007). 
Both PIAS1 and PIAS3 were initially identified as potent repressors of the 
transcription factors STAT1 and STAT3 respectively, thus acting as negative 
regulators of JAK-STAT signalling pathway (Chung et al., 1997; Liu et al., 1998). 
Structurally, all PIAS proteins contain five distinct domains or motifs in the 
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following order: an N-terminal SAP (Scaffold attachment factor-A/B, Acinus and 
PIAS) domain, a PINIT motif, an SP-RING domain, a SIM (SUMO-Interaction 
Motif) and a serine/threonine rich C-terminal region. The SAP domain is 
responsible for binding A/T rich DNA sequences that are usually present near 
enhancer regions on the chromatin, and can also interact with proteins such as 
p53 (Okubo et al., 2004). The SAP domain also contains the typical nuclear 
receptor interacting motif LxxLL (where x is any amino acid and L is leucine) that 
mediates protein-protein interactions with nuclear receptors and transcriptional 
co-regulators (Heery et al., 1997). The PINIT motif, at least for PIAS3, is 
involved in its nuclear retention (Duval et al., 2003). Other studies suggest that it 
may be required for substrate specificity. In case of Siz1 (the yeast homologue 
of PIAS), the PINIT motif is required for binding and SUMO modification of the 
proliferating cell nuclear antigen (PCNA) (Yunus and Lima, 2009).  
The SP-RING domain of PIAS proteins is functionally similar to the RING 
(Really Interesting New Gene) domain present in E3 ubiquitin ligases. However, 
the SP-RING domain does not contain the two zinc-binding cysteine residues 
found in the canonical RING domain consensus sequence. Instead, other 
conserved residues present in the SP-RING domain coordinate to bind one Zn2+ 
ion. The SP-RING domain is crucial for the E3 ligase activity of PIAS proteins. 
Unlike the ubiquitin RING domain, they do not form thioester intermediates with 
SUMO, but simply acts as a scaffold, to bring a SUMO charged Ubc9 in close 
proximity to the target lysine on the substrate (Johnson and Gupta, 2001; Yunus 
and Lima, 2009).  
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The SIM motif is a cluster of hydrophobic residues composed of ψxψψ or 
ψψxψ (where ψ is I/V/L and x is any amino acid) followed by a patch of 
negatively charged residues, which interacts non-covalently with SUMO 
(Geoffroy and Hay, 2009). Although its exact function in the context of E3 ligase 
activity remains unclear, it is proposed that SIMs may promote interactions with 
other SUMO-conjugated proteins, and may direct PIAS proteins to specific sub-
cellular structures or complexes (Gareau and Lima, 2010). The C-terminal tail of 
PIAS (except PIASy) contains the serine/threonine rich region, and is the least 
conserved region amongst different PIAS family members. Their function is 
presently unknown. Figure 1.14 shows the structure of PIAS family of E3 SUMO 
ligases. 
 
1.7.5.2 Non-SP-RING containing E3 SUMO ligases 
Several other proteins in humans have been reported to have E3 SUMO 
ligase activity despite lacking any obvious similarity to other E3 ligases. Some 
examples include Ran-binding protein 2 (RanBP2), Polycomb protein 2 (PC2), 
and Histone deacetylases 4 and 7 (HDAC4, HDAC7) (Wilkinson and Henley, 
2010). Interestingly, some ubiquitin E3 ligases have also been shown to 
possess SUMO ligase activity, which include TOPORS, MDM2 and TRIM 
proteins (Weger et al., 2005; Chu and Yang, 2011; Stindt et al., 2011). 
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Figure 1.14 PIAS family of SUMO E3 ligases 
Schematic showing the conserved structural domains of the four PIAS family members (Adapted 
from Jentsch and Psakhye, 2013). SAP-Scaffold Attachment factor-A/B; Acinus and PIAS; 
PINIT- motif composed of proline, isoleucine, asparagine, isoleucine and threonine; SP-RING-
Siz/PIAS Really Interesting New Gene domain; SIM-SUMO Interaction Motif; S/T-
serine/threonine rich domain  
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1.7.6 SENP 
Sentrin specific proteases (or SENP) are a class of enzymes that perform 
two important functions in the SUMO pathway. Firstly, they are involved in the 
maturation of newly synthesised SUMO in cells, by cleaving their C-terminus to 
expose the di-glycine motif required for SUMO conjugation. Secondly, they 
catalyse removal of SUMO monomers and polymers from target substrate, thus 
maintaining the balance of global SUMOylation in cells. The high activity of 
SENP in cells makes detection of SUMOylated proteins very difficult in cell 
lysates. Humans express six SENP family members, designated SENP1-3 and 
SENP5-7 (Wilkinson and Henley, 2010). It should be noted that there is another 
SENP called SENP8 (or DEN1) in humans, but it acts on another ubiquitin-like 
protein NEDD8, instead of SUMO (Wu et al., 2003). 
The SENP family members can be broadly divided on the basis of their 
function, localisation and SUMO paralogue specificity. Interestingly, only 
SENP1, SENP2 and SENP5 are capable of processing SUMO precursors to 
active SUMO (Yeh, 2009). SENP1 and SENP2 are capable of deconjugating all 
three SUMO isoforms, and are localised to the nuclear pore complex and 
nucleoplasm. Both contain a nuclear localisation signal (NLS) and nuclear 
export signal (NES), which allows them to shuttle between the cytoplasm and 
the nucleus. Senp1 appears to be the main SUMO1 C-terminal hydrolase as 
Senp1 -/- embryos cannot process SUMO1 (Cheng et al., 2007). SENP3 and 
SENP5 are mostly localised to the nucleolus, and preferentially deconjugate 
SUMO2/3. SENP6 and SENP7 are localised in the nucleoplasm, and also prefer 
SUMO2/3 chains to SUMO1. In addition, SENP6 and SENP7 possess SUMO 
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chain editing activity, meaning they can remove individual SUMO moieties from 
the chain, without cleaving the whole chain (Hickey, Wilson and Hochstrasser, 
2012). 
More recently, two additional SUMO proteases were identified. These 
include DeSI1 and DeSI2 (Shin et al., 2012) and USPL1 (Schulz et al., 2012). 
DeSI1 and DeSI2 appear to be specifically deSUMOylate the transcriptional 
repressor BZEL. On the other hand, USPL1 is unique among SUMO proteases 
as it localise to cajal bodies in the nucleus, with preference for SUMO2/3. 
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1.7.7 SUMO targeted Ubiquitin ligases (STUbLs) 
SUMO and ubiquitin have been shown to target the same proteins with 
different outcomes, and were therefore considered functionally antagonistic. 
However, emerging evidence suggests that the two pathways are not completely 
distinct, but may function in cooperation, under certain contexts. The SUMO 
targeted ubiquitin ligase (or STUbL) links the SUMO pathway with the ubiquitin 
system. A STUbL is a RING-domain containing E3 ubiquitin ligase that has a 
strong binding affinity towards proteins that are polySUMOylated. Binding of 
STUbL to a polySUMOylated protein recruits a ubiquitin-charged E2 enzyme, 
leading to ubiquitination of the polySUMOylated protein, and subsequent 
degradation by the proteasome. An important feature of STUbL that 
distinguishes it from other E3 ubiquitin ligases is the presence of multiple 
functional SUMO-interaction motifs (SIMs), that mediates non-covalent 
interactions with polySUMO chains attached on proteins (Geoffroy and Hay, 
2009). Currently, only two functional STUbL, RNF4 (or SNURF) and RNF111 (or 
Arkadia) have been identified in humans, and described below. 
 
1.7.7.1 RNF4 
RNF4 was first discovered as a novel RING finger protein that interacted 
with androgen receptor (AR) and was shown to increase steroid receptor 
mediated gene transcription (Moilanen et al., 1998; Poukka et al., 2000). It was 
later shown to colocalise with SUMO1 in PML nuclear bodies (Häkli et al., 2005). 
The first evidence of RNF4 acting as a STUbL came from studies performed in 
yeast. Yeast lacking Slx8-Rfp (yeast homologue of RNF4) showed accumulation 
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of SUMOylated proteins and genomic instability, which could be reversed by 
expression of human RNF4 (Prudden et al., 2007). This led to the identification 
of PML as the first physiological substrate of RNF4 in human cells (Lallemand-
Breitenbach et al., 2008; Tatham et al., 2008). RNF4 contains four N-terminal 
SIM and a RING domain at the C-terminal (Figure 1.15A). 
Acute promyelocytic leukemia (APL) is a type of blood cancer 
characterised by the presence of the driving oncogenic fusion protein called 
PML-RARα.  The chemical, arsenic trioxide (As2O3) is used for the treatment of 
APL as it specifically induces degradation of the PML-RARα protein. It was 
found that arsenic induces polySUMOylation of PML on K160 residue (and also 
PML nuclear bodies) in cells, which recruits RNF4 leading to its ubiquitination 
and degradation (Lallemand-Breitenbach et al., 2008; Tatham et al., 2008). This 
is illustrated in figure 1.15. Interestingly, depletion of RNF4 in human cells 
caused an increase in levels of SUMOylated proteins suggesting that 
SUMOylation plays a bigger role in targeting proteins for ubiquitin-mediated 
proteolysis (Tatham et al., 2008).  
Apart from regulating PML, RNF4 also plays an important role in the DNA 
damage response. RNF4 mediates clearance of several SUMOylated proteins 
such as MDC1 during DNA damage, which facilitates DNA double strand break 
repair (Luo et al., 2012). RNF4 has also been shown to regulate transcriptional 
activity of PARP1 by mediating its degradation during heat-shock (Martin et al., 
2009), and of Hypoxia Inducible Factor 2α (HIF2α) during hypoxia and normoxia 
(van Hagen et al., 2009). This suggests a broader role of SUMOylation and 
RNF4 in regulating important cellular processes. A recent study showed that 
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Ubiquitin-specific protease 11 (or USP11) could counteract the effects of RNF4 
by deubuiquitinating ubiquitin-SUMO hybrid chains, upon DNA damage induced 
by methyl methanesulfonate (Hendriks et al., 2015). 
 
1.7.7.2 RNF111  
RNF111 was identified through a bioinformatic search of proteins that 
shared sequence homology with RNF4 (Sun and Hunter, 2012). Like RNF4, 
RNF111 can also trigger ubiquitination and degradation of SUMOylated PML in 
response to As2O3 (Erker et al., 2013) and requires the presence of all three 
SIM and RING domain (Figure 1.15B). Interestingly, a study showed that in the 
presence of the E2 UBC13-MMS2, RNF111 catalysed the formation of the non-
proteolytic K63 chains on SUMOylated Xeroderma Pigmentosum (XPC) protein 
(Poulsen et al., 2013). The association of RNF4 with UBC13 was not found in 
this study, which suggests that RNF111 is capable of interacting with a wider 
range of E2 enzymes than RNF4, which explains the formation of K63-linked 
chains by RNF111. It should be noted that RNF111 mediated ubiquitination of 
SnoN/Ski does not require the presence of SIMs, suggesting that it can also 
function as a SUMO-independent ubiquitin ligase (Erker et al., 2013).  
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Figure 1.15 SUMO targeted ubiquitin ligases 
(A) Schematic showing the SUMO targeted E3 ubiquitin ligases, RNF4 and RNF111 with their 
functional domains. RING (Really New Interesting Gene) recruits a ubiquitin loaded E2 enzyme 
to the SUMOylated protein. SIM (SUMO Interaction motif) is required for the recognition and 
binding of polySUMO chains on the target protein. (B) Arsenic trioxide induces formation of 
polySUMO chains on the promyelocytic leukemia (PML) protein. RNF4 binds to these SUMO 
chains and recruits a ubiquitin E2, and together they form polyubiquitin chains on PML, leading 
to its degradation by the proteasome. 
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1.8 Regulation of global SUMOylation by cellular stress  
Numerous stimuli have been reported to cause alteration in the global 
levels of SUMOylation, which is consistent with the role of SUMO in mediating a 
stress response. However, there is a significant increase in SUMO2/3 
conjugates rather than SUMO1 conjugates in cells upon heat shock (Saitoh and 
Hinchey, 2000). It is also important to emphasise that specific substrates are 
differentially SUMOylated under these conditions, as opposed to a general 
increase or decrease of all substrates. Although heat shock results in a global 
increase of SUMO modification in cells, SUMOylation of some substrates 
remains unchanged (eg. DNA Topoisomerases), while SUMOylation of some 
substrates is increased (eg. Heat shock proteins) (Golebiowski et al., 2009). 
Stress-dependent increase in conjugation of both SUMO1 and SUMO2/3 has 
also been observed under conditions of oxygen and glucose deprivation (or 
ischemia) in hippocampal neurons (Cimarosti and Henley, 2008). 
Reactive oxygen species such as hydrogen peroxide (H2O2) and nitric 
oxide (NO) are constantly produced during metabolic reactions in the human 
body, and also in response to external factors such as UV radiation and 
chemotherapeutic agents, resulting in oxidative stress in cells. While high levels 
of oxidative stress cause global hyperSUMOylation, low doses result in a global 
decrease of SUMO conjugation (Bossis and Melchior, 2006). Mechanistically, at 
low doses of H2O2, a disulphide bond is formed between UBA2 (E1) and UBC9 
(E2), which impairs the activity of both E1 and E2. Interestingly, SUMO 
isopeptidases are not affected unless exceedingly high concentrations of ROS 
are present (Bossis and Melchior, 2006). In contrast, NO induced oxidative 
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stress also results in hypoSUMOylation, but by a different mechanism, involving 
proteasomal degradation of the SUMO E3 ligase PIAS3 (Qu et al., 2007). 
Products of infectious pathogens also negatively affect SUMOylation. The 
adenoviral protein Gam1 causes proteasomal degradation of the SUMO E1 
enzyme, while the toxin Lysteriolysin O produced by Lysteria monocytogenes 
leads to proteasome-independent degradation of UBC9 (Boggio et al., 2004; 
Ribet et al., 2010). 
 
1.9 Regulation of SUMOylation by phosphorylation and acetylation 
 Regulation of SUMOylation is largely controlled at the substrate level by 
the concerted action of E3 ligases, SENP and the stimuli involved. Other PTMs 
such as phosphorylation, ubiquitination and acetylation also play an important in 
the regulation of SUMOylation. However, these effects are more substrate 
specific rather than a global change in SUMOylation. Some important examples 
have been discussed here. 
Phosphorylation of a substrate can also enhance or inhibit its 
SUMOylation. Upon DNA damage, PML gets phosphorylated by HIPK2 and 
other kinases, which further enhances PML SUMOylation (Gresko et al., 2009). 
Similarly, phosphorylation of the nuclear receptor TR2 in response to retinoic 
acid by ERK2 leads to its SUMOylation and association with PML bodies (Gupta 
et al., 2008). Furthermore, prior phosphorylation of MEF2 and HSF1 enhances 
their SUMOylation (Guo et al., 2007). Both MEF2 and HSF1 contain a 
phosphorylation dependent SUMO motif (PDSM), whereas the phosphorylation 
site in PML and TR2 does not lie within a PDSM. In PDSM, the additional 
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negative charge of the phosphate group enhances substrate and UBC9 binding, 
thus promoting SUMOylation (Hietakangas et al., 2006). In the latter case, it can 
be speculated that phosphorylation might lead to a change in cellular localisation 
and/or changes in protein structure, which favour SUMO modification of the 
substrate. On the other hand, phosphorylation of substrates can also inhibit 
SUMOylation, such as in the case of IκBα (Desterro et al., 1998), c-JUN/c-FOS 
(Bossis et al., 2005), p53 (Lin et al., 2004) and ELK1 (Yang et al., 2003).  
Another way of regulating SUMOylation is by competing for the same 
target lysine residue, such as in the case of SP3 and p300, where SUMOylation 
and acetylation have antagonistic effects on the substrate activity (Sapetschnig 
et al., 2002; Bouras et al., 2005). Recently, acetylation of some proteins such as 
Histone H3 was shown to promote SUMOylation, which has prompted the 
existence of a SUMO-acetylation dependent SUMO motif (Hendriks et al., 
2014). However, in this case acetylation and SUMOylation of the substrate 
occur at two different lysine residues. The functional consequence of H3 
SUMOylation remains unknown. 
Interestingly, SUMO itself can be acetylated at a key lysine residue 
(SUMO1 at K37, SUMO2 at K33 and SUMO3 at K32), which controls SUMO-
SIM interaction in a selective manner (Ullmann et al., 2012). SUMO chains on a 
substrate typically act as recognition or binding platforms for other proteins 
containing SIMs. These interactions are crucial in regulating a number of 
SUMO-associated functions such as targeting RanGAP1 to the nuclear pore 
complex, recruitment of PML into nuclear bodies and activation or repression of 
various transcription factors. While acetylation of SUMO does not seem to 
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impair binding of RanGAP1-SUMO1 to RanBP2, it negatively affects its 
interaction with PML, PIAS and DAXX proteins. This adds another layer of 
complexity to the regulation of substrate-specific SUMOylation. 
 
1.10 Crosstalk between SUMOylation and ubiquitination 
Lysine is a versatile amino acid as it is amenable to multiple PTMs such 
as ubiquitination, SUMOylation, methylation and acetylation among many 
others. This section highlights scenarios in which SUMO and ubiquitin target the 
same residue, but have antagonistic effects.  
 The first evidence showing that ubiquitin and SUMO compete for the 
same acceptor lysine residue for modification in proteins came from studies 
performed on Inhibitor of NF-κB α (or IκBα). Nuclear factor κB (or NF-κB) is a 
group of transcription factors involved in growth factor signalling and cell 
survival. Under steady state, NF-κB is bound to its negative regulator IκBα, 
which sequesters it into the cytoplasm. In response to cytokines or DNA 
damage, Ser32/36 phosphorylated IκBα is ubiquitinated on K21 and is rapidly 
degraded. This allows NF-κB to translocate to the nucleus and activate 
transcription of NF-κB target genes. It was shown that IκBα is also SUMOylated 
on K21, which blocks its ubiquitination, stabilises IκBα and represses NF-κB 
(Desterro et al., 1998). Moreover, activation of IκB kinase (IKK) is achieved 
through the sequential modification of its regulatory subunit NEMO (NF-κB 
essential modulator) by SUMO and ubiquitin. SUMOylation of NEMO at K277 
and K309 results in its nuclear accumulation, where upon DNA damage it is 
phosphorylated by ATM. This phosphorylation allows modification of K277 and 
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K309 by ubiquitin, which allows it to translocate to the cytoplasm and associate 
with other IKK subunit forming an active kinase (Huang et al., 2003).  
 Another example where SUMO and ubiquitin target the same lysine 
residue is yeast PCNA (Proliferating Cell Nuclear Antigen). PCNA acts a sliding 
clamp, and a processivity factor for DNA polymerases, and other proteins 
involved in DNA replication and repair (Ulrich, 2009). Since PCNA is a homo-
trimer, individual subunits can be modified simultaneously by SUMO and 
ubiquitin. Yeast PCNA is SUMOylated at K164 during the S-phase, which 
recruits the helicase Srs2. This prevents homologous recombination during DNA 
replication. During DNA damage, K164 can be monoubiquitinated or 
polyubiquitinated at K164. Monoubiquitinated PCNA triggers an error-prone 
DNA repair process called translation synthesis, by recruiting the DNA 
Polymerases Polη and Rev1. Interestingly, the monoubiquitination on PCNA can 
be extended to form a K63-linked polyubiquitin chain, which activates an error-
free repair pathway (Denuc and Marfany, 2010). Thus, the same lysine can be 
modified in three different ways leading to distinct outcomes.  
 
1.11 Consequences of SUMOylation 
The functional consequences of SUMOylation depend entirely on the 
target protein and its associated cellular process, and are thus difficult to predict 
or generalise. However, consequences of SUMOylation at the molecular levels 
can be broadly divided into three main categories, and illustrated in figure 1.16 
(Everett et al., 2013).  
First, the covalent attachment of SUMO to the substrate may lead to 
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conformational or structural changes in the target protein, directly modifying its 
function. This has been seen in the case of Thymine DNA glycosylase (TDG). 
The function of TDG is to recognise and remove mismatched base pairs. 
SUMOylation of TDG at the C-terminus induces a conformation change of its N-
terminus, which reduces it DNA binding ability without affecting the catalytic 
activity. This results in dissociation of TDG from the DNA, allowing the next 
cycle of base excision repair to take place (Hardeland et al., 2002; Steinacher 
and Schär, 2005). 
Second, SUMOylation may block a binding site for another protein on the 
substrate, which can lead to decrease in protein activity. For example, 
SUMOylation of the ubiquitin conjugating enzyme E2-25k blocks its interaction 
with E1 ubiquitin enzyme, leading to decrease in its ability to conjugate ubiquitin 
to target proteins (Pichler et al., 2005). Similar observation has also been made 
in the Mitogen activated protein kinase (MAPK) pathway, where the MEK 
specific E3 ligase, MEKK1, promotes SUMOylation of MEK1/2. MEK1/2 
SUMOylation hinders its interaction with a downstream kinase called ERK1/2, 
preventing ERK1/2 phosphorylation and activation of the MAPK pathway 
(Kubota et al., 2011). 
Third, the covalently attached SUMOylation may promote formation of 
protein complexes by recruiting proteins that interact directly with the substrate 
or through non-covalent SUMO binding. The classical example is the nuclear 
protein RanGAP1. Unmodified RanGAP1 is localised to the cytoplasm, whereas 
SUMOylated RanGAP1 is localised to the nuclear pore. The localisation is 
strictly SUMO dependent as it promotes the interaction of RanGAP1 with the 
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nuclear pore associated protein RanBP2 (Mahajan et al., 1997). SUMOylation 
also regulates assembly of complexes involved in DNA methylation (or 
silencing) by covalently modifying Methyl-CpG binding domain protein MBD1. 
SUMOylation of MBD1 promotes the formation of heterochromatin foci by 
recruiting MCAF1 and HP1 by non-covalent SUMO-SIM interaction (Uchimura et 
al., 2006). 
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Figure 1.16 Consequences of SUMOylation on the target protein 
SUMOylation can affect the substrate protein in many ways. Different kinds of post-translational 
modifications (PTM) occurring on the same lysine such as ubiquitination, acetylation (Ac) or 
methylation (Me) can have distinct functional consequences on the substrate. SUMO might 
compete with these PTM, and hence affect the function of the protein. SUMOylation can 
interfere with protein-protein interactions by masking binding sites for other proteins. It can also 
create novel binding platforms that promote interaction with other proteins in a SUMO-
dependent manner. SUMOylation can also induce a change in conformation of the substrate 
protein, altering its activity (Adapted from Everett et al., 2013) 
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1.12 Aims of the project 
Oncogenic proteins, particularly kinases, which promote survival and 
proliferation of cancer cells, have remained sought after drug targets. While 
many inhibitors such as Imatinib (an inhibitor of BCR-ABL fusion protein in CML) 
and Vemurafenib (an inhibitor of V600E mutant of B-RAF in melanomas) have 
been approved for use in the clinic, resistance remains a major obstacle. PIM 
kinases have been found to play a role in the development of resistance to 
various forms of cancer therapy, and as mentioned previously various small 
molecule inhibitors are currently undergoing clinical trials. Unfortunately, the first 
two PIM kinase inhibitors, SGI-1776 and AZD1208, to enter Phase-I clinical 
trials failed due to cardiotoxicity. So, presently there are no clinically approved 
PIM kinase inhibitors on the market.  
Considerable research has been conducted on identifying targets of PIM1 
kinase, and studying the effects of PIM1 inhibition in preclinical settings, but 
there is very little information on how PIM1 protein itself is regulated in normal or 
cancer cells. This can prove to be a drawback in realising the complete potential 
of existing drugs, and can have a significant impact on how PIM kinase inhibitors 
work or can be improved in terms of efficacy or sensitivity. In the present study, I 
wished to fill in the crucial gaps in our understanding of PIM1, and so the 
research aims were  
- To identify mechanism(s) that regulate or control PIM1 levels in cells 
- To identify novel therapeutic or alternative strategies to target PIM1 in 
cancer 
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CXR Biosciences, a Dundee based small biotech company, identified a 
novel inhibitor of PIM kinases named CXR1002, which also underwent Phase I 
clinical trial (Personal communication). However, the IC50 values of this drug in 
cell lines is in high micromolar range, and so this project was set up, in 
collaboration, to identify strategies to improve the sensitivity of CXR1002 (or 
other PIM kinase inhibitors) by modulating cross-talking pathways. At the 
beginning of my PhD, I attempted to validate CXR1002 as a PIM kinase 
inhibitor, however, with time the focus of the project shifted from CXR1002 to 
studying mechanisms regulating PIM1. Therefore, results of the CXR1002 study 
have been presented in appendix, as they do not directly relate to the main topic 
of this thesis. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Chapter 2 
 
Materials & Methods 
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2.1 Reagents and buffers 
2.1.1 Stock solutions 
All chemicals were purchased from Sigma, and dissolved in autoclaved Milli-Q 
water, unless stated otherwise.  
Chemical Concentration  
Tris buffer (pH 7.5, 8, 8.5) 1 M 
Sodium chloride (NaCl) 5 M 
Ethylenediaminetetraacetic acid (EDTA) pH 8 0.5 M 
Magnesium chloride (MgCl2) 1 M 
Dithiothreitol (DTT) 1 M 
Ammonium persulfate (APS) 10% (w/v) 
Sodium dodecyl sulfate (SDS) 10% (w/v) 
Tris buffer pH 6.8 1.25 M 
Tris buffer pH 8.8 1.25 M 
Potassium chloride (KCl) 3 M 
Ampicillin 100 mg/ml 
KanaMYCin 50 mg/ml 
Chloramphenicol 34 mg/ml in ethanol 
Doxycycline hyclate 1 mg/ml 
Polybrene 10 mg/ml in PBS 
HygroMYCin B Readymade 
(Thermo Fisher Scientific)  
50 mg/ml  
Triton X-100 10% (v/v) 
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Puromycin Readymade  
(Thermo Fisher Scientific) 
10 mg/ml  
Cycloheximide 100 mg/ml Dimethyl 
sulfoxide (DMSO) 
Calcium chloride (CaCl2.2H2O) 1 M 
Morpholinepropanesulfonic acid (MOPS) pH 6.8 0.5 M 
Manganese chloride (MnCl2.4H2O) 1 M 
Potassium acetate (CH3COOK) pH 7.5 1 M 
Sodium hydroxide (NaOH) 5 M 
Imidazole 1 M 
Protease inhibitors EDTA-free (Roche) 25X 
Phosphatase inhibitor (Roche) 10X 
Adenosine triphosphate (ATP) 20 mM 
Sodium dihydrogen phosphate 
(NaH2PO4.2H2O) 
1 M 
Disodium hydrogen phosphate 
(Na2HPO4.2H2O) 
1 M 
Luminol 90 mM in DMSO 
p-Coumaric acid 250 mM in DMSO 
Hydrogen peroxide (H2O2) Readymade 30%  
Isopropyl β-D-1-thiogalactopyranoside (IPTG) 1M 
MG132 (Selleckchem) 100 mM in DMSO 
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2.1.2 Buffers 
Bacterial culture 
Luria Broth (LB) broth 
10 g LB mix per 400 ml water  
(1% w/v Bacto-tryptone, 0.5% w/v Bacto-yeast extract, 171 mM NaCl) 
 
LB agar 
9.25 g per 250 ml water (same as LB broth plus 1.5% w/v Bacto agar) 
 
Transformation Buffer-1 
10 mM CaCl2.2H2O 
15% (v/v) Glycerol 
30 mM CH3COOK pH 7.5 
50 mM MnCl2.4H2O 
100 mM RbCl 
pH adjusted to 5.8 using 0.2 M acetic acid 
 
Transformation Buffer-2 
75 mM CaCl2.2H2O 
0.15% (v/v) Glycerol 
10 mM MOPS pH 6.8 
10 mM RbCl 
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Western Blotting 
10X Tris buffered saline (TBS) 
200 mM Tris 
1.368 M NaCl – final pH adjusted to 7.6 
 
1X TBS-Tween (TBST) 
1 part 10X TBS 
9 parts water 
0.1% (v/v) Tween-20 
 
Blocking buffer 
5% (w/v) non-fat dry milk (Marvel) in 1X TBST 
 
Antibody dilution buffer 
5% (w/v) milk/TBST or 5% (w/v) Bovine Serum Albumin (BSA)/TBST 
 
Enhanced Chemiluminescence (ECL) Solution-1 
2.5 mM Luminol 
396 µM p-Coumaric acid 
100 mM Tris pH 8.5 
 
ECL Solution-2 
0.0192% (v/v) Hydrogen peroxide 
100 mM Tris pH 8.5 
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10X SDS-Polyacrylamide gel electrophoresis (PAGE) Running buffer 
250 mM Tris base 
1.92 M Glycine 
34.67 mM SDS 
 
10X Wet-Transfer buffer  
250 mM Tris base 
1.92 M Glycine 
 
1X Transfer buffer 
1 part 10X transfer buffer 
7 parts water 
2 parts methanol 
 
2X SDS sample buffer 
125 mM Tris-HCl (pH 6.8) 
20% (v/v) glycerol 
4% (w/v) SDS  
0.04% (v/v) Bromophenol blue 
 
Ponceau S solution 
0.1% (w/v) Ponceau S 
5% Acetic acid 
 
! 77!
Gel staining 
Coomassie stain 
0.2% (w/v) Coomassie Brilliant Blue R250 
50% (v/v) ethanol  
10% (v/v) acetic acid  
 
Destainer-I 
40% (v/v) ethanol 
7% (v/v) acetic acid 
 
Destainer-II 
10% (v/v) ethanol 
7% (v/v) acetic acid  
 
Agarose Gel Electrophoresis 
1% Agarose Gel 
1 g Agarose in 100 ml 1X Tris acetate EDTA (TAE) 
 
Agarose Gel Running Buffer (50X TAE) 
2 M Tris acetate 
0.05 M EDTA 
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Ni2+-NTA Pulldown 
2X Sodium phosphate buffer pH 8 
47.35 ml - 200 mM Na2HPO4.2H20  
2.65 ml - 200 mM NaH2PO4.2H2O 
 
2X Sodium phosphate buffer pH 6.3 
11.25 ml - 200 mM Na2HPO4.2H20  
38.75 ml - 200 mM NaH2PO4.2H2O 
 
Denaturing lysis buffer (pH 8) 
6 M Guanidium-HCl 
10 mM Tris-HCl (pH 8) 
100 mM sodium phosphate buffer (pH 8) 
5 mM Imidazole 
5 mM β-mercaptoethanol (β-ME) 
 
Lysis buffer wash (pH 8) 
6 M Guanidium-HCl 
10 mM Tris-HCl (pH 8) 
100 mM sodium phosphate buffer (pH 8) 
5 mM β-mercaptoethanol 
0.1% (v/v) Triton X-100 
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Urea wash buffer (pH 8) 
8 M Urea 
10 mM Tris-HCl (pH 8) 
100 mM sodium phosphate buffer (pH 8) 
5 mM β-mercaptoethanol 
0.1% (v/v) Triton X-100 
 
Urea Wash Buffer (pH 6.3) 
8 M Urea 
10 mM Tris-HCl (pH 8) 
100 mM sodium phosphate buffer (pH 6.3) 
5 mM β-mercaptoethanol 
0.1% (v/v) Triton X-100 
 
Ni2+-NTA Elution buffer 
200 mM Imidazole 
5% (w/v) SDS 
150 mM Tris-HCl (pH 6.7) 
30% (v/v) glycerol 
720 mM β-mercaptoethanol 
0.0025% (v/v) Bromophenol blue 
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6XHis Protein purification 
Wash buffer 
50 mM Tris pH 7.5 
500 mM NaCl 
20 mM Imidazole 
 
Elution buffer 
50 mM Tris pH 7.5 
500 mM NaCl 
1 mM DTT 
200 mM Imidazole 
 
Dialysis buffer 
50 mM Tris pH 7.5 
500 mM NaCl 
1 mM DTT 
 
Immunofluorescence (IF) 
Blocking buffer/Antibody dilution buffer 
5% (w/v) BSA  
0.1% (v/v) Triton 
1X TBS 
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Fixation buffer 
4% (w/v) p-formaldehyde in 1X PBS 
 
Wash buffer 
1X PBS or 1X TBS 
 
Permeabilisation Buffer 
0.1% (v/v) Triton 
1X PBS 
 
Other buffers 
Co-immunoprecipitation buffer 
50 mM Tris-HCl pH7.5           
150 mM NaCl                            
1% (v/v) NP-40 (Igepal)                   
Protease Inhibitors (EDTA free)  
Phosphatase inhibitors  
 
Cytoplasmic extraction buffer 
50 mM Tris-HCl pH 7.5 
10 mM KCl 
5 mM MgCl2 
0.5% (v/v) NP40 (Igepal) 
1 mM DTT 
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Protease inhibitor (EDTA-free) 
Phosphatase inhibitors 
 
Cell freezing buffer 
90% Fetal Bovine Serum (FBS) 
10% Dimethyl sulfoxide (DMSO) 
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2.1.3 Antibodies 
2.1.3.1 Primary antibodies 
Antibody Species Company  
(Cat. No.) 
Dilution for 
Western blot (WB) 
PIM1 (12H8) Mouse 
monoclonal 
Santa Cruz 
(sc-13513) 
1:200 (endogenous)  
1:1000 (transfected) 
1:50 (for IF) 
PIM1 Rabbit 
polyclonal 
Bethyl 
(A300-313) 
1:1000 
ACTIN Mouse 
monoclonal 
Abcam 
(ab-6276) 
1:10,000 
ACTIN Rabbit  
polyclonal 
Sigma  
(A2066) 
1:10,000 
GAPDH Mouse 
monoclonal 
Sigma  
(G8795) 
1:10,000 
GFP Rabbit 
polyclonal 
Santa Cruz 
(sc-8334) 
1:800 
MYC tag (9E10) Mouse 
monoclonal 
In-house 
(hybridoma) 
1:3 
HA tag (12CA5) 
 
Mouse  
monoclonal 
Sigma 1:1000 
FLAG tag M2 
 
Mouse 
monoclonal 
Sigma 
(F1804) 
1:1000 
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His tag Mouse 
monoclonal 
GE Healthcare 
(27471001) 
1:5000 
GST tag Rabbit 
polyclonal 
Santa Cruz 
(sc-459) 
1:1000 
Phospho Ser62 
c-MYC 
Rabbit 
monoclonal 
Cell Signalling 
(13748) 
1:1000 
Total c-MYC Rabbit 
monoclonal 
Cell Signalling 
(5605) 
1:1000 
Phospho Ser10 
Histone H3 
Rabbit 
polyclonal 
Millipore 
(06-570) 
1:1000 
Total Histone H3 Rabbit 
monoclonal 
Cell Signalling 
(4499) 
1:1000 
Phospho Ser112  
BAD 
Rabbit 
monoclonal 
Cell Signalling 
(5284) 
1:1000 
Total BAD Rabbit 
monoclonal 
Cell Signalling 
(9239) 
1:1000 
Phospho Thr37/46 
4E-BP1 
Rabbit 
monoclonal 
Cell Signalling 
(2855) 
1:1000 
Total 4E-BP1 Rabbit 
monoclonal 
Cell Signalling 
(9644) 
1:1000 
Phospho Thr389 
p70 S6 Kinase 
Rabbit 
monoclonal 
Cell Signalling 
(108D2) 
1:1000 
Total p70  Rabbit Cell Signalling 1:1000 
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S6 Kinase monoclonal (49D7) 
Ubiquitin Mouse 
monoclonal 
Cell Signalling 
(3936) 
1:1000 
SUMO2 Rabbit 
polyclonal 
Thermo Fisher 
Scientific 
(51-9100) 
1:1000 
 
UBC9 Sheep 
polyclonal 
Ron Hay Lab, 
Dundee 
1:1000 
RNF4 Chicken  
polyclonal 
Ron Hay Lab, 
Dundee 
1:1000 
Phospho Ser473 
Akt 
Rabbit 
Monoclonal 
Cell Signalling 
(D9E) 
1:1000 
Total AKT Mouse 
monoclonal 
Cell Signalling 
(40D4) 
1:1000 
Total ERK1/2 Mouse 
monoclonal 
Transduction Lab 
(ER16) 
1:1000 
Phospho Thr202/204 
ERK1/2 
Mouse 
monoclonal 
Cell Signalling 
(9106) 
1:1000 
MDM2 
(SMP14+4B2) 
Mouse 
monoclonal 
Moravian Biotech 1:1000 (SMP14)+ 
1:2000 (4B2) 
Phospho-Tyrosine Mouse 
monoclonal 
Cell Signalling 
(9411) 
1:1000 
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2.1.3.2 Secondary antibodies 
Secondary antibody Company Dilution  
HRP-anti mouse Biorad 1:2000 for WB 
HRP-anti rabbit Biorad 1:2000 for WB 
HRP-anti sheep Jackson ImmunoResearch 1:10,000 for 
WB 
HRP-anti chicken Jackson ImmunoResearch 1:10,000 for 
WB 
Anti-mouse 
Alexa Fluor 488  
Thermo Fisher Scientific 1:1000 for IF 
Anti-mouse 
Alexa Fluor 568 
Thermo Fisher Scientific 1:1000 for IF 
Anti-rabbit 
Alexa Fluor 488 
Thermo Fisher Scientific 1:1000 for IF 
Anti-rabbit 
Alexa Fluor 568 
Thermo Fisher Scientific 1:1000 for IF 
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2.1.4 siRNA 
A SMART-pool consisting of 4 individual siRNAs was purchased from 
Dharmacon at 5 nM pack size. Upon receipt, the siRNA was resuspended in 250 
µl of sterile Nuclease-free water (Thermo Fisher Scientific) to get a stock 
concentration of 20 µM. It was then aliquoted (to reduce the number of freeze-
thaw cycles) and stored at -80 0C for long-term storage. 
 
Target protein Oligo name  siRNA sequence (5’-3’) 
Non-targeting 
control 
siNT Pool of 4 siRNAs 
UGGUUUACAUGUCGACUAA 
UGGUUUACAUGUUGUGUGA 
UGGUUUACAUGUUUUCUGA 
UGGUUUACAUGUUUUCCUA 
Human PIM1  siPIM1  Pool of 4 siRNAs 
GAUGGGACCCGAGUGUAUA 
GAUAUGGUGUGUGGAGAUA 
UCGAGAGGCCCGACAGUUU 
GGGGAGAGCUGCCUAAUGG 
Human UBC9 
(UBE2I) 
siUBC9 Pool of 4 siRNAs 
GGGAAGGAGGCUUGUUUAA 
GAAGUUUGCGCCCUCAUAA 
GGCCAGCCAUCACAAUCAA 
GAACCACCAUUAUUUCACC 
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Human RNF4 siRNF4 Pool of 4 siRNAs 
GCUAAUACUUGCCCAACUU 
GAAUGGACGUCUCAUCGUU 
GACAGAGACGUAUAUGUGA 
GCAAUAAAUUCUAGACAAG 
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2.1.5 Plasmids 
Description Vector Lab No. Source 
MDM2 WT 
 
pCMV 
 
1127 
 
Published 
(Hogan et al., 2008) 
PIM1 cDNA pOTB7 1347 Geneservice Ltd. UK 
PIM1 cDNA pCR2.1 1350 Meek Lab stock 
GST-PIM1 WT 
 
pGEX-4T-1 
 
1352 
 
Published 
(Hogan et al., 2008) 
PIM1 WT 
 
pSG5-MYC tag 
 
1354 
 
Published  
(Hogan et al., 2008) 
PIM1 K67M 
(kinase dead) 
pSG5-MYC tag 
 
1359 
 
Published 
(Hogan et al., 2008) 
PIM1 K5R pSG5-MYC tag 1692 Mutagenesis of 1354 
PIM1 K24R pSG5-MYC tag 1693 Mutagenesis of 1354 
PIM1 K29, 31R pSG5-MYC tag 1676 Mutagenesis of 1354 
PIM1 K67R pSG5-MYC tag 1694 Mutagenesis of 1354 
PIM1 K71R pSG5-MYC tag 1677 Mutagenesis of 1354 
PIM1 K94, 95R pSG5-MYC tag 1657 Mutagenesis of 1354 
PIM1 K169R pSG5-MYC tag 1645 Mutagenesis of 1354 
PIM1 E171Q pSG5-MYC tag 1748 Mutagenesis of 1354 
PIM1 K183R pSG5-MYC tag 1678 Mutagenesis of 1354 
PIM1 E181A pSG5-MYC tag 1679 Mutagenesis of 1354 
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PIM1 K194R pSG5-MYC tag 1655 Mutagenesis of 1354 
PIM1 K313R pSG5-MYC tag 1695 Mutagenesis of 1354 
6Xhis-SUMO1 
 
pcDNA3 
 
1681 
 
Published  
(Jacobs et al., 2007) 
6Xhis-SUMO2 
 
pcDNA3 
 
1682 
 
Published 
(Jacobs et al., 2007) 
6Xhis-SUMO3 
 
pcDNA3 
 
1648 
 
Published 
(Jacobs et al., 2007) 
6Xhis-Ubiquitin 
 
pcDNA3 
 
1432 
 
Published 
(Hogan et al., 2008) 
HA-UBC9 pcDNA3 1680 R. Hay Lab, Dundee 
YFP-PIM1 WT pEYFP-C1 1675 Cloning 
YFP-PIM1 WT pcDNA5/FRT/TO 1715 Cloning 
YFP-K169R pcDNA5/FRT/TO 1724 Mutagenesis and cloning 
YFP-E171A pcDNA5/FRT/TO 1725 Mutagenesis and cloning 
YFP-K67M pcDNA5/FRT/TO 1726 Mutagenesis and cloning 
YFP alone pcDNA5/FRT/TO 1728 Mutagenesis and cloning 
Flp recombinase pOG44 1714 A. Saurin Lab, Dundee 
HA-PIAS1 
 
pKW2T 
 
1651 
 
Published 
(Jacobs et al., 2007) 
Flag-PIAS3 
 
pCMV 
 
1649 
 
Published 
(Jacobs et al., 2007) 
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HA-PIASy 
 
pKW2T 
 
1652 
 
Published 
(Jacobs et al., 2007) 
Flag-RNF4 (rat) 
 
pcDNA3 
 
1706 
 
Published 
(Tatham et al., 2008) 
Flag-RNF4 (rat) 
mSIM 
pcDNA3 
 
1707 
 
Published 
(Tatham et al., 2008) 
Flag-RNF4 (rat) 
mRING 
pcDNA3 
 
1708 
 
Published 
(Tatham et al., 2008) 
Flag-SENP1 WT pcDNA3 1698 de la Vega Lab, Dundee 
Flag-SENP1 MT pcDNA3 1699 de la Vega Lab, Dundee 
6Xhis-PIM1 WT pcDNA3 1730 Cloning 
PIM1 pBABE-puro 1755 Cloning 
K169R pBABE-puro 1760 Mutagenesis of 1755 
E171A pBABE-puro 1761 Mutagenesis of 1755 
K67M pBABE-puro 1762 Mutagenesis of 1755 
6Xhis-PIM1 pHAT2 1754 Cloning 
6Xhis-K169R pHAT2 1756 Mutagenesis of 1754 
6Xhis-E171A pHAT2 1757 Mutagenesis of 1754 
6Xhis-K67M pHAT2 1758 Mutagenesis of 1754 
6Xhis-E171Q pHAT2 1759 Mutagenesis of 1754 
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2.2 DNA manipulation and analysis 
2.2.1 Preparation of competent cells 
A 5 ml overnight culture was set up using a previous stock of competent 
Escherichia coli (E. coli) cells in LB. No antibiotics were used for preparation of 
competent DH5α cells. However, chloramphenicol was added at 34 µg/ml for 
preparation of competent Rosetta2 (DE3) pLys cells. The following day, 200 ml 
LB was inoculated with 1 ml from overnight culture and cultured in a 37 0C 
incubator-shaker until optical density (OD) at 600 nm reached 0.3-0.4. The 
culture was split into four 50 ml tubes and incubated on ice for 30 min. Cells 
were pelleted by centrifugation at 2000 xg for 5 min at 4 0C. The pellets were 
resuspended in 16 ml of Transformation buffer-1 per 50 ml of original culture 
and incubated on ice for 15 min. The cells were pelleted again as before and 
resuspended in 4 ml of Transformation buffer-2 per 50 ml of original culture. The 
cells were finally aliquoted in desired amounts and stored at -80 0C until use. 
 
2.2.2 Transformation of plasmid DNA into competent cells 
Transformation of competent E. coli cells was carried out by mixing 50-
100 µl competent cells with 10-100 ng plasmid DNA or 10 µl ligation mix. The 
transformation reaction was incubated on ice for 20 min followed by heat shock 
at 42 0C for 30 seconds. The tube was quickly returned on ice for 2 min. SOC 
media (Thermo Fisher Scientific, 500 µl) was added immediately to the reaction 
mix, and the tube further incubated for 1 hour at 37 0C with gentle agitation. The 
transformation mix (50 µl) was spread evenly over an LB plate with the 
appropriate antibiotic and incubated overnight at 37 0C.  
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2.2.3 Plasmid Miniprep 
Three to six random individual bacterial colonies from the plate were 
screened for the plasmid of interest by inoculating a mini-culture (5 ml LB 
supplemented with antibiotics) and incubating it overnight. Next day, 1.5 ml of 
overnight culture was transferred to fresh eppendorf tubes and centrifuged at 
12,000 xg for 2 min at RT.  The plasmid DNA was then purified using the 
QIAprep Miniprep Kit (Qiagen) according to manufacturer’s instructions and 
reagents supplied in the kit. 
The bacterial pellet was first resuspended in Buffer P1 (250 µl) followed 
by addition of Buffer P2 (250 µl). After 5 min incubation at RT, Buffer N3 (350 µl) 
was added, and centrifuged at 12,000 xg for 10 min at RT. The supernatant was 
carefully removed and applied to QIAprep spin column (provided with the kit) 
and centrifuged for 1 min at 12,000 xg at RT. The column was washed 
successively by adding Buffer PB (500 µl) and Buffer PE (750 µl). The QIAprep 
column was placed in a fresh eppendorf tube. The DNA was eluted by adding 50 
µl of sterile water to the centre of the column, and centrifuging it for 1 min at 
12,000 xg. Positive colonies were then identified on the basis of plasmid size by 
agarose gel electrophoresis and DNA sequencing. An overnight culture (500 ml) 
of the positive colony was set up and a bacterial glycerol stock was obtained for 
future use.  
 
2.2.4 Plasmid Maxiprep 
Large-scale purification of plasmid DNA was done using PureLink HiPure 
Plasmid Maxiprep kit (Thermo Fisher Scientific) according to manufacturer’s 
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instructions and reagents supplied in the kit. An overnight culture of E. coli (500 
ml) was first centrifuged at 4000 xg (Jouan CR412 centrifuge) for 10 min at RT, 
and the pellet was resuspended in Resuspension Buffer (10 ml). The cell 
suspension was transferred to a 50 ml centrifuge tube followed by addition of 
Lysis Buffer (10 ml) and incubated for 5 min at RT. Precipitation Buffer (10 ml) 
was added immediately to the cell suspension, gently mixed and centrifuged at 
15,000 xg (Eppendorf Centrifuge 5804 R) for 10 min at RT. The supernatant 
was then carefully loaded onto an equilibrated column and allowed to drain by 
gravity flow to allow binding of the DNA to the column. The column was then 
washed with Wash Buffer (60 ml) and a sterile 30 ml centrifuge tube was placed 
under the column after the column was completely drained. Elution buffer (15 
ml) was added to the column to elute the DNA, followed by the addition of 
isopropanol (10.5 ml) to the eluted DNA. The elution tube was centrifuged at 
15,000 xg for 30 min at 4 0C and the pellet was resuspended in 70% ethanol (5 
ml), centrifuged again at 15,000 xg for 5 min at 4 0C. The pellet was then air-
dried for 10-15 min and resuspended in 500 µl sterile water.  The concentration 
of isolated DNA was determined by measuring its absorbance at 260 nm using 
Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific). The DNA was 
diluted with sterile water to a final concentration of 1 µg/µl and stored at -200C 
until further use. 
 
2.2.5 Colony PCR 
The colony PCR method was used for screening large number of 
colonies when the miniprep method failed to identify positive bacterial colonies. 
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A PCR master mix (220 µl) for 10 reactions was prepared consisting of 2 µl of 
forward primer (10  µM), 2 µl of reverse primer (10  µM), 4 µl dNTPs (25 mM), 
40 µl of 5X Taq Polymerase Buffer (Promega), 6 µl of MgCl2 (25 mM, Promega), 
164 µl of sterile water and 2 µl of Taq DNA polymerase (5U/µl, Promega). 20 µl 
of master mix was aliquoted out into 10 sterile labelled PCR tubes. A single 
bacterial colony was carefully picked from the plate was subsequently dipped 
into the PCR mix and subjected to DNA amplification reaction in a thermal cycler 
using the conditions described below. The bacterial colonies were 
simultaneously streaked on an ampicillin plate and incubated overnight at 37 0C. 
The positive colony was identified by agarose gel electrophoreses of the 
samples on a 1% agarose gel. A large-scale culture (500 ml) of the positive 
colony from the ampicillin plate was eventually set up and DNA purified as 
previously described. 
 
PCR setup 
1. Initial Denaturation at 94 0C for 5 min 
2. Denaturation at 94 0C for 30 seconds  
3. Annealing at 60 0C  
4. Extension at 72 0C for 2 min 
5. Final Extension at 72 0C for 10 min 
 
2.2.6 Agarose gel electrophoresis and PCR purification 
An aliquot of PCR or plasmid DNA was run on a 1% agarose gel (with 0.5 
µg/ml ethidium bromide) alongside a DNA ladder (Fermentas Generuler) as a 
30 cycles 
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reference at 120 V for 40-50 min in 1X TAE running buffer, and viewed under a 
UV-transilluminator. The amplified product was subsequently purified using 
QIAquick PCR Purification kit (Qiagen) using reagents supplied in the kit. Five 
volumes of Buffer PB was added to one volume of the PCR sample, mixed and 
applied to the QIAquick spin column. To bind DNA, the column was centrifuged 
at 16,000 xg for 1 min and the flow through was discarded. The column was 
washed by adding Buffer PE (750 µl) and centrifuged twice as done previously 
and discarding the flow through. The column was then placed in a sterile 
labelled eppendorf tube, and 50 µl of sterile water was added to the centre of 
the QIAquick membrane and centrifuged again to obtain purified PCR product.   
 
2.2.7 Gel extraction 
This was performed following restriction digestion of plasmid DNA. The 
desired DNA fragment (of the right size) was excised carefully from the gel and 
purified using QIAquick Gel Extraction Kit (Qiagen) according to manufacturer’s 
instructions. In a tube, three volumes of Buffer QG was added to one volume of 
gel and incubated at 50 0C for 10 min to dissolve the gel completely. The sample 
was applied to the column after mixing it with one gel volume of isopropanol and 
centrifuged for 1 min at 16,000 xg. The column was washed sequentially with 
Buffer QG (500 µl), Buffer PE (750 µl) respectively and centrifuged 1 min 
between each wash with the flow through being discarded. The QIAquick 
column was placed in a fresh tube and the DNA was eluted in 50 µl sterile water 
by centrifugation at 16,000 xg for 1 min. 
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2.2.8 A-tailing and TA-cloning of the PCR product 
PCR products generated using Taq Polymerase contain adenine base (A) 
overhangs at the 5’ and 3’ ends, which can be directly used to ligate into a 
vector containing thymine (T) overhangs. However, high-fidelity DNA 
Polymerases such as Pfu, Pfx and KOD generate blunt ended PCR products 
without any overhangs. Therefore, A-tails or overhangs were added to these 
PCR products prior to TA-cloning procedure. 
The PCR products were A-tailed using NEBNext dA-Tailing module 
(NEB, UK) to enable ligation into TA Cloning plasmid vector pCR 2.1 (Thermo 
Fisher Scientific). The A-tailing reaction (25 µl) consisted of 15 µl purified PCR 
product (~2 µg DNA), 2.5 µl 10X dA-tailing reaction buffer, 1.5 µl Klenow 
fragment (3’!5’ exo-) and 6 µl sterile water. The reaction was incubated in a 
thermal cycler for 30 min at 37 0C. 
The A-tailed PCR product was ligated into pCR®2.1 vector in a reaction 
mixture (10 µl) containing 3 µl of A-tailed PCR, 1 µl of 10X Ligation Buffer  
(Thermo Fisher Scientific), 2 µl of 25 ng/µl pCR2.1 vector (Thermo Fisher 
Scientific), 1 µl of T4 DNA Ligase (4U/µl, Thermo Fisher Scientific) and sterile 
water (3 µl). The ligation mixture was incubated overnight at RT. 
 
2.2.9 Restriction digestion and ligation 
Restriction digestion of the plasmid was carried out using Type-II 
Restriction enzymes (New England Biosciences, UK). A restriction digestion 
reaction (20 µl) was set up containing plasmid DNA (up to 5 µg), 10X NEB 
Buffer (2 µl), EcoRI (1 µl of 10,000 U/ml) or KpnI (1 µl of 10,000 U/ml) and sterile 
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water. The reaction was incubated at 37 0C for 1-2 hours. The reaction was 
supplemented with 100 µg/ml BSA in case of KpnI digestion. 10X NEB buffer-1 
was used for KpnI, and 10X ECoRI buffer for EcoRI enzyme digestions. The 
restriction enzyme digested products were viewed on a 1% agarose gel.  
The insert DNA was ligated into the desired plasmid vector, both cut with 
the same restriction enzyme, using 1:3 (vector:insert) molar ratio. The vector 
and insert were incubated overnight at RT with 1X T4 ligase buffer supplied with 
the kit, and 1 unit T4 DNA ligase (Thermo Fisher Scientific) in a total reaction 
volume of 20 µl. 
 
2.2.10 Site-directed mutagenesis 
Mutagenesis was performed using Quikchange Lightning Site-Directed 
Mutagenesis kit (Agilent Technologies) according to manufacturer’s instructions. 
Primer pairs used to insert a mutation were designed using the primer design 
tool available online (http://www.genomics.agilent.com/primerDesignProgram) 
and purchased from Sigma. The primer pairs have been listed in table 2.1. 
Reaction setup and thermal cycling conditions are described below. 
Following the PCR cycles, 2 µl of DpnI restriction enzyme (from the kit) was 
added directly to the reaction and incubated at 37 0C for 10-15 min to digest the 
methylated, non-mutated parental template DNA. The DNA (2 µl) was then 
transformed using standard procedure as described in section 2.2.2 into XL-10 
Gold-ultracompetent cells (45 µl, kit component) supplemented with β-ME (2 µl, 
kit component). Several colonies of transformed cells were cultured in 
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appropriate antibiotic containing media, the DNA was purified and the insert was 
sequenced to identify a clone with the desired mutation. 
Component (stock conc.) Volume 
10X Quikchange Lightning Buffer 5 µl 
dNTP mixture 1 µl 
QuikSolution reagent 1.5 µl 
125 ng/µl Forward primer 1 µl 
125 ng/µl Reverse primer 1 µl 
100 ng/µl Template DNA  1 µl 
Quikchange Enzyme mix 1 µl 
Sterile nuclease free water 38.5 µl 
Total 50 µl 
 
The conditions followed for PCR were as follows: 
1. Initial denaturation at 95 0C for 2 min 
2. Denaturation at 95 0C for 20 seconds 
3. Annealing at 60 0C for 10 seconds 
4. Extension at 68 0C for 30 seconds/kb of 
    plasmid length 
5. Final extension at 68 0C for 5 min 
 
 
 
18 cycles 
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Table 2.1 Primers used for mutagenesis 
Primer name Sequence (5’-3’) 
PIM1 K5R For TTC AAT GCT CTT GTC CAG AAT CAA CTC GCT 
TTG CCC 
PIM1 K5R Rev GGG CAA GCG AGT TGA TTC TGG ACA AGA GCA 
TTG AA 
PIM1 K24R For GGG CGC CAG CCT GGT GGC GTG CA 
PIM1 K24R Rev TGC ACG CCA CCA GGC TGG CGC CC 
PIM1 K29, 31R For AGG GGC TCC CTC TCC CTG CCG GGC GCC 
PIM1 K29, 31R Rev GGC GCC CGG CAG GGA GAG GGA GCC CCT 
PIM1 K67R For CTC CAC GTG TCT GAT GGC CAC CGG CAA GTT 
PIM1 K67R Rev AAC TTG CCG GTG GCC ATC AGA CAC GTG GAG 
PIM1 K67M For GTC CTT CTC CAC GTG CAT GAT GGC CAC CGG 
CA 
PIM1 K67M Rev TGC CGG TGG CCA TCA TGC ACG TGG AGA AGG 
AC 
PIM1 K71R For AAA TCC GGT CCC TCT CCA CGT GTT TGA TGG 
CCA 
PIM1 K71R Rev TGG CCA TCA AAC ACG TGG AGA GGG ACC GGA 
TTT 
PIM1 K94, 95R For CCG AGC TCA CCC TCC TCA GCA GGA CCA CTT 
CCA TGG 
! 101!
PIM1 K94, 95R Rev CCA TGG AAG TGG TCC TGC TGA GGA GGG TGA 
GCT CGG 
PIM1 K169R For GTG CTC CAC CGC GAC ATC AGG GAC GAA AAC 
ATC 
PIM1 K169R Rev GAT GTT TTC GTC CCT GAT GTC GCG GTG GAG 
CAC 
PIM1 E171A For CCG CGA CAT CAA GGA CGC AAA CAT CCT TAT 
CGA CC 
PIM1 E171A Rev GGT CGA TAA GGA TGT TTG CGT CCT TGA TGT 
CGC GG 
PIM1 E171Q For GAG GTC GAT AAG GAT GTT CTG GTC CTT GAT 
GTC GCG GTG 
PIM1 E171Q Rev CAC CGC GAC ATC AAG GAC CAG AAC ATC CTT 
ATC GAC CTC 
PIM1 E181A For CGA TGA GCT TGA GCG CGC CGC GAT TGA GG 
PIM1 E181A Rev CCT CAA TCG CGG CGC GCT CAA GCT CAT CG 
PIM1 K183R For GAA GTC GAT GAG CCT GAG CTC GCC GCG ATT G 
PIM1 K183R Rev CAA TCG CGG CGA GCT CAG GCT CAT CGA CTT C 
PIM1 K194R For GAC GGT GTC CCT GAG CAG CGC CCC C 
PIM1 K194R Rev GGG GGC GCT GCT CAG GGA CAC CGT C 
PIM1 K313R For GAA AGG CTG CTA TCT GCT GGG CCC CGG 
PIM1 K313R Rev CCG GGG CCC AGC AGA TAG CAG CCT TTC 
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2.2.11 DNA sequencing 
Following ligation or mutagenesis, the insert was sequenced to confirm 
the correct nucleotide sequence and to rule out any unwanted incorporation or 
deletion of bases in the insert. DNA sequencing was carried out by the Genetics 
Core Services at Ninewells Hospital and Medical School.  
Table 2.2 Sequencing primers 
Vector/Insert Primer name Sequence (5’-3’) 
pcDNA3 T7 Forward TAA TAC GAC TCA CTA TAG GG 
pcDNA3 SP6 Reverse CAT TTA GGT GAC ACT ATA G 
pcDNA5/FRT/TO CMV Forward CGC AAA TGG GCG GTA GGC CTG 
pcDNA5/FRT/TO BGH Reverse TAG AAG GCA CAG TCG AGG 
pSG9M T7 Forward TAA TAC GAC TCA CTA TAG GG 
pCR 2.1 M13 Forward TGT AAA ACG ACG GCC AGT 
pCR 2.1 M13 Reverse CAG GAA ACA GCT ATG ACC 
pHAT2 T7 Forward TAA TAC GAC TCA CTA TAG GG 
pBABE-puro pBABE Forward CTT TAT CCA GCC CTC AC 
PIM1 internal Seq Reverse-1 GAC TCC AGG GGC TCC TTC TC 
PIM1 internal Seq Reverse-2 GCC AAG CAC CAT CTA ATG AGA 
PIM1 internal Seq Forward TCT CAT TAG ATG GTG CTT GGC 
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2.3 Plasmid construction 
2.3.1 Generation of 6Xhis tagged PIM1 mammalian expression vector 
To allow purification of PIM1 under denaturing conditions using Ni2+-NTA 
beads, a hexa-histidine tagged PIM1 plasmid was generated in pcDNA3 
mammalian expression vector. Full-length human PIM1 cDNA sequence was 
PCR amplified from Mammalian Gene Collection (MGC) clone (available as 
glycerol stock DWM 1347) using primer pair described below. The forward 
primer was designed to insert a 5’ EcoRI restriction site followed immediately by 
transcription start site (ATG) with six histidine tag codons to be in frame with 
PIM1 coding sequence. The reverse primer contained a SalI restriction site. 
EcoRI and SalI sites were chosen for two main reasons. Firstly, they are absent 
from the PIM1 coding sequence. Secondly, presence of these sites allows 
cloning into the multiple-cloning site (MCS) of commonly used expression 
vectors such as pcDNA3. 
The PCR product was then purified and A-tailed using the procedure 
described in section 2.2.6 and 2.2.8 respectively. The A-tailed PCR product was 
ligated directly into pCR2.1 by means of TA-cloning. Ligated plasmid was 
transformed into DH5α cells and minipreps from randomly selected colonies 
were sequenced to verify the DNA sequence. The pCR2.1 vector itself contains 
EcoRI site at 5’ and 3 ends; hence EcoRI digestion alone released the 6Xhis-
PIM1 fragment, which was then ligated into EcoRI digested pcDNA3 vector 
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Component (stock conc.) Volume 
10X PfX Buffer 5 µl 
10 mM dNTP 1.5 µl 
25 mM MgSO4 2 µl 
10 µM Forward primer 1 µl 
10 µM Reverse primer 1 µl 
10 ng/µl Template DNA (1347) 1 µl 
Pfx Polymerase 1 µl 
Sterile nuclease free water 37.5 µl 
Total 50 µl 
 
The conditions followed for PCR were as follows: 
1. Initial denaturation at 94 0C for 5 min 
2. Denaturation at 94 0C for 30 seconds 
3. Annealing at 56 0C for 1 min 
4. Extension at 72 0C for 2 min 
5. Final extension at 72 0C for 10 min 
Primer name Sequence (5’ – 3’) 
6Xhis-PIM1  
Forward primer 
AGA ATT CAT GGC TCA TCA TCA TCA TCA TCA TGG 
GAT GCT CTT GTC CAA AAT C 
6Xhis-PIM1 
Reverse primer 
AGT CGA CAG AAA CTA TTT GCT GGG CCC CGG 
CGA CAG GCT GTG 
 
30 cycles 
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2.3.2 Generation of YFP-tagged PIM1 mammalian expression vector 
Full-length human PIM1 cDNA sequence was PCR amplified from 
Mammalian Gene Collection (MGC) clone (available as glycerol stock DWM 
1347) using primer pair described below and the same PCR conditions as 
described in 2.3.1. The forward primer was designed to insert a 5’ EcoRI 
restriction site and the reverse primer contained a 3’-XbaI restriction site to be in 
frame with the pEYFP-C1 vector (containing a 5’-Yellow Fluorescent Protein 
tag). 
Primer name Sequence (5’ – 3’) 
PIM1 PCR 
Forward primer 
AGA ATT CCA TGC TCT TGT CCA AAA TCA ACT CGC 
PIM1 PCR 
Reverse primer 
ATC TAG AGC CAG AAA GGC TGC TAT TTG C 
 
The PCR product was then purified and A-tailed using the procedure 
described previously. The A-tailed PCR product was ligated directly into pCR2.1 
by means of TA-cloning. Ligated plasmid was transformed into DH5α cells and 
minipreps from randomly selected colonies were sequenced to verify the DNA 
sequence. Although the insert contained both EcoRI and XbaI sites, EcoRI 
digestion was sufficient to release the desired PIM1 fragment as the pCR2.1 
vector contains internal EcoRI sites flanking the ligated insert. The vector 
pEYFP-C1 was hence also digested with only EcoRI, and the PIM1 fragment 
was ligated directly into it. Positive clones were identified by DNA sequencing. 
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2.3.3 Generation of tet-inducible YFP-tagged PIM1 mammalian expression 
vector 
A cDNA encoding YFP-PIM1 was PCR amplified from pEYFP-PIM1 
(DWM 1675) using a forward primer containing 5’ KpnI site and a reverse primer 
with 3’ SalI site as described in the table below. As control, YFP alone was also 
PCR amplified. The amplified fragments were PCR purified, A-tailed and ligated 
into pCR2.1 vector by TA-cloning procedure. Site-directed mutagenesis was 
performed with the YFP-PIM1/pCR2.1 plasmid to generate the K169R, E171A, 
and K67M mutants.  
 
Primer name Sequence (5’ – 3’) 
YFP-PIM1 
Forward primer 
AGG TAC CAT GGT GAG CAA GGG CGA GGA G 
YFP-PIM1 
Reverse primer 
AGT CGA CGC CAG AAA GGC TGC TAT TTG C 
YFP only PCR 
Forward primer 
AGG TAC CAT GGT GAG CAA GGG CGA GGA G 
YFP only PCR 
Reverse primer 
TGG TAC CCT AGA AGC TTG AGC TCG AGA TCT G 
 
Sequencing of the pCR2.1/YFP-PIM1 plasmid showed that the insert had 
ligated in the opposite orientation such that it now had KpnI site on both 5’ and 
3’ (internal site present in pCR2.1) ends. Therefore, KpnI digest alone was 
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sufficient to release the YFP-PIM1 fragment. The vector containing tet-inducible 
elements pcDNA5/FRT/TO was also digested with only KpnI, and both the insert 
and the plasmid ligated to obtain YFP-PIM1/pcDNA5/FRT/TO plasmid. 
Following transformation, colonies were grown and minipreps done. Plasmids 
were sequenced and checked for YFP expression following transfection under a 
fluorescent microscope (EVOS FLoid Cell Imaging platform, Thermo Fisher 
Scientific).  
 
2.3.4 Generation of 6Xhis tagged PIM1 bacterial expression vector 
The plasmid vector for generating 6Xhis-PIM1 fusion protein for protein 
production and purification, pHAT2, was a kind gift from Dr. Marko Hyvonen, 
University of Cambridge (UK). The PIM1 insert was obtained by EcoRI 
restriction digestion of DWM 1350, and ligated into EcoRI digested pHAT2 
vector. The resulting ligation was transformed into competent cells and a 5 ml 
overnight culture was set up to isolate plasmid DNA. Positive clones were 
identified by sequencing using T7 Forward and SP6 reverse primers. Site-
directed mutagenesis was performed with DWM 1754 plasmid to generate the 
K169R, E171A, K67M and E171Q mutants.  
 
2.3.5 Generation of PIM1 expression vector for retrovirus production 
PIM1 cDNA was obtained by EcoRI restriction digestion of plasmid DWM 
1350. The fragment was then cloned into the EcoRI site of pBABE-puro vector 
using standard cloning procedure, and mutagenesis was performed to generate 
K169R, E171A and K67M mutants.  
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2.4 Protein expression, purification and analysis 
2.4.1 Recombinant protein expression in E. coli 
The E. coli strain Rosetta 2 (DE3) pLys (Novagen) was used for the 
expression of GST and 6Xhis fusion proteins. This strain of bacteria was chosen 
as it supplies tRNAs for the seven codons rarely used in E. coli (AUA, AGG, 
AGA, CUA, CCC, GGA and CGG) on a compatible chloramphenicol-resistant 
plasmid pRARE, thus allowing efficient translation of eukaryotic proteins.  
For GST-PIM1 expression, cells were transformed with the desired 
pGEX-4T-1 derivative plasmids (DWM 1352). For 6Xhis-PIM1 protein 
expression, cells were transformed with pHAT2 derivative plasmids (DWM 1754, 
1756, 1757, 1758, 1759). Approximately 50 µl of transformation mix was plated 
on LB-agar plates containing 100 µg/µl ampicillin, and incubated overnight at 37 
0C. The following day, a single colony was picked and grown overnight in 5-10 
ml LB selection media at 37 0C in an incubator-shaker.  
For protein expression, 400 ml LB selection media was inoculated with 10 
ml of starter culture and grown at 37 0C in an incubator-shaker until OD at 600 
nm reached between 0.4-0.6 (usually in 3-4 hours). An aliquot (1 ml) was taken 
at this point to analyse as pre-induction sample for later analysis, after which 
IPTG was added to a final concentration of 0.2 mM. The culture was then 
incubated at 30 0C with shaking at 225 rpm for a further 3 hours, after which 
another 1 ml aliquot (post-induction) was taken to analyse on gel. The cells were 
pelleted by centrifugation at 4000 xg for 20 min at 4 0C, supernatant was 
discarded and the pellet was stored at -80 0C once prior to protein extraction. 
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It is necessary to check protein induction before performing the next 
protein purification step. To do this, the pre- and post-induction samples were 
centrifuged at maximum speed for 2 min at RT and the pellet was lysed in 50 µl 
2X sample buffer. The lysate was then sonicated once or twice at 30% 
amplitude for 20 sec, centrifuged at maximum speed for 10 min at RT, quantified 
as described under section 2.4.4, and ran on an 8% SDS-polyacrylamide gel. 
The gel was then stained with coomassie as described under 2.4.7 to visualise 
the protein bands. The desired recombinant protein appears as a clearly 
distinguishable band running at the correct molecular weight in the post-
induction sample, but is absent in the pre-induction sample.  
 
2.4.2 GST-PIM1 protein purification 
Once protein induction was successfully confirmed, the pellet was thawed 
on ice, lysed in 20 ml of B-PER Complete Bacterial Protein Extraction Reagent 
(Thermo Fisher Scientific). It was then incubated for 30 min at RT on a tube 
rotator. Since B-PER lysis buffer contains a non-ionic detergent in a Tris-buffer 
with lysozyme and universal nuclease, it eliminates the need of sonicating the 
bacterial lysate. Following incubation, the lysate was centrifuged at 10,000 xg for 
20 min at 4 0C and the pellet discarded.  
The GST-fusion protein was then affinity-purified using Glutathione 
Sepharose 4B (GST) beads (Amersham). GSH beads were prepared by 
washing them extensively with 10 volumes of PBS to remove any residual 
ethanol (preservative) and stored as 50% slurry in PBS at 4 0C until use. 
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Approximately 1 ml of GST beads was then added to the lysate in a 15 ml 
falcon tube, placed on a tube rotator and incubated at 4 0C for 2 hours to allow 
binding of GST-fusion protein to the beads. The beads were pelleted gently by 
centrifugation at 400 xg for 2 min, and then washed three times (10 min each) 
with 10 ml of 50 mM Tris pH 7.5 on a tube rotator at 4 0C. The GST-fusion 
protein was eluted by incubating the beads with 500 µl of 10 mM reduced 
glutathione in 50 mM Tris (final pH readjusted to 7.5) for 30 min on a rotator at 
RT. The beads were centrifuged as before and the supernatant was collected 
(elution 1). The elution process was repeated again (elution 2) and stored at 4 
0C until further analysis by SDS-PAGE.  
A dialysis was set up to remove the reduced glutathione from the 
elutions. The positive fraction (elution 1 or 2, or both pooled together) was 
carefully injected into a Slide-A-Lyzer Dialysis cassette (10 K MWCO, Thermo 
Fisher Scientific) and placed in a beaker containing dialysis buffer (50 mM Tris 
pH 7.5, 20% glycerol) and a magnetic stirrer overnight at 4 0C. The 
concentration of the purified protein was estimated by SDS-PAGE, using known 
amounts of BSA as standards, aliquoted and stored at -80 0C until further use. 
  
2.4.3 Purification of 6Xhis-PIM1 and mutants 
Protein induction was first confirmed by SDS-PAGE of the pre and post-
induction samples. The pellet was thawed on ice, lysed in 20 ml of B-PER 
Complete Bacterial Protein Extraction Reagent (Thermo Fisher Scientific) and 
incubated for 30 min at RT on a tube rotator. Following incubation, the lysate 
was centrifuged at 10,000 xg at 4 0C for 20 min and the pellet discarded. 
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Imidazole was added to the clarified lysate at 10 mM final concentration. The 
6Xhis-fusion protein was then affinity-purified using Ni2+-NTA agarose beads 
(Qiagen). The beads were prewashed extensively with 10 volumes of PBS to 
remove any residual ethanol (preservative) and stored as 50% slurry in B-PER 
reagent at 4 0C until use. The following steps were performed in a cold room. 
Approximately 1 ml of Ni2+-NTA beads was added to a Poly-prep column 
(Biorad) with the lysate, and allowed to flow through by gravity. The flow-through 
was re-loaded on the column twice to maximise protein binding. The column 
was then washed thrice with 20 ml cold wash buffer. Approximately 3-4 ml of 
fresh elution buffer was added to the column, and elutions were collected in 500 
µl fractions. Ten microliters of each eluted protein fraction was run on a gel and 
stained with coomassie to identify the positive fractions. The desired elutions 
were pooled and dialysis was set up to remove the imidazole. The elution was 
carefully injected into a Slide-A-Lyzer Dialysis cassette (10 K MWCO, Thermo 
Fisher Scientific) and placed in a beaker containing dialysis buffer and a 
magnetic stirrer overnight at 4 0C. The concentration of the purified protein was 
estimated by SDS-PAGE, using known amounts of BSA as standards, aliquoted 
and stored at -80 0C until further use.  
 
2.4.4 Protein extraction and quantification 
Cells were washed twice in PBS and lysed directly in 2X SDS sample 
buffer without reducing agent, and transferred to labelled eppendorf tubes. 
Lysates were then sonicated once at 30% amplitude for 20-30 sec using a 
SONICS Vibra-Cell sonicator (model VCX 130). Sonicated lysates were 
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centrifuged for 10 min at 12,000 xg at RT to pellet the insoluble particles. Total 
protein concentration in the cell lysates was determined using BCA-DC protein 
assay kit (Biorad) in a 96-well plate format. In brief, Reagent A and Reagent S 
were first combined in a ratio of 50:1 (v/v), and 25 µl of this solution was 
transferred per well of a 96-well plate. This was followed by addition of 17 µl 
water and 3 µl of cell lysate or protein sample per well of a 96-well plate. 200 µl 
of Reagent B was then added per well, and the plate was incubated in the dark 
for 15 min. At this point, the absorbance of each sample was measured at 750 
nm using a GloMax-Multi detection system (Promega). To obtain protein 
concentration (in mg/ml), the absorbance values were plotted on MS Excel 
against a pre-determined standard curve generated with BSA. The cell lysates 
were diluted to the desired concentration using 2X SDS sample buffer and DTT 
was added at a final concentration of 100 mM. Samples were heated to 95 0C 
for 5 min, allowed to cool and ran on a polyacrylamide gel for western blotting.  
 
2.4.5 SDS-PAGE using hand made gels 
Protein samples were separated based on their molecular weight on a 
sodium dodecyl sulfate-polyacrylamide gel (SDS-PAG) of the desired 
percentage. 5 µl of protein marker (PageRuler, Fermentas) was loaded as a 
reference on the gel.  The composition of polyacrylamide gel used is given in 
table 2.3. The gels were run at 120 V until the samples had stacked properly 
and began to separate. The gel was then run at 170 V till the dye front had 
almost reached the bottom of the gel. 
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Table 2.3 Composition of SDS-PAGE gels 
STACKING GEL Volume for 1 gel 
Sterile water 2.15 ml 
1.25 M Tris pH 6.8 300 µl 
30% (w/v) Acrylamide (Severn Biotech Ltd) 500 µl 
10% SDS 30 µl 
10% APS 25 µl 
TEMED 2.5 µl 
 
SEPARATING GEL  8% 10% 12.5% 
Sterile water 3.95 ml 3.3 ml 2.475 ml 
1.25 M Tris pH 8.8 3 ml 3 ml 3 ml 
30% (w/v) Acrylamide 2.65 ml 3.3 ml 4.125 ml 
10% SDS 100 µl 100 µl 100 µl 
10% APS 100 µl 100 µl 100 µl 
TEMED 7.5 µl 7.5 µl 7.5 µl 
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2.4.6 SDS-PAGE using precast gels 
Novex NuPAGE Precast gels (4-12% Bis-Tris) were used in conjugation 
with XCell SureLock Mini Cell Electrophoresis system using 1X MOPS or 1X 
MES running buffer at 180 V till the dye front reached the bottom of the gel. The 
gel was then either transferred onto a nitrocellulose membrane for western 
blotting or stained with coomassie. All the above-mentioned reagents and 
equipment were purchased from Thermo Fisher Scientific. 
 
2.4.7 Coomassie staining of gels 
The gel was incubated with 20-30 ml coomassie stain for 1 hour at RT 
with gentle shaking. Following this, the gel was washed with Destainer-I for 1 
hour at RT on a shaker. The gel was further washed with Destainer-II overnight 
or until the background was clear and the protein bands became visible. The 
washing buffer was changed frequently during the procedure. 
 
2.4.8 Western Blotting 
The protein samples (on SDS-PAG) were transferred onto a nitrocellulose 
membrane (Hybond, GE Healthcare) using a wet transfer blotting unit (Mini 
Trans-Blot Cell, Bio-Rad). The gel sandwich was prepared as follows: one pre-
wetted filter paper was placed on a pre wetted fibre pad placed on the cassette, 
and the gel gently placed over it. Next, a pre wetted NC membrane was placed 
on top of the gel and stacked on top with a filter paper and a fibre pad (both pre 
wetted) respectively. The cassette was placed in the electrophoresis tank 
module filled with transfer buffer and ran at 100 V constant for 1 hour. 
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Nitrocellulose membranes were routinely stained with Ponceau S solution after 
protein transfer to check transfer efficiency and equal protein loading.  
For protein detection, the membranes were first blocked in 5% non-fat dry 
milk in TBST (Marvel) for 1 hour at RT (30 min for endogenous PIM1), following 
overnight incubation with primary antibodies either in 5% milk or 5% BSA (as 
recommended by the antibody manufacturer). Next day, the membranes were 
washed thrice, 5 min each, in TBST on a roller. The membranes were incubated 
for one hour at RT in secondary antibodies diluted in 5% milk/TBST. Excess 
antibody was removed by washing as done previously. Equal volume of ECL 
solution-1 and ECL solution-2 were mixed in a tube and added to the 
membranes for chemiluminescent detection of proteins on the membranes. 
Images were acquired either on a film (Konica Monolta) using an X-ray film 
processor (SRX-101A, Konica Minolta) or using the ChemiDoc MP Imaging 
system (Biorad). 
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2.5 Cell culture and other methods 
2.5.1 Cell lines 
Cell lines described in the table 2.4 were cultured in a humidified 5% CO2 
incubator (Heraeus, HeraCell) at 37 0C. Cell lines were maintained in Dulbecco’s 
Modified Eagle Medium (DMEM, Thermo Fisher Scientific) supplemented with 
10% (v/v) fetal bovine serum (FBS, Biosera) and 2 mM L-glutamine (Thermo 
Fisher Scientific). HeLa-FRT cells expressing YFP-PIM1 were maintained in 
media containing 200 µg/ml hygroMYCin B. U2OS-FRT cells expressing YFP-
PIM1 were maintained in media containing 100 µg/ml hygroMYCin B. DU145 
cells stably expressing PIM1 were maintained in media containing 0.25 µg/ml 
puroMYCin.  
H1299 and COS7 cells were from Meek Lab liquid nitrogen stocks 
(originally purchased from ATCC). HeLa-FRT cells were a kind gift from Prof. 
Stephen Taylor (University of Manchester) and U2OS-FRT cells were a kind gift 
from Prof. Kevin Hiom (University of Dundee). DU145 cells were a kind gift from 
Dr. Ghulam Nabi (University of Dundee) and Phoenix-AMPHO cells were a kind 
gift from the Skin tumour Laboratory (University of Dundee). 
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Table 2.4 Cell lines 
S. No Cell Line Description Media 
1. H1299  Human non-small cell lung cancer; 
derived from metastatic lymph node 
DMEM 
2. COS7 African green monkey kidney cells; 
SV40 transformed 
DMEM 
3. HeLa-FRT 
(Parental) 
Human cervical cancer; HPV positive DMEM 
4. U2OS-FRT 
(Parental) 
Human osteosarcoma (bone cancer) DMEM 
5. DU145 Human prostate cancer; derived from 
brain metastatic site 
DMEM 
7. Phoenix-
AMPHO 
Human embryonic kidney cells; 
adenovirus E1a and SV40 transformed 
HEK293T cells 
DMEM 
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2.5.2 Subculturing cells 
Cell lines were maintained in growth phase by subculturing them every 2-
3 days or when they reached 80-90% confluency in a Laminar flow hood 
(Scanlaf). Cells were washed twice in pre-warmed sterile 1X PBS before the 
addition of 1-2 ml 0.25 % Trypsin-EDTA (Thermo Fisher Scientific), following 
which they were placed back in the incubator for 2-3 min to allow the cells to 
detach from the plate. Detached cells were re-suspended in medium containing 
FBS, and the desired percentage of cells was transferred to a new dish 
containing fresh media, and placed back in the CO2 incubator.  
 
2.5.3 Cell Seeding 
Cells were trypsinised and resuspended in an appropriate volume of 
medium. A small aliquot of cell suspension was added to each end of an 
Improved Neubauer Haemocytometer (1/400m2, Hawksley UK) and cells within 
four corner square grids were counted by a microscope. The average number of 
cells recorded in the grids represented: number of cells x104 per ml in the cell 
suspension.  The suspension was then diluted as required for the experiment. 
 
2.5.4 Cryopreservation of cells 
Cells from a confluent T75 flask were trypsinised and resuspended in 10 
ml of complete growth media. The cells were pelleted gently by centrifugation at 
1000 xg for 3 min at RT, prior to aspirating the growth media. The cell pellet was 
then resuspended in 5 ml or 10 ml (depending on pellet size) cold freezing 
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media. A total of 1 ml cell suspension was transferred to individual cryogenic 
vials (Corning), and incubated on ice for 15 min. The vials were placed in a Cryo 
1 0C Cool box (VWR) to ensure slow freezing and transferred to a -80 0C freezer 
for 2 days. The frozen vials were subsequently transferred to a liquid nitrogen 
tank for long-term preservation. 
 
2.5.5 Revival of cryopreserved cells 
A frozen vial of the desired cell line was removed from the liquid nitrogen 
tank, and thawed rapidly in a 37 0C water bath. The thawed cells were 
transferred to a 15 ml tube and 9 ml of pre-warmed media was added before cell 
centrifugation at 1000 xg for 3 min at RT. The media was aspirated and the cell 
pellet was resuspended in 10 ml fresh media and transferred to a T75 flask 
containing 10 ml media. The cells were placed in a humidified CO2 incubator at 
37 0C. Cells were also tested for MYCoplasma contamination prior to using them 
for experiments. 
 
2.5.6 Mycoplasma testing 
Cell lines were tested for the presence of MYCoplasma using the 
MycoAlert Mycoplasma detection kit (Lonza) according to manufacturer’s 
instructions. Cell lines to be tested were grown for 4-7 days in the same growth 
media, and an aliquot of growth media was then used in the test. The growth 
media (around 1 ml) was centrifuged at 1000 xg for 3 min at RT to pellet any 
cells, and 100 µl of the supernatant was added to a well of white-bottom 96-well 
microplate. A total of 100 µl MycoAlert reagent was added to the sample and 
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incubated for 5 min at RT following which luminescence was detected on a 
GloMax-Multi detection system (Promega). This reading was designated as A. 
Next, 100 µl of MycoAlert substrate was added to the same sample and 
incubated for 10 min at RT, followed by reading luminescence as before. This 
reading was designated B. The value determining the Mycoplasma status was 
obtained by dividing reading B by reading A (or B/A). A value of <0.9 is 
indicative of no Mycoplasma contamination (negative), 0.9-1.2 indicative of 
borderline contamination and >1.2 indicative of Mycoplasma contamination 
(positive).  
 
2.5.7 Transient transfection using Lipofectamine 2000 
Cells were seeded 24 hours prior to transfection to achieve a confluence 
of ~70% on the day of transfection. Plasmid transfection was performed using 
DNA (µg) to Lipofectamine 2000 (µl) ratio of 1:3 according to manufacturer’s 
instructions. Firstly, the plasmid DNA to be transfected was diluted in OptiMEM 
in a tube. In a second tube, the required amount of Lipofectamine 2000 was 
diluted in the same volume of OptiMEM as the plasmid mix and incubated for 5 
min at RT. The transfection mixes were combined 1:1 (v/v), and incubated for 
15-20 min at RT (see table below for volumes). After this, the mix was added 
dropwise to the cells, the media in the plates mixed and the cells returned to the 
CO2 incubator. The cells were usually harvested 24-72 hours post transfection 
depending on the nature of the experiment.  
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Plate Final volume 
of 
transfection 
mix 
Maximum amount 
of plasmid used 
Maximum volume 
of Lipofectamine 
2000 used 
6-well 
(per well) 
200 µl 6 µg 18 µl 
10 cm2 1000 µl 15 µg 45 µl 
 
 
2.5.8 Transient transfection using Fugene HD 
Cells to be transfected were seeded in a 6-well plate 24 hours before 
transfection at 60-70% confluency. In general, cells were transfected using a 
DNA (µg) to Fugene HD (µl) ratio of 1:6 according to manufacturer’s 
instructions. Prior to transfection, both serum free media and Fugene HD were 
equilibrated to RT. For each well to be transfected, the required amount of DNA 
was diluted in 100 µl serum free media in a tube. In another tube, the calculated 
amount of Fugene HD was diluted in 100 µl serum free media. After 5 min 
incubation at RT, the diluted Fugene HD was mixed with DNA and allowed to sit 
for 15 min at RT. Transfection mixes were then added dropwise to cells, mixed 
by gentle swirling, and incubated for at least 24 hours in a CO2 incubator before 
checking protein expression. 
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2.5.9 siRNA knockdown using Lipofectamine RNAiMAX 
The optimal seeding density of cells for a successful siRNA transfection 
experiment was first determined by plating cells at varying densities ranging 
from 0.25x105 to 2x105 cells/well in a 6-well plate. The cell number that gave 80-
90% confluent cells 72 hours (for a 48 hour siRNA treatment) or 96 hours (for a 
72 hour siRNA treatment) post seeding was chosen as the optimum seeding 
density.  
All siRNA transfections were performed using Lipofectamine RNAiMAX 
reagent and 20 µM siRNA stocks as listed under 2.1.4. The method described 
here is for one well of a 6-well plate. Briefly, 3 µl of siRNA was first added to 100 
µl OptiMEM in an eppendorf tube and mixed gently by pipetting up and down. In 
another eppendorf tube, 4 µl of RNAiMAX was added to 100 µl OptiMEM, mixed 
by pipetting and incubated for 5 min at RT. Following incubation, the diluted 
RNAiMAX solution was mixed with the siRNA solution, mixed by pipetting, and 
incubated for 15-20 min at RT. During this time, the media on the 6-well plate 
was replaced by adding 2.8 ml of fresh media. Finally, The siRNA-RNAiMAX mix 
was added to the cells in a dropwise manner, and incubated further for 48 or 72 
hours at 37 0C in a CO2 incubator. Final siRNA concentration used was 20 nM. 
 
2.5.10 Generation of tet-inducible cell lines 
Stable cell lines expressing WT PIM1 or different mutants were created 
using the Flp-In TRex system (Thermo Fisher Scientific). This system was 
chosen as it enables targeted integration of gene of interest into a single FRT 
(Flp Recombination Target) site present in Flp-In cells using Flp-recombinase 
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mediated DNA recombination. The resulting cell lines are hence ‘isogenic’ and 
prevent spurious effects observed with random integration of plasmid DNA into 
host cell line. The Flp-In cells also stably express the Tet-repressor protein (from 
pcDNA6/TR plasmid) that allows us to modulate levels of expression of our gene 
of interest in a tetracycline-inducible manner. A schematic diagram illustrating 
the process of creating a cell line by this method is shown in figure 2.1. 
HeLa-FRT (parental) or U2OS-FRT (parental) cells were used to 
generate tetracycline inducible YFP-PIM1-expressing cell lines. Cells (1x105) 
were seeded in a 6-well dish and transfected the following day with 0.1 µg 
pcDNA5/FRT/TO (encoding YFP-PIM1 or YFP alone) and 0.3 µg pOG44 
(encoding Flp-recombinase) using Fugene HD. Two days post transfection, cells 
were trypsinised and reseeded in 10 cm2 plates in complete DMEM media 
containing 200 µg/ml hygromycin B (for HeLa-FRT) or 100 µg/ml hygromycin B 
(for U2OS-FRT). The cells were allowed to grow, with media being changed 
every 2-3 days, until colonies began to appear (usually 2 weeks). Colonies that 
survived hygromycin B selection were considered positive for the integration of 
pcDNA5/FRT/TO. All colonies for each plasmid were pooled, expanded and 
frozen before testing them for expression. Cell lines were tested for expression 
of protein by the addition of doxycycline at 1 µg/ml, in the first instance, 24 hours 
prior to lysis for western blotting or checking under a fluorescence microscope. 
Hereafter, the resulting cell lines were maintained in complete DMEM with 200 
µg/ml or 100 µg/ml hygromycin B to ensure propagation of positive clones. 
Hygromycin B was not used in actual experiments. 
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Figure 2.1 Generation of tet-inducible cell lines using Flp-In system (Adapted from Flp-In 
TRex manual) The HeLa-FRT or U2OS-FRT cells used here already contain a stably integrated 
copy of the FRT gene locus, which allows us to insert a gene of interest in this locus by 
homologous recombination. In the first step, pcDNA5/FRT/TO vector containing the gene of 
interest (YFP-PIM1) is cotransfected with pOG44 plasmid in these cells. The Flp recombinase 
expressed from the pOG44 plasmid catalyses a recombination event between the FRT sites in 
the host cell line and the pcDNA5/FRT/TO vector. Successful integration confers hygromycin 
resistance to the cells. The host cell lines used here also stably express the Tet repressor 
protein (TetR), which binds to the 2X Tet operator (TetO2) sequences and inhibits expression of 
gene of interest. Tetracycline addition results in a change in conformation of TetT and its 
dissociation from the TetO2, thus activates expression of the gene of interest in these cells. 
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2.5.11 Generation of DU145-PIM1 cell lines using retroviral transduction 
The retroviral packaging cell line, Phoenix-AMPHO, expressing the viral 
gag-pol and envelope proteins was used for the production of replication-
incompetent retroviral particles. The viral package signal, transcription initiation 
and other processing elements, along with the gene of interest (PIM1) were 
expressed from the pBABE-puro vector, derived from the Moloney murine 
leukemia virus (MMLV). The following procedure was carried out in accordance 
with Biosafety Level-2 protocols.  
Phoenix cells were seeded at 4x106 cells in T25 flasks and transfected 
the following day with 5 µg pBABE-puro plasmid (expressing WT PIM1 or 
mutants) using Lipofectamine 2000 as described previously. After 48 hours, the 
cells were expanded into a T175 flask and further incubated till the cells reached 
80-90% confluency. At this point, the media was replaced with 20 ml fresh 
DMEM media and the flask was transferred to a 32 0C incubator for production 
of viral particles. The target cells to be infected (DU145) were seeded at 4x104 
cells per T25 flask and incubated overnight at 37 0C prior to first round of 
retroviral transduction. 
After 24 hours incubation at 32 0C, the conditioned media (containing viral 
particles) from the Phoenix cells was collected and filtered through a 0.45 µm 
non-pyrogenic filter to remove any Phoenix cells from the media. Fresh media 
(20 ml) was added to the flask and again placed in the 32 0C incubator for 
further 48 hours. The conditioned media was mixed 1:1 with fresh DMEM media, 
and polybrene was added at 10 µg/ml final concentration. The media on target 
cells (DU145) was replaced with the above-mentioned media and the flasks 
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were placed overnight at 32 0C for efficient transduction. The following day, 
media on target cells was replaced with fresh DMEM and the flask was placed 
back in the 37 0C incubator for 24 hours to allow cell recovery. The cells were 
transduced a second time using the 48 hour conditioned media from Phoenix 
cells as done previously. The target cells were allowed to recover for 48 hours 
after the second round of transduction at 37 0C, and puroMYCin was added at 
0.25 µg/ml final concentration for selection of transduced cells. After one week 
of puroMYCin selection i.e. when there were no viable cells present in the non-
transduced flask of DU145, the surviving colonies in the transduced flaks were 
pooled, expanded and the expression of PIM1 was examined by western 
blotting.  
 
2.5.12 Co-immunoprecipitation 
H1299 cells (6-8x105) were seeded in 10 cm2 dish and transfected 24 
hours later with the indicated plasmids for 36-48 hours. Cells were washed twice 
in cold PBS and lysed directly by scraping in 500 µl of cold CO-IP buffer. The 
lysate was incubated in the cold room for 30 min on a tube rotator, sonicated 
once at 30% amplitude for 20 secs, and centrifuged at maximum speed for 20 
min at 4 0C to remove cell debris. The supernatant was carefully transferred to a 
new-labelled tube and the pellet was discarded. The lysate were then pre-
cleared by addition of 50 µl of Protein-A/G sepharose beads (50% slurry in PBS) 
and kept rotating in the cold room for 45 min. The bead-lysate mixture was 
centrifuged at 2000 xg for 2 min and the supernatant was again transferred to a 
new-labelled tube. Approximately 10% volume of the lysate was kept aside, as 
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input, to check protein expression later. The remaining lysate was divided into 
two or three equal parts (one for IgG negative control, and others for test 
antibody) and 2 µg of the appropriate antibody was added. The total volume of 
lysate in each tube was made up to 600 µl using CO-IP buffer and incubated 
overnight on a tube rotator in the cold room. Next day, 50 µl of Protein-A/G 
sepharose beads (previously washed and stored as 50% slurry in CO-IP buffer) 
was added to the lysate-antibody mixture and incubated for 1-2 hours on a tube 
rotator in the cold room. The beads were then pelleted by centrifugation at 800 
xg for 2 min, and washed three times in CO-IP buffer on a tube rotator for 5 min 
per wash in the cold room, and supernatant discarded after each wash. After the 
last wash, 50 µl of 2X SDS sample buffer (with DTT) was added to the beads 
and boiled for 5 min to elute the proteins before analysing them by western 
blotting. 
 
2.5.13 Nuclear-Cytoplasmic protein fractionation 
Cells from one confluent 10 cm2 dish were washed twice in cold PBS, 
scraped in 1 ml PBS and transferred to a new eppendorf tube. The cells were 
pelleted by centrifugation, lysed in 350 µl of cytoplasmic extraction buffer and 
incubated on ice for 10 min with gentle vortexing every 2-3 min. The lysates 
were then centrifuged at 1000 xg for 5 min at 4 0C. The supernatant 
(cytoplasmic extract) was collected in a fresh tube. The remaining cell pellet was 
washed three times in 0.5-1 ml of cytoplasmic extraction buffer and centrifuged 
as before. The pellet was lysed in 100 µl of 2X SDS sample buffer, sonicated 
once at 30% amplitude for 20 sec, and centrifuged at 12, 000 xg for 15 min to 
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pellet cell debris. The supernatant (nuclear extract) was collected and the pellet 
discarded. The protein concentration of the cytoplasmic and nuclear extracts 
was determined and equal amounts were loaded on a gel for analysis of protein 
of interest by western blotting.   
 
2.5.14 Immunofluorescence 
Cells (2-5x104) were seeded on 13 mm coverslips in a 24-well dish for at 
least 24 hours prior to staining. The cells were washed twice in PBS to remove 
excess media, and fixation buffer (prewarmed to 37 0C) was added for 10 min at 
RT. Following two washes with PBS, the cells were then permeabilised for 5 min 
at RT by adding permeabilisation buffer. The cells were washed three times, 5 
min each, in PBS and blocked in blocking solution for 15-20 min at RT with 
gentle shaking. The coverslips were incubated with the primary antibody (diluted 
in blocking buffer) for 1 hour at RT or overnight at 4 0C in a humidified chamber. 
The coverslips were then washed thrice in TBS, 5 min each with gentle shaking. 
Next, the coverslips were incubated with the desired combination of secondary 
antibodies for 1 hour at RT in a dark-humidified chamber. After a further three 
washes in TBS, the coverslips were incubated for 5 min with DAPI (1:10,000 in 
blocking buffer) at RT, and washed five times with TBS. Excess liquid from the 
coverslips was carefully removed with filter paper, and the coverslips were 
mounted with ProLong Gold antifade reagent (Thermo Fisher Scientific) on 
microscopic glass slides. The slides were allowed to dry overnight in the dark. 
The next day, the edges of the coverslip were sealed using nail-polish and let to 
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dry at RT. The stained cells were visualised using an SP5 confocal microscope 
(Leica microsystems). 
 
2.5.15 SUMOylation and Ubiquitination assay 
Affinity purification of hexa-histidine (6Xhis) tagged SUMOylated or 
ubiquitinated proteins was done under denaturing conditions using Ni2+-NTA 
agarose beads (Qiagen) and procedure described in Tatham et al., 2009. 
COS7 (1x106) or H1299 (8x105) cells were seeded in 10 cm2 dishes 
overnight and transfected with plasmids encoding either 6Xhis tagged SUMO 
(for SUMOylation assay) or 6Xhis tagged Ubiquitin (for ubiquitination assay) 
along with other plasmids as indicated in respective figures. After 36-48 hours, 
cells were washed twice in PBS and scraped in 1 ml of PBS. Ten percent of the 
cell suspension was lysed directly in 2X SDS buffer (input), and the remaining 
was lysed in 5 ml 6M Guanidium-HCl lysis buffer (pH 8). The samples were 
sonicated once at 35% amplitude for 30 sec and centrifuged at maximum speed 
for 20 min at RT. The supernatant was transferred to a new tube with the 
addition of 5mM imidazole and 5 mM β-ME. 70 µl of Ni2+-NTA beads (50% slurry 
in lysis buffer) was then added to the lysate and left on a tube rotator for 2 hours 
at RT. The beads were gently centrifuged at 400 xg for 1 min and washed 
successively, once with 4 ml of Guanidium-HCl wash buffer (pH 8), once with 
8M Urea wash buffer (pH 8) and thrice with 8M Urea wash buffer (pH 6.3). The 
proteins were eluted by incubating in 50 µl of Ni2+-NTA elution buffer for 30 min 
at RT on a tube rotator, boiled for 5 min before running on a gel. 
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2.5.16 Anchorage-independent growth assay 
DU145 cells stably expressing WT PIM1 or mutants were assessed for 
their ability to grow as colonies in soft-agar. First, the base layer was prepared 
by mixing equal volumes of 2X RPMI media with 1.8% agarose. About 0.8 ml of 
this solution was quickly added (avoiding any air bubbles) per well in a 12-well 
plate. The base layer was allowed to set for 2 hours at RT inside the hood. 
During this time, cells were trypsinised and diluted to 1.6X104 cells/ml in 2X 
RPMI media. Equal volume of cell suspension was then mixed with equal 
volume of 0.9% agarose to obtain the cell layer. Around 0.9 ml of the cell layer 
was carefully pipetted on top of the base layer. The plates were then allowed to 
set for one hour at RT in the hood, following which they were placed in a CO2 
incubator. Cells were fed with 200 µl of 1X RPMI media twice each week until 
colonies began to appear.  
 
2.6 In vitro assays 
2.6.1 Kinase assay by western blotting 
PIM1 kinase assays were carried out using recombinant 6Xhis-PIM1 
(wild-type and mutants) with histone H3.3 (NEB, UK) or c-MYC (DSTT, 
University of Dundee) as substrate. Reactions were carried out in a total volume 
of 20 µl containing 50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.5 mM ATP, 1 µg 
substrate and approximately 0.5-1 µg PIM1 kinase. Appropriate negative control 
reactions without any substrate or kinase were also set up simultaneously. 
Reactions were incubated in a 30 0C water bath for 30 min, and terminated by 
addition of 2X SDS sample buffer (with DTT). The reactions were boiled for 5 
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min followed by either coomassie staining of the gel or SDS-PAGE and western 
blotting using a phospho-specific antibody. 
 
2.6.2 In vitro SUMOylation assay 
The following recombinant proteins were purified and kindly provided by 
the Hay lab (University of Dundee): untagged SAE1/2, untagged UBC9, GST-
SUMO1/2, untagged SUMO1/2, Creatine kinase, SENP1, PIAS1 and IR1+M 
fragment. 
 
2.6.2.1 Using 35S-methionine labelled PIM1 
This procedure was performed with Ellis Jaffray from Prof. Ron Hay’s 
laboratory at the School of Life Sciences, University of Dundee. 35S-methionine 
labelled PIM1 was generated using a wheat germ lysate coupled in vitro 
transcription/translation system (Promega) from 1 µg MYC-PIM1 plasmid or 1 µg 
SP100 (positive control) according to manufacturer’s procedure. The reaction 
(25 µl) containing wheat germ lysate (12.5 µl), 25X reaction buffer (1 µl), T7 
RNA Polymerase (0.5 µl), amino acid mix without methionine (0.5 µl), RNAsin 
ribonuclease inhibitor (0.5 µl), DNA template (1 µl), 35S methionine (1.25 µl) and 
nuclease free water (1.25 µl) was incubated for 2 hours at 30 0C.  
SUMOylation of 35S-methionine labelled substrate was performed in a 20 
µl reaction mix containing an ATP-regeneration system (50 mM Tris pH 7.5, 5 
mM MgCl2, 2 mM ATP, 10 mM creatine phosphate, 3.5 U/ml creatine kinase, 0.6 
U/ml inorganic pyrophosphatase), 120 ng SAE1/2, 750 ng UBC9, 500 ng 
SUMO1 or SUMO2, EDTA-free protease inhibitor (Roche) and 5 mM DTT. The 
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reaction was incubated for 4 hours at 37 0C and terminated by adding SDS-
sample buffer. Proteins were separated by standard SDS-PAGE, transferred on 
a PVDF membrane. The film was exposed overnight on the membrane and 
visualised on a phosphorimager (Fuji BAS 1500, MacBAS software, Fuji Film, 
Tokyo, Japan). 
 
2.6.2.2 Using recombinant GST-PIM1  
SUMOylation of recombinant GST-PIM1 was performed in 25 µl reaction 
mix containing 50 mM Tris pH 7.5, 5 mM MgCl2, 2 mM ATP, 5 mM DTT, 900 ng 
GST-PIM1, 150 ng SAE1/2, 1.5 µg UBC9, 6.25 µg SUMO1 or SUMO2. The 
reaction was incubated for 4 hours at 37 0C and terminated by adding SDS-
sample buffer. Proteins were separated by SDS-PAGE, subjected to western 
blotting, and probed with anti-GST antibody. 
 
2.6.3 Kinase assay using SUMOylated PIM1 
2.6.3.1 In vitro SUMOylation and affinity purification of SUMOylated-PIM1 
In vitro SUMOylation of 6Xhis-PIM1 was carried out overnight at 37 0C in 
100 µl reaction containing 50 mM Tris pH 7.5, 3 mM ATP, 5 mM MgCl2, 5 mM 
DTT, 20 µg 6Xhis-PIM1, 50 µg GST-SUMO2, 5 µg UBC9, 0.9 µg SAE1/2 and 
1.5 µg IR1+M fragment of RanBP2. The reaction was diluted 5-fold with 50 mM 
Tris pH 7.5 and SUMOylated proteins were captured by adding 400 µl (50% 
slurry) GST beads (GE Healthcare) overnight at 4 0C. The beads were washed 
three times in wash buffer (50 mM Tris pH 7.5 and 150 mM NaCl) and eluted by 
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adding 400 µl elution buffer (20 mM reduced glutathione, 50 mM Tris pH 8, 150 
mM NaCl and 1 mM DTT) for 2 hours at 4 0C on a rotating mixer.  
 
2.6.3.2 DeSUMOylation assay and kinase assay 
Elutions from in vitro SUMOylation reactions were divided into two equal 
parts. Active SENP1 (aa 415-643) was added to one of them at 20 nM final 
concentration. First, the reactions were incubated at 30 0C for 1 hour for 
deSUMOylation to occur, following which 5 µg Histone H3.3 (substrate) and 
kinase buffer (50 mM Tris pH 7.5, 10 mM MgCl2, 0.5 mM ATP final 
concentration) was added. The reactions were further incubated at 30 0C for 
kinase assay with aliquots (40 µl) being collected at 0, 15, 30 and 45 min. The 
samples were subjected to SDS-PAGE and western blotting was performed 
using indicated antibodies. 
 
2.6.4 Lambda phosphatase treatment 
Dephosphorylation of PIM1 was carried out using lambda protein 
phosphatase kit from NEB, UK. Reactions were carried out in 10 µl final volume 
containing up to 1 µg 6Xhis tagged PIM1 (WT and mutants), 1 mM MnCl2, 400 U 
lambda phosphatase and 1X PMP buffer (50 mM HEPES, 100 mM NaCl, 2 mM 
DTT, 0.01% Brij-35, buffer pH 7.5). The reactions were incubated at 30 0C for 1 
hour, and terminated by addition of 2X SDS sample buffer with DTT. Reactions 
were boiled for 5 min and ran on a gel followed by coomassie staining.  
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3.1 Introduction 
Signal transduction by protein kinases is a complex process that 
involves rapid activation, deactivation or degradation of other proteins, 
including the kinases themselves. Small fluctuations in the activity of a single 
kinase can have profound effects on the cells, and lead to the development 
of diseases such as cancer. Hence, the activity of a kinase in a cell is tightly 
controlled by various post-translational modifications (PTM) such as 
phosphorylation, acetylation and ubiquitination, to name a few. In contrast to 
most kinases, PIM kinases naturally adopt a catalytically active conformation, 
and do not rely on any external phosphorylation events for their activity. 
Nevertheless, in one report the tyrosine kinase, ETK, was shown to increase 
the kinase activity of PIM1 by phosphorylating PIM1 at Tyr218 (Kim et al., 
2004). Additionally, PLK1 and PIM1 were also shown to phosphorylate each 
other in vitro, but the functional consequence remains unclear (Van Der Meer 
et al., 2014). 
As mentioned earlier, PIM1 has a very short-half life in primary cells 
(5-10 min), which indicates that under physiological conditions, the levels of 
PIM1 mRNA and protein are strictly maintained at very low levels. However, 
in cancer cells the mechanisms controlling the stability of PIM1 are 
dysregulated leading to hyperactivation of PIM1. This observation also 
suggests that the absolute levels of PIM1 in a cell determine the level of its 
activity. Therefore, it is important to identify the mechanisms that regulate the 
levels or activity of PIM1 in cancer cells, so that they can be exploited 
therapeutically. 
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To date, there is only one published study on the regulation of PIM1 
protein levels in cells (Shay et al., 2005). Here, it was shown that the 
ubiquitin-proteasome system regulates PIM1 turnover in cells, in a manner 
that is influenced by the binding of the heat shock proteins - HSP90 and 
HSP70. However, neither the E3 ubiquitin ligases involved nor the modified 
lysine(s) in PIM1 were investigated in this study. Since the mechanisms 
regulating PIM1 kinase activity and stability have remained largely 
unexplored, I wanted to investigate whether PIM1 undergoes any other 
PTMs. In this chapter, I will discuss the PTM of PIM1 by the Small Ubiquitin-
like Modifier (SUMO) protein, and identify the functional components involved 
in this PTM. 
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3.2 Bioinformatics based prediction of potential post-translational 
modification sites in PIM kinases  
In order to identify novel sites of PTM in PIM1, I utilised several 
bioinformatic tools. One of which, PhosphoSitePlus, is a freely available 
online database containing PTM site data for human and mouse proteins 
reported in the published scientific literature, and identified through high-
throughput mass-spectrometry by Cell Signaling Technology (Hornbeck et 
al., 2004). A basic search for the available information on the three PIM 
kinases revealed several sites of phosphorylation (on serine, threonine and 
tyrosine) and ubiquitination (on lysine). Since none of these sites were 
validated experimentally, they were considered as predicted sites of 
modification. Although many sites of modification were suggested for PIM 
kinases on the website, only those sites that appeared in more than one 
mass-spectrometry record were considered for further analysis. Interestingly, 
this method highlighted sites of ubiquitination and Ser8 as a site of potential 
phosphorylation. Ser8 was previously shown to be autophosphorylated by 
PIM1 (Bullock et al., 2005; Jacobs et al., 2005)  and therefore not examined 
further. Table 3.1 lists the predicted sites of modification listed on 
PhosphoSitePlus (www.phosphosite.org). 
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Table 3.1 Predicted sites of PTM in PIM kinases by PhosphoSitePlus 
Protein Site  Modification Sequence No. of 
records 
PIM1 Ser8 Phosphorylation MLLSKINSLAHLRAA 7 
Lys169 Ubiquitination GVLHRDIKDENILID 2 
Lys183 Ubiquitination DLNRGELKLIDFSG 2 
Lys194 Ubiquitination FGSGALLKDTVYTDF 10 
PIM2 Lys40 Ubiquitination RLGPLLGKGGFGTVF 23 
Lys61 Ubiquitination DRLQVAIKVIPRNRV 26 
Lys89 Ubiquitination LEVALLWKVGAGGGH 4 
Lys132 Ubiquitination LFDYITEKGPLGEGP 4 
Lys165 Ubiquitination GVVHRDIKDENILID 14 
Lys179 Ubiquitination DLRRGCAKLIDDFGSG 11 
PIM3 Ser8 Phosphorylation MLLSKFGSLAHLCGP 4 
Lys38 Ubiquitination ADKESFEKAYQVGAV 2 
Lys172 Ubiquitination GVVHRDIKDENLLVD 4 
Lys186 Ubiquitination DLRSGELKLIDFGSG 4 
Lys197 Ubiquitination FGSGALLKDTVYTDF 10 
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As mentioned previously, PIM kinases share a high level of homology 
at the amino acid level, and hence some of the PTMs predicted for PIM1 
were also present in PIM2 and PIM3. These were assumed to be of high 
importance as not only do they suggest evolutionary conservation, but point 
towards a common mechanism of regulation of the three kinases. Of note, all 
four sites listed for PIM1 were also found in PIM3. However, only two sites 
were found in common amongst the three family members i.e. K169 and 
K194 in PIM1, K165 and K179 in PIM2 and K172 and K186 in PIM3 
respectively.  
Interestingly, the amino acid sequence surrounding K169 of PIM1, 
K165 of PIM2 and K172 of PIM3 resembles a consensus SUMO-recognition 
motif. The classic SUMO consensus motif is ψKxE/D, where ψ (psi) is a 
hydrophobic residue (usually I/V/L/F/M) and x is any amino acid (Rodriguez 
et al., 2001). In addition, the SUMO-motif lies in the active site of PIM1 
responsible for substrate binding as evidenced from the crystal structure of 
PIM1 (Figure 3.1). Hence, it could be speculated that SUMOylation at this 
site would affect PIM1 kinase activity. Therefore, I wanted to test if PIM 
kinases could also be SUMOylated, and if this has an impact on its activity 
and/or stability. PIM1 was chosen for further investigation, as it is the most 
widely studied member of the PIM kinase family. 
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Figure 3.1 Crystal structure of PIM1 highlighting the consensus SUMO motif 
Crystal structure was obtained from Protein Data Bank (PDB ID: 2BIL) and edited in PyMOL. 
PIM1 is shown in red here. An ATP analogue, highlighted in blue, shows the ATP binding 
site in PIM1. The consensus SUMO motif present in PIM1 is shown in yellow. A PIM 
consensus peptide (PIMitide), highlighted in green, shows the substrate binding site in PIM1. 
The overlap between the consensus SUMO site and the substrate binding site can be clearly 
seen in this figure. 
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3.3 Modification of PIM1 by SUMO1, 2 and 3 in cultured cells 
To determine whether PIM1 can by modified by SUMO in cells, a Ni2+-
NTA pull-down experiment was performed under denaturing conditions as 
described previously (Tatham et al., 2009). Lysis of cells under denaturing 
conditions has two main advantages. Firstly, it rapidly and irreversibly 
inactivates the deSUMOylating enzymes, which preserves the otherwise 
highly labile SUMO modification. Secondly, only covalent modifications such 
as SUMOylation or ubiquitination are kept intact under these conditions. The 
protocol relies on the high binding affinity of Ni2+-NTA beads towards proteins 
carrying a hexa-histidine (6Xhis) tag, usually on SUMO1, 2 or 3. All proteins 
modified by or covalently attached with SUMO are enriched through this 
procedure and can be detected by western blotting using an antibody against 
the protein of interest. 
COS7 cells were transfected with plasmids encoding 6Xhis tagged 
SUMO1, SUMO2 or SUMO3 with MYC-tagged PIM1. PIM1 was also co-
transfected with empty pcDNA3 as a negative control. After 42-48 hours, the 
SUMOylated proteins were captured by Ni2+-NTA beads, separated by SDS-
PAGE and western blotted with the anti-MYC tag (clone 9E10) antibody to 
visualise SUMOylated PIM1. As seen in Figure 3.2A, slowly migrating bands 
of PIM1 were observed in cells transfected with 6Xhis-SUMO family 
members but not with empty vector, suggesting that PIM1 can be modified by 
SUMO1, 2 and 3. The apparent shift in the molecular weight of PIM1 from 34 
kDa to 55 kDa is also consistent with the covalent addition of a 15-20 kDa 
SUMO moiety. Importantly, it was observed that SUMOylated PIM1 runs as a 
! 141!
doublet indicating that there are at least two independent sites of 
SUMOylation in PIM1..  
PIM1 was expressed at equal levels in all samples as determined by 
western blotting using inputs (whole cell lysate, Figure 3.2B). The 
SUMOylated PIM1 bands, as expected, were indistinguishable in the inputs 
even though several bands of higher molecular weight were observed. This 
is because only a small fraction of any protein is modified at a given time, 
and unless enriched the SUMOylated proteins are difficult to detect in whole 
cell lysates. 
The expression of the three SUMO isoforms and their purification was 
also checked using the Ni2+-NTA pull-down samples by western blotting for 
His-tag antibody. As shown in Figure 3.2C, SUMO1 was expressed at a 
lower level than SUMO2 and 3 which explains the lower level of PIM1 
SUMOylation seen with SUMO1 in Figure 3.2A. It was also observed that 
unmodified PIM1 itself binds non-specifically to the Ni2+-NTA beads even in 
the absence of 6Xhis-SUMO. However, this does not affect the results as 
SUMOylated PIM1 runs at a higher molecular weight than unmodified PIM1.  
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Figure 3.2 Modification of PIM1 by SUMO1, 2 and 3 in cultured cells 
COS7 cells were transfected with plasmids encoding MYC-tagged PIM1 with 6Xhis-SUMO1, 
2 or 3. Cell lysates were prepared 42-48 hours after transfection. An aliquot of whole cell 
lysate was taken as input, and the remainder subjected to Ni2+-NTA pull-down to capture 
SUMOylated proteins. Note that unmodified PIM1 binds non-specifically to Ni2+-NTA beads. 
(A) PIM1 SUMOylation was analysed by western blotting of Ni2+-NTA pull-down samples 
using MYC-tag antibody. (B) Total levels of PIM1 expressed under each transfection 
condition was analysed by western blotting of Input samples using MYC-tag antibody. (C) 
The levels of total SUMOylated proteins under each case was analysed by western blotting 
of Ni2+-NTA pull-down samples using His-tag antibody. The data shown here is 
representative of three independent experiments. 
 
! 143!
3.4 In vitro SUMOylation of PIM1 
To show that SUMOylation of PIM1 was not an artefact of 
overexpression, an in vitro SUMOylation experiment was performed using 
two different approaches.  
In the first set of experiments, in vitro transcribed and translated 35S-
methionine labelled MYC-PIM1 was incubated with recombinant SUMO E1 
enzyme SAE1/2, SUMO E2 enzyme Ubc9 and SUMO1 or SUMO2, in the 
presence of an ATP-regeneration system. A PIM1 alone reaction was also 
set up as a negative control. Additionally, a well-known substrate for 
SUMOylation, SP100, was used as a positive control to check the efficiency 
of the in vitro SUMOylation reaction. As shown in Figure 3.3A, both SUMO1 
and SUMO2 modified PIM1 to the same extent resulting in the shift of PIM1 
to a double band running at 55 kDa. The modification was not very efficient 
when compared with the positive control, SP100. However, this could be 
because in vitro reactions do not recapitulate cellular conditions, and 
sometimes other factors or E3 SUMO ligases might be necessary for optimal 
SUMOylation.  
In the second experiment, recombinant GST-PIM1 was incubated with 
recombinant SUMO1 or SUMO2, in the presence of SAE1/2, Ubc9 and ATP. 
GST-PIM1 alone was used as a negative control. The expression and 
purification of GST-PIM1 has been described in chapter-2 (section 2.4.1 and 
2.4.2). Equal amounts of SUMO1 and SUMO2 were used in these reactions. 
Figure 3.3B shows that GST-PIM1 can be modified in vitro by SUMO1 and 2 
to a similar extent. The results obtained with both approaches were identical. 
Interestingly, the doublet pattern observed for SUMO1 modified PIM1 was 
different to that of SUMO2 modified PIM1. It is possible that SUMO1 and 2 
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might target different sites for modification, which could result in different 
electrophoretic gel mobility. Since SUMO2 is the predominant SUMO isoform 
found in cells, and the fact that a significantly larger number of proteins are 
modified by SUMO2/3 than SUMO1 (Saitoh and Hinchey, 2000), subsequent 
experiments were done using only SUMO2. 
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Figure 3.3 In vitro SUMOylation of PIM1 
(A) In vitro transcribed and translated 35S-methionine labelled PIM1 was incubated with 
recombinant SAE1/2, Ubc9 with SUMO1 or SUMO2 in the presence of ATP-regeneration 
system. The reactions were terminated and SDS-PAGE was performed. SUMOylation of 
radiolabelled PIM1 was visualised on a Phosphorimager. SP100 was used as a positive 
control in the SUMOylation reaction. (B) Recombinant GST-PIM1 was incubated in the 
presence of ATP, recombinant SAE1/2, Ubc9 with SUMO1 (left) or SUMO2 (right). The 
reactions were terminated and resolved by SDS-PAGE. Western blotting was performed 
using a GST-tag antibody to detect SUMOylated PIM1. The data shown here is 
representative of two independent experiments. 
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3.5 Modification of ectopically expressed PIM1 by endogenous SUMO2  
From the experiments described above, it is reasonable to suppose 
that PIM1 can be SUMOylated. But since the conditions used i.e. ectopic 
expression and in vitro reconstitution are not truly physiological, it is crucial to 
demonstrate SUMOylation of protein at the endogenous level. Several 
methods have been proposed in the literature for the detection of 
endogenous SUMOylated proteins.  
The most common method is immunoprecipitation of the endogenous 
protein followed by western blotting with a SUMO antibody. Inversely, SUMO 
can be immunoprecipitated from cells, followed by western blotting for the 
test protein. The latter method, however, is less sensitive as the proportion of 
SUMOylated protein in the pool will be very small. Another factor to consider 
is that under native conditions, antibodies might not bind SUMOylated 
proteins because of issues such as epitope masking. Immunoprecipitation of 
SUMOylated PIM1 was challenging for various reasons. Firstly, the levels of 
endogenous PIM1 were found to be very low in all adherent cell lines tested. 
Secondly, commercially available PIM1 antibodies were found to be not 
suitable for immunoprecipitation of endogenous PIM1. Thirdly, the IgG heavy 
chain runs at the same size as SUMOylated PIM1 at 55 kDa on a gel, which 
makes detection of SUMOylated PIM1 more difficult. 
SUMOylated proteins can also be enriched from HeLa cells stably 
expressing 6Xhis-SUMO1 or 2 by a Ni2+-NTA pull-down experiment, followed 
by western blotting for the protein of interest. Unfortunately, the results from 
these cell lines were not reproducible mainly because the PIM1 antibody 
detected several non-specific bands in the negative control cells that do not 
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express any 6Xhis-SUMO. Several attempts using other antibodies were also 
unsuccessful.  
In an attempt to resolve the antibody issues and the low levels of 
endogenous PIM1, I decided to ectopically express only PIM1 in cells and 
analyse its modification by endogenous SUMO2. To do this, I tagged PIM1 
with a 6Xhis-tag, and transfected H1299 cells which express low levels of 
PIM1, and performed a Ni2+-NTA pull-down experiment under denaturing 
conditions. The generation of a plasmid expressing 6Xhis-PIM1 has been 
described under section 2.3.1. H1299 cells transfected with empty vector 
was used as a negative control. The lysates were resolved by SDS-PAGE, 
and western blotting was performed using His-tag (PIM1) and SUMO2 
(endogenous) antibody. Figure 3.4A shows that PIM1 was efficiently affinity 
purified from cells expressing 6Xhis-PIM1.  Bands of high molecular weight 
were also observed in both the input and Ni2+-NTA pull-down samples, 
suggestive of ubiquitinated and SUMOylated forms. Figure 3.4B shows that 
PIM1 was modified by endogenous SUMO2 in H1299 cells. PolySUMOylated 
bands were also detected under these conditions. Western blotting was also 
performed on the Ni2+-NTA samples using an Ubiquitin-specific antibody. 
Figure 3.4C shows the PIM1 is also polyubiquitinated in H1299 cells.  
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Figure 3.4 Modification of ectopically expressed PIM1 by endogenous SUMO2 
H1299 cells were transfected with a plasmid expressing 6Xhis-PIM1, and harvested 48 
hours after transfection. An aliquot of whole cell lysate was taken as input, and the 
remainder subjected to Ni2+-NTA pull-down to capture His-PIM1. (A) Western blotting was 
performed on Ni2+-NTA and input samples to confirm PIM1 expression and purification. The 
same Ni2+-NTA samples were western blotted for endogenous SUMO2 (B) or ubiquitin (C) to 
confirm presence of SUMOylated and ubiquitinated PIM1 in cells. The data shown here is 
representative of two independent experiments. 
!
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3.6 Identification of the sites of SUMOylation in PIM1 
The 34 kDa PIM1 protein contains 12 lysine residues (Figure 3.5A). 
Since only lysine 169 (K169) is present within a consensus SUMO motif 
(ΨKxD/E, where Ψ is usually I/V/L and x is any amino acid), only one site 
was expected to be SUMOylated in PIM1. However, result shown in figure 
3.2A suggests that PIM1 is modified at multiple sites. In order to identify the 
sites of SUMO modification in PIM1, all lysine residues were mutated to 
arginine individually by site-directed mutagenesis. Since other PTMs such as 
ubiquitination, methylation, acetylation, neddylation etc also occur on lysine 
residues, therefore any effects observed with the lysine to arginine mutants 
must be carefully interpreted, as they may be the result of inhibition of other 
PTM. Mutation of the glutamic acid adjacent to the modified lysine has also 
been shown to disrupt SUMOylation. Hence, E171 was also mutated to 
alanine. Glutamic acid E181 was also mutated to alanine as it forms an 
inverted SUMO motif (D/ExKΨ) with lysine 183 (K183). A kinase dead 
mutant of PIM1 referred to as K67M, was also included to examine if kinase 
activity was required for SUMOylation. 
Wild-type PIM1 and various mutants were tested for their ability to 
undergo SUMOylation when co-expressed with 6Xhis-SUMO2 in COS7 by 
performing a Ni2+-NTA pull-down experiment. All proteins were expressed at 
near equal levels in this experiment using pre-determined plasmid 
concentrations for each mutant. In all cases, the total amount of plasmid 
transfected was normalised with empty vector. Figure 3.5B (left panel) shows 
that wild-type PIM1 was modified with SUMO2 resulting in a doublet running 
at 55 kDa. The kinase dead mutant, K67M, was also modified to the same 
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extent as the wild-type (WT) indicating that SUMOylation of PIM1 occurs 
independently of its kinase activity. This also rules out that the possibility that 
the PIM1-SUMO doublet band represents the autophosphorylated and 
nonphosphorylated form of PIM1, as the K67M mutant is incapable of 
autophosphorylation (Padma and Nagarajan, 1991). Substitution of lysine 
residues present in the N-terminal lobe of PIM1 to arginine (K5R, K24R, K29, 
31R, K67R, K71R and K94, 95R) did not affect SUMOylation suggesting that 
these lysines were not individually targeted for SUMOylation. On the other 
hand, Figure 3.5B (right panel) shows that K169R mutation partially 
abolished SUMOylation, as evident from the loss of the upper band from the 
doublet observed with wild-type PIM1, confirming that K169 is one of the 
main sites of SUMOylation. Interestingly, the E171A mutant completely 
abolished SUMOylation of PIM1. This result was unexpected, as the K to R 
and E to A mutants, so far in the literature, have been shown to produce the 
same effect on SUMOylation. It is possible that E (negatively charged amino 
acid) to A (nonpolar amino acid) substitution alters the structure of the 
SUMO-motif in PIM1 significantly such that it is no longer recognised by the 
enzymes of the SUMO pathway. To investigate this further, E171 was 
mutated to glutamine (Q), which is a slightly more conservative substitution. 
As anticipated, the E171Q mutant only partially abolished SUMOylation of 
PIM1, in a manner identical to the K169R mutant. Mutation of other sites 
(E181A, K183R, K194R and K313R) also did not affect PIM1 SUMOylation 
suggesting that they were not involved in SUMOylation. Overall, only K169 
was identified as a specific site of SUMO modification, whereas the second 
(non-consensus) site of modification is promiscuous.  
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The mutational analysis of PIM1 shown in Fig 3.5B suggests two 
important things. Firstly, the sites of SUMO modification in PIM1 may be 
mutually exclusive. This is based on the calculation that covalent attachment 
of a single 20 kDa SUMO moiety to a 34 kDa PIM1 would result in the 
formation of a ~55 kDa PIM1 species, whereas attachment of two or more 
SUMO moieties at distinct sites simultaneously should result in the formation 
of a ~75 kDa or >75 kDa PIM1 species (Fig 3.5C). Although I detected a 
doublet of PIM1 at ~55 kDa upon coexpression of SUMO2 consistent with 
monoSUMOylation, I did not observe any multi-monoSUMOylated (>75 kDa) 
species of PIM1 on the gel (Fig 3.5B). Secondly, the PIM1 doublet observed 
at 55 kDa is consistent with PIM1 being SUMOylated at two independent 
sites. The top band of the ~55 kDa represents PIM1 SUMOylated at K169 as 
mutation of this site to R169 led to the disappearance to the top band of the 
PIM1-SUMO doublet at ~55 kDa. Therefore, the bottom band of the doublet 
may represent PIM1 SUMOylated at the non-consensus site. It appears that 
PIM1 SUMOylated at K169 runs at a slightly higher mobility compared to 
PIM1 SUMOylated at the non-consensus lysine.  
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Figure 3.5 Identification of the sites of SUMOylation in PIM1 
(A) Schematic showing the functional domains in PIM1, and the position of various lysine 
residues and glutamic acid predicted to be involved in SUMOylation. (B) COS7 cells were 
transfected with the various PIM1 mutants and 6Xhis-SUMO2. An aliquot of whole cell lysate 
was taken as input, and the remainder subjected to Ni2+-NTA pull-down to capture 
SUMOylated proteins. The samples were subjected to SDS-PAGE followed by western 
blotting using a PIM1 antibody. The data shown here is representative of two independent 
experiments. 
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Figure 3.5 (C) Schematic illustrating changes in the electrophoretic gel mobility of PIM1 
upon covalent attachment of SUMO at the consensus (K169) and non-consensus site. 
SUMOylation at these sites may occur in a mutually exclusive manner, as a 75 kDa species 
of PIM1 is not observed in the SUMOylation assay. 
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3.7 DeSUMOylation of PIM1 by SENP1 
SUMOylation is a reversible process mediated by members of the 
SUMO protease family (SENP1-3 and SENP5-7). SENPs catalyse removal 
of SUMO from SUMOylated substrates, and also cleavage of inactive SUMO 
to yield active SUMO (Hickey et al., 2012). SENP1 was used as a 
representative in this experiments as it shows little specificity towards 
SUMO1 or SUMO2/3 modified substrates, and thus is a good tool to confirm 
SUMOylation of a protein. 
  To demonstrate that SENP1 was capable of deSUMOylating PIM1, 
COS7 cells were co-transfected with plasmids expressing PIM1, 6Xhis-
SUMO2 with either active SENP1 or a catalytically inactive SENP1 (C602S 
mutant). SUMOylated proteins were captured by Ni2+-NTA pull-down method, 
and PIM1 SUMOylation was analysed by western blotting. As shown in 
Figure 3.6 inputs, both active and inactive SENP1 were expressed at equal 
protein levels. Expression of SUMO2 led to PIM1 SUMOylation (observed as 
a 55 kDa doublet band), which disappeared upon co-expression of wild-type 
SENP1 but not the inactive SENP1 mutant. The results shown in figure 3.6 
indicates that SENP1 can deSUMOylate PIM1, and also strengthens the 
observation that the 55 kDa bands are indeed SUMOylated forms of PIM1. 
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Figure 3.6 DeSUMOylation of PIM1 by SENP1 
COS7 cells were transfected with plasmids expressing PIM1 alone, or with 6Xhis-SUMO2 in 
combination with active Flag-SENP1 (WT) or inactive Flag-SENP1 (MT), and Ni2+-NTA pull-
down was performed to isolate SUMOylated proteins, followed by SDS-PAGE and western 
blotting for PIM1. Western blotting of whole cell lysate or input was done using Flag-tag 
antibody to show expression of SENP1. The data shown here is representative of two 
independent experiments. 
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3.8 Identification of PIAS family members as E3 SUMO ligases for PIM1  
           SUMO E3 ligases regulate global protein SUMOylation by acting as a 
platform, which can recruit UBC9, SUMO and substrate in different ways, 
thus facilitating efficient transfer of SUMO to protein substrates. Unlike the 
ubiquitin-proteasome system, a large number of proteins can be modified in 
the absence of an E3 SUMO ligase. They are therefore, thought to mediate 
substrate and substrate-lysine specificity under specific cellular conditions. 
Various E3 SUMO ligases have been identified such as the Protein 
Inactivator of Activated STATs (PIAS) family, TOPORS, PC2, RanBP2 and 
HDAC4 to name a few. It was not possible to test all identified E3 SUMO 
ligases for their activity on PIM1. So, as a starting point, I hypothesised that 
PIAS family members might act as E3 SUMO ligases since, like PIM1, they 
are themselves regulated by the JAK-STAT pathway. PIAS1 and PIAS3 were 
shown to inhibit binding of the transcription factors STAT1 and STAT3 
respectively to their target gene promoters, thus negatively regulating the 
JAK-STAT pathway (Chung et al., 1997; Liu et al., 1998). 
          I tested the ability of three PIAS family members – PIAS1, PIASy (or 
PIAS4) and PIAS3 for their ability to stimulate PIM1 SUMOylation. PIM1 was 
transfected in COS7 cells with 6Xhis-SUMO2 alone or in combination with 
HA-tagged PIAS1, HA-tagged PIASy or Flag-tagged PIAS3, and a Ni2+-NTA 
pull-down experiment was performed. As shown in Figure 3.7, a small 
proportion of PIM1 was SUMOylated upon co-expression of 6Xhis-SUMO2 
alone. However, this was dramatically increased in the presence of PIAS3 
under basal conditions leading to polySUMOylated forms of PIM1, consistent 
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with the role of an E3 SUMO ligase. PIAS1 and PIASy did not stimulate PIM1 
SUMOylation to the same extent as PIAS3. Nevertheless, the stimulation 
observed was higher when compared with the no E3 ligase sample.  To rule 
out that this difference was simply because of the higher levels of PIM1 
observed when co-expressed with PIAS3 (as shown in the inputs), the same 
set of samples were also treated with the proteasome inhibitor MG132 (20 
µM for 6 hours) in an effort to stabilise or equalise PIM1 levels. Under these 
conditions, PIAS3 was more potent than PIAS1 and PIASy in enhancing 
PIM1 SUMOylation. Intriguingly, PIAS1 could also stimulate 
polySUMOylation of PIM1, an effect that was not noticeable under basal 
conditions. PIASy did not stimulate PIM1 SUMOylation any further when 
compared with the no E3 ligase sample. Taken together, these results 
suggest that PIAS1 and PIAS3 might serve as E3 SUMO ligases for PIM1. 
Although PIAS proteins are highly active in cells, one limitation of this 
experiment is that the equal levels of E3 SUMO ligases expressed here may 
not directly correlate with their activity. This difference in the E3 SUMO 
activity can be identified by western blotting of Ni2+-NTA pull-down samples 
using a His-tag antibody to detect the total increase in the levels of 
SUMOylated proteins in the cellular extracts upon expression of the PIAS 
proteins. 
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Figure 3.7 Identification of PIAS family members as E3 SUMO ligases for PIM1 
Western blots of Ni2+-NTA pull-down samples showing PIM1 SUMOylation, from COS7 cells 
transfected with plasmids expressing PIM1, 6Xhis-SUMO2 with PIAS1, PIAS3 or PIASy in 
the absence or presence of MG132 (20 µM for 6 hours). A western blot of whole cell lysate 
(input) was also performed to confirm the expression PIM1, PIAS1, PIAS3 and PIAS3 using 
the indicated antibodies. The data shown here is representative of two independent 
experiments. 
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3.9 Interaction of PIM1 with PIAS1 and PIAS3 
         Various studies have shown that SUMO E3 ligases primarily interact 
with a SUMO bound UBC9, while the Ubc9 itself binds the substrates. 
However, in some cases, the E3 ligase is required for both substrate and 
Ubc9 binding acting as a bridge (Gareau and Lima, 2010). To test if PIM1 
directly interacted with PIAS3, H1299 cells were transiently transfected with 
plasmids encoding MYC-tagged PIM1 and Flag-tagged PIAS3, and co-
immunoprecipitation was performed using anti-flag antibody or mouse IgG as 
negative control. The immunoprecipitated proteins were analysed by SDS-
PAGE and western blotting. Figure 3.8A shows that PIM1 was detected in 
the PIAS3 immunoprecipitated sample, showing that the two proteins can 
indeed interact. No PIAS3 or PIM1 protein was detected in the control IgG 
samples suggesting that the antibodies were specific.  
The ability of PIM1 to interact with PIAS1 was also tested by co-
immunoprecipitation. Plasmids encoding MYC-tagged PIM1 and HA-tagged 
PIAS1 were co-transfected in H1299 and immunoprecipitated using anti-HA 
antibody or mouse IgG as negative control. Since PIAS1 mediated 
SUMOylation was clearly seen when the proteasome was inhibited (Figure 
3.5), the transfected cells were also treated with MG132 as done previously. 
The concentration of the protein in the lysate was determined using BCA-DC 
assay, and equal amount of lysate was used in the experiment to accurately 
reflect the levels of proteins before and after proteasome inhibition. The 
inputs from Figure 3.8B show that the levels of PIAS1 remain largely 
unchanged, however, levels of PIM1 protein increase following MG132 
treatment, as expected. No PIM1 or PIAS1 was detected in the IgG negative 
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control immunoprecipitation reactions. Roughly equal amount of PIAS1 was 
immunoprecipitated under both conditions. Importantly, interaction of PIAS1 
with PIM1 was only observed under conditions of proteasome inhibition 
suggesting this PIAS1 might target PIM1 for degradation by a SUMO-
dependent ubiquitination mechanism.  
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Figure 3.8 Interaction of PIM1 with PIAS1 and PIAS3 
(A) H1299 cells were co-transfected with PIM1 and PIAS3 expression plasmids, and co-
immunoprecipitation was performed using Flag-antibody to pull-down PIAS3 associated 
complexes. The immunoprecipitated (IP) samples were western blotted using Flag-tag and 
PIM1 antibody to show that PIAS3 and PIM1 can form a complex in cells. Mouse IgG was 
used as a negative control. (B) H1299 cells were transfected with plasmids expressing PIM1 
and PIAS1 in the presence or absence of MG132 (20 µM for 6 hours), and equal amount of 
lysate were subjected to immunoprecipitation using HA-tag (PIAS1) antibody. The IP 
samples were western blotted for the presence of PIAS1 and PIM1 using anti-HA and PIM1 
(Bethyl) antibodies. Mouse IgG was used as a negative control. The data shown here is 
representative of two independent experiments. 
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3.10 Summary and Discussion 
              In this chapter, I wanted to identify novel sites of PTM in PIM1. 
Based on the bioinformatic analysis of the amino acid sequence of PIM 
kinases, I identified the presence of a conserved SUMO consensus motif in 
the active site of PIM1. The presence of a consensus SUMO-motif in the 
active site is quite intriguing as it overlaps with the conserved Ser/Thr kinase 
domain motif, HRDxKxxN (Hanks and Hunter, 1995). Based on the study of 
other protein kinases, at least two residues within this motif are directly 
involved in catalysis: an invariant aspartic acid that acts by accepting a 
proton from the attacking hydroxyl substrate and a lysine (K169 in PIM1) that 
is thought to neutralise the negative charge of the γ-phosphate during 
transfer. However, it is now known that K169 in PIM1 actually does not form 
the conventional salt bridge with the nucleotide phosphate group of ATP as 
seen with other kinases (Qian et al., 2005). Therefore, the possibility that 
SUMOylation may occur at K169 is particularly interesting as it may regulate 
the catalytic activity of PIM1 through a novel mechanism. Moreover, the 
same motif was shown to be SUMOylated in other kinases such as Aurora B 
and AKT, and has been described in the final discussion (Fernández-
Miranda et al., 2010; Li et al., 2013).   
I showed that PIM1 could be modified covalently by SUMO1, SUMO2 
and SUMO3 in vitro and in cultured cells and appear as a closely migrating 
doublet around 55 kDa. In a recent study, over one-third of all SUMOylated 
proteins were predicted to contain more than one SUMOylation site. Also, 
proteins such as PARP and hnRNPM were found to contain over 10 
SUMOylation sites. There is also evidence of multiple SUMOylation sites 
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being modified simultaneously (Tammsalu et al., 2014). By site-directed 
mutagenesis of individual lysine residues in PIM1, I showed that K169 is one 
of the main sites of modification while the second site is promiscuous. 
Interestingly, mutation of E171 to alanine was sufficient to abolish 
SUMOylation at both sites. Promiscuity of the modified lysine is not 
uncommon in the SUMO system, and has been observed previously with 
other substrates such as PARP, BLM and DAXX (Eladad et al., 2005; Lin et 
al., 2006; Martin et al., 2009). Similar effects have also been observed in the 
ubiquitin system (Danielsen et al., 2011). Why this happens is not very clear, 
although, it can be speculated that mutation of a lysine residue where the 
modification usually occurs, forces the modification to occur on an adjacent 
lysine. Unfortunately, in these cases, mutation of a single lysine is not 
sufficient to abolish SUMOylation, and different combinations of lysine need 
to be mutated to arginine simultaneously. A major disadvantage of 
substituting all the lysine to arginine in a protein is that the SUMO-specific 
effects become indistinguishable from other modifications such as 
ubiquitination and acetylation that also occur on lysine residues. However, in 
case of PIM1, the K169R is SUMOylated at one site, while the E171A mutant 
is impaired in overall SUMOylated allowing us to ascertain individual effects 
of SUMOylation at a single site versus SUMOylation at both sites. The 
functional effects of these mutants are discussed in the next chapter.  
             I also showed that the SUMO protease, SENP1, could deconjugate 
SUMO from SUMOylated PIM1. It should be noted that most SENPs have 
overlapping substrates, so under a cellular condition, one or more SENPs 
could be involved in deSUMOylation of PIM1. I also identified members of 
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the PIAS family as E3 SUMO ligases for PIM1. Interestingly, inhibition of the 
proteasome activity by MG132 not only stabilised unmodified PIM1 but also 
the SUMOylated form of PIM1, suggesting that SUMO modification and PIM1 
turnover could be related. PIAS3 enhanced polySUMOylation of PIM1 under 
basal conditions and upon proteasomal inhibition. On the other hand, PIAS1 
mediated PIM1 polySUMOylation was only observed under conditions of 
proteasomal inhibition. I further showed that PIAS1 and PIAS3 could directly 
interact with PIM1 in cells. The interplay of the SUMO and ubiquitin systems 
in regulating PIM1 levels will be discussed in the next chapter. 
 
 
 
 
 
 
 
 
Chapter 4 
 
Effect of SUMOylation on PIM1 
activity and stability 
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4.1 Introduction 
SUMOylation is a highly dynamic and reversible post-translational 
modification that is known to affect several biological processes such as 
transcription, translation, cell cycle progression and DNA repair. Covalent 
attachment of SUMO to one or more lysine residues on target proteins can 
alter the structure, and hence the function of the target protein by promoting 
or inhibiting specific cellular protein interactions under physiological and/or 
stress conditions. In broad terms, SUMOylation has been shown to affect the 
activity, cellular localisation and stability of its substrates (Wilkinson & Henley 
2012).  
The proto-oncogene, PIM1, is induced in response to cytokines and 
growth factors mainly via the JAK-STAT pathway. While mechanisms 
regulating the stability of PIM1 mRNA have been studied extensively, there is 
little information on the regulation of PIM1 protein. Although it is known that 
the ubiquitin-proteasome pathway degrades PIM1, it is presently unknown 
how the activity and substrate specificity of PIM1 activity is regulated prior to 
its destruction. In addition, factors influencing PIM1 stability and localisation 
are still poorly understood. Given that SUMOylation of PIM1 occurs in the 
kinase domain, it is plausible that SUMOylation might alter its kinase activity. 
This would, thus, have an impact on the stability of the protein, and its 
function altogether. Therefore, in this chapter, I wanted to investigate the 
functional consequences of SUMOylation on PIM1, and how SUMOylation 
may impact PIM1 stability or interaction with the ubiquitin pathway. 
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4.2 Autophosphorylation of PIM1 and SUMO-mutants 
PIM kinases are capable of autophosphorylation on serine, threonine 
and even tyrosine residues. It was suggested that autophosphorylation is 
required for PIM1 activity (Telerman et al., 1988; Palaty et al., 1997), but 
there is no substantial evidence to support these claims. Therefore, I wanted 
to investigate this aspect, and also find out if the SUMO-mutants, K169R and 
E171A, are capable of undergoing autophosphorylation. To do this 
recombinant 6Xhis-PIM1 proteins were expressed in bacteria and purified as 
previously described in chapter-2 (section 2.4.1 and 2.4.3). The generation of 
a 6Xhis-PIM1 bacterial expression plasmid and its mutagenesis has also 
been described in chapter-2 (section 2.3.4 and 2.2.10).  
Phosphorylation usually results in a small but distinguishable shift in 
the electrophoretic mobility of a protein on an SDS-polyacrylamide gel. To 
check if there were any visible differences in the mobility of WT PIM1 and the 
various PIM1 mutants, the purified proteins were resolved by SDS-PAGE 
and stained with coomassie to visualise the protein. As shown in figure 4.1A, 
WT PIM1 runs at a slightly higher molecular weight when compared with the 
K67M mutant, showing that PIM1 indeed undergoes autophosphorylation in 
bacteria as the K67M is incapable of autophosphorylation (Padma and 
Nagarajan, 1991). In terms of gel mobility, the K169R mutant was identical to 
the K67M mutant, while the E171A and E171Q mutants were identical to 
WT-PIM1. There are no commercially available antibodies against the sites 
of autophosphorylation in PIM1, so I used a general phospho-Tyrosine 
antibody that is capable of detecting phosphorylated tyrosine residues 
irrespective of the identity of the surrounding residues to detect 
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autophosphorylation of the purified PIM1 proteins on a western blot. As 
expected, tyrosine phosphorylation was observed with WT PIM1 but not with 
the K67M mutant. The E171A and E171Q mutants were also capable of 
autophosphorylation like WT, but the K169R mutants showed very little to no 
tyrosine autophosphorylation.  
To confirm that the difference in mobility was due to 
autophosphorylation of PIM1, the proteins were treated with lambda 
phosphatase and resolved by SDS-PAGE (Figure 4.1B). Lambda 
phosphatase catalyses dephosphorylation of serine, threonine and tyrosine 
residues, which should down shift the WT and E171A protein bands to the 
same level as the K67M and K169R mutants. As expected, phosphatase 
treatment altered the mobility of the WT and E171A on a gel, but not the 
K169R and K67M mutants, further confirming the results. 
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Figure 4.1 Autophosphorylation of WT PIM1 and mutants 
6Xhis-PIM1 (WT and mutants) was expressed and purified from bacterial cells, and resolved 
by SDS-PAGE. Panel (A) shows the relative mobility of the purified proteins on a coomassie 
stained gel. A western blot for the same samples was also performed using a pan-phospho 
tyrosine antibody to show autophosphorylation. (B) The purified PIM1 proteins were treated 
with lambda phosphatase (+) to remove overall phosphorylation or untreated (-). Samples 
were resolved by SDS-PAGE, and stained with coomassie to visualise a shift in mobility, 
which is indicative of dephosphorylation. The data shown here is representative of two 
independent experiments. 
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4.3 In vitro kinase activity of PIM1 and SUMO-mutants 
Next, I wanted to determine if the PIM1 SUMO-mutants, K169R and 
E171A, were catalytically active or inactive on PIM1 substrates. To do this, I 
performed in vitro kinase assays using purified recombinant 6Xhis-tagged 
PIM1 (wild-type or mutants) with Histone H3.3 (Zippo et al., 2007) or c-MYC 
(Zhang et al., 2008) as a substrate. For kinase assays, equal amount of 
substrate was incubated with WT or mutant PIM1 in the presence of MgCl2 
and ATP as described under section 2.6.1. Following 30 min incubation at 30 
0C, the reactions were terminated by addition of 2X SDS lysis buffer and 
resolved by SDS-PAGE. The gels were either stained with coomassie to 
check total protein levels, or transferred onto a nitrocellulose membrane for 
western blotting using phospho-specific antibodies against phospho-Ser10 of 
H3.3 and phospho-Ser62 of c-MYC, as a read-out of kinase activity.  
Wild-type PIM1 was used as a positive control in these reactions, and 
also as a baseline against which the kinase activity of the K169R and E171A 
mutants were measured. An E171Q mutant was also generated to verify the 
effects of mutating E171 on PIM1 kinase activity. A kinase-dead version of 
PIM1, K67M, was included as a negative control. In addition, a no kinase 
control reaction was set up to confirm the specificity of the phospho-specific 
antibody. 
The in vitro kinase assay performed using Histone H3.3 as a substrate 
(Fig. 4.2) shows that nearly equal amount of substrate (H3.3) and kinase 
(PIM1) were used in each reaction. As expected, wild-type PIM1 
phosphorylated Histone H3.3 at Ser10 residue, whereas the K67M (kinase-
dead) mutant did not. The K169R (to a lesser extent), E171A and E171Q 
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mutants were also able to phosphorylate Ser10 of Histone H3.3, indicating 
that these mutants were active, at least in vitro. To confirm these results, a 
second well-known substrate of PIM1, c-MYC, was used in an in vitro kinase 
assay. Again, wild-type PIM1 phosphorylated c-MYC at Ser62 but the K67M 
mutant did not. Surprisingly, both K169R and E171A mutants showed a 
similar significant decrease in their ability to phosphorylate c-MYC at Ser62. 
The E171Q mutant was also incapable of phosphorylating c-MYC, indicating 
that these PIM1 mutants show reduced kinase activity towards c-MYC as a 
substrate in vitro.  
The results obtained here show that the SUMO mutants display 
reduced kinase activity towards c-MYC but not Histone H3.3. The E171A and 
E171Q mutants behaved similarly in the kinase assay suggesting the effects 
were specific to the E171 of PIM1. These results also raise the possibility 
that these sites may be determinants of PIM1 substrate specificity or are 
required for protein-protein interactions with some substrates (such as c-
MYC) but not others (such as H3.3), which would explain why they could 
phosphorylate one of them better than the other. Another possibility is that 
SUMOylation of PIM1 guides substrate specificity, which would depend upon 
a number of factors such as the site of modification and the biological context 
under which PIM1 gets SUMOylated. 
 
 
 
 
 
! 171!
 
Figure 4.2 In vitro kinase assays using WT PIM1 and mutants 
In vitro kinase assays were carried out using recombinant c-MYC or Histone H3.3 in the 
absence or presence of the indicated purified PIM1 protein. The reactions were incubated at 
30 0C for 30 min and terminated by the addition of 2X sample buffer. The samples were 
resolved by SDS-PAGE, and either stained with coomassie or transferred to a nitrocellulose 
membrane for western blotting using phospho-specific antibodies. The data shown here is 
representative of two independent experiments. 
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4.4 Development of a method to purify SUMOylated PIM1 from in vitro 
SUMOylation reaction 
Since the PIM1 SUMO-mutants do not directly mimic the effect of 
SUMOylation on PIM1 activity, I attempted to purify SUMOylated PIM1 from 
in vitro SUMOylation reactions, for subsequent use in a kinase assay to 
measure its activity. The experimental steps leading to the final experiment 
are described first below. 
 
4.4.1 Small scale in vitro SUMOylation reactions 
Previous in vitro SUMOylation experiments performed in chapter-3 
using GST-PIM1 and SUMO2 generated a very little amount of SUMOylated 
PIM1. Therefore, to eliminate the possibility that the GST-tag on PIM1 itself 
was inhibitory, SUMOylation of 6Xhis-PIM1 was also tested. Addition of an 
E3 SUMO ligase can also increase the amount of SUMOylated protein in 
vitro. I used purified PIAS1 in the assay as an E3 SUMO ligase since it was 
readily available from Prof. Ron Hay’s lab (University of Dundee). Active 
recombinant PIAS3 was not available, so I decided to use the IR1+M 
fragment as a proxy for SUMO E3 ligase to increase the levels of 
SUMOylated PIM1 in the reactions. The IR1+M fragment is a small portion of 
the SUMO E3 ligase RanBP2 that exerts complete E3 SUMO ligase activity 
in vitro with little substrate specificity (Pichler et al., 2004). A combination of 
6Xhis-PIM1 with GST-SUMO2 or GST-PIM1 with 6Xhis-SUMO2 was used, 
as I wanted to perform affinity purification of SUMOylated PIM1 using Ni2+-
NTA or GST beads. 
Figure 4.3 shows the small scale in vitro SUMOylation reactions that 
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were carried out using GST-PIM1 and 6Xhis-SUMO2 with increasing 
amounts of either IR1+M or PIAS1, to identify the condition under which 
maximum PIM1 SUMOylation was achieved. Lane-2 of coomassie stained 
gel shows appearance of multiple higher molecular weight bands consistent 
with SUMOylated GST-PIM1 (around 75-100 kDa) in the absence of an E3 
SUMO ligase. Addition of IR1+M, but not PIAS1, led to a small increase in 
levels of higher molecular weight bands. To confirm that these bands 
corresponded to SUMOylated PIM1, a western blot was performed on the 
same samples using a GST-tag antibody (Fig 4.3B). SUMOylated PIM1 was 
observed even in the absence of an E3 ligase but increased in the presence 
of IR1+M. However, addition of PIAS1 did not enhance PIM1 SUMOylation. 
This might be because PIAS proteins themselves are autoSUMOylated 
(Kotaja et al., 2002), and this might affect their ability to SUMOylate some 
substrates in vitro.  
Figure 4.4 shows the small scale in vitro SUMOylation reaction that 
was carried out using 6Xhis-PIM1 and GST-SUMO2 under the same 
conditions as described above. As before, higher molecular weight bands 
corresponding to SUMOylated PIM1 were observed in the presence of GST-
SUMO2 alone without any E3 SUMO ligase. IR1+M led to polymerisation of 
GST-SUMO2 as evidenced by the disappearance of monomeric GST-
SUMO2 in the reactions. PIAS1 failed to utilise the free SUMO2 suggesting 
that once autoSUMOylated PIAS1 was incapable of SUMOylating PIM1 in 
vitro. To check the levels of SUMOylated PIM1, western blotting was 
performed on the same samples, which showed that the presence of IR1+M 
slightly increased the levels of polySUMOylated PIM1, whereas PIAS1 did 
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not affect the levels of total SUMOylated PIM1 (Fig 4.4B). Under the 
experimental conditions tested, it was not possible to substantially increase 
the amount of SUMOylated PIM1; therefore, I chose to scale up the reaction 
containing 6xhis-PIM1 with GST-SUMO2 and IR1+M for further purification 
experiments. A detailed procedure has been described in chapter-2 (section 
2.6.3). 
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Figure 4.3 In vitro SUMOylation using purified GST-PIM1 and 6Xhis-SUMO2 
(A) In vitro SUMOylation reactions were carried out using GST-PIM1 and 6Xhis-SUMO2 in 
the absence of an E3 ligase, or in the presence of increasing concentrations of an E3 SUMO 
ligase (IR1+M or PIAS1). The reactions were incubated overnight at 37 0C, and terminated 
by the addition of 2X sample buffer. The samples were resolved by SDS-PAGE and stained 
with coomassie. (B) Western blotting was also performed on the same sample using anti-
GST antibody to detect SUMOylated PIM1. This experiment was only performed once.  
* indicates an unknown protein (non-specific) co-eluting with GST-PIM1 during protein 
purification and also cross-reactive with the GST-tag antibody. 
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Figure 4.4 In vitro SUMOylation using purified 6Xhis-PIM1 and GST-SUMO2 
(A) In vitro SUMOylation reactions were carried out using 6Xhis-PIM1 and GST-SUMO2 in 
the absence of an E3 ligase, or in the presence of increasing concentrations of an E3 SUMO 
ligase (IR1+M or PIAS1). The reactions were incubated overnight at 37 0C, and terminated 
by the addition of 2X sample buffer. The samples were resolved by SDS-PAGE and stained 
with coomassie. (B) Western blotting was also performed on the same sample using anti-His 
tag antibody to detect SUMOylated PIM1. The data shown here is representative of two 
independent experiments. 
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4.4.2 Purification of SUMOylated PIM1 
The experimental strategy devised for the affinity purification of 
SUMOylated PIM1 has been shown in figure 4.5A. The washing and dialysis 
buffers used here contained 50 mM Tris pH 7.5 and 500 mM NaCl because 
the recombinant 6Xhis-PIM1 was purified under these conditions, and 
remained active in this buffer. The elution buffer was additionally 
supplemented with 1 mM DTT. In the first step, 6Xhis-tagged proteins i.e. the 
total pool of PIM1 (unmodified and SUMO-modified) was captured using Ni2+-
NTA beads. The captured proteins were eluted using imidazole and then 
dialysed to remove any imidazole. Next, GST-beads were added to 
specifically capture GST-SUMO2 modified PIM1, while getting rid of the 
unmodified PIM1 from the mix. Finally, SUMOylated PIM1 was eluted from 
the GST-beads using reduced glutathione, dialysed and concentrated using 
a spin column concentrator. As shown in figure 4.5B, both SUMOylated and 
unmodified PIM1 were mostly present in the first elution, showing that the 
pull-down worked. However, some PIM1 was still bound to the Ni2+-NTA 
post-elution despite using a high concentration of imidazole (200 mM), 
suggesting that the protein was getting precipitated on the beads. The same 
problem was observed with elutions from GST-beads. Unfortunately, neither 
the concentrated elution nor the flow-through from the GST-beads showed 
any enrichment of SUMOylated PIM1, indicating that the protein was getting 
lost at some step during the process. It is possible that the binding of 
SUMOylated PIM1 with GST-beads was not successful, and hence 
SUMOylated PIM1 was washed away. Alternatively, some proteins stick to 
the membranes of the concentrator, which makes their elution quite difficult. 
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The following changes were made to the protocol in order to circumvent the 
problems observed above: 
1. SUMOylated PIM1 was captured using GST-beads first followed by Ni2+-
NTA, to check if this method worked better. 
2. To avoid protein precipitation on the beads, the reaction mix was diluted at 
least five in 50 mM Tris pH 7.5 before adding the beads. 
3. The beads were incubated overnight at 4 0C instead to 1-2 hours to 
increase the binding of proteins to the beads. 
4. The concentration of NaCl was reduced from 500 mM to 150 mM in wash 
and elution buffers. 
5. Dialysis and concentration steps were skipped to avoid loss of protein and 
activity. This also reduced the time of the procedure by 2-3 days. 
The purification experiment was repeated again with the changes 
described above, and the results are shown in figure 4.6A. The elutions 
obtained here were named GST elution-1 or Ni2+-NTA-1, denoting the type of 
beads used in the first affinity purification step. The GST-beads efficiently 
captured the SUMOylated proteins from the reaction, and unmodified PIM1 
was washed away in the flow through as desired. Most of the SUMOylated 
protein was found in the two elutions and very little was left uneluted from the 
beads. On the other hand, the Ni2+-NTA beads seemed to pull-down all the 
protein from the SUMOylation reaction as the flow through did not contain 
much protein. This was not observed when 500 mM NaCl was used 
previously (Figure 4.4B), which would suggest that PIM1 might interact non-
covalently with SUMO and/or SUMOylated proteins, and a salt concentration 
of 150 mM used here was insufficient to disrupt these interactions. 
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In the second affinity-purification step, fresh Ni2+-NTA beads were 
added to GST-elution-1, or fresh GST-beads were added to Ni2+-NTA elution-
1 to purify SUMOylated PIM1. The resulting final elutions were named Ni2+-
NTA elution-2 or GST elution-2. Unfortunately, under both conditions the 
SUMOylated PIM1 failed to elute from the beads as observed in figure 4.6B. 
The most common way of eluting such proteins is by using a strong 
denaturing agent such as urea. The disadvantage of this method is that the 
proteins lose their structural and functional integrity, and can no longer be 
used in enzymatic assays without successful renaturation of the protein. 
Because of the limitations of this process, I decided to test the GST elution-1 
(containing SUMOylated PIM1 and SUMO2) in a kinase assay, which is 
described in the next section. 
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Figure 4.5 Purification of SUMOylated PIM1 from in vitro SUMOylation reaction 
(A) Schematic outlining the proposed method of purification of SUMOylated PIM1 from in 
vitro SUMOylation reactions. (B) Coomassie stained gel showing the different steps of 
outlined purification procedure. 6Xhis-PIM1 (unmodified and SUMO modified) was first 
pulled down using Ni2+-NTA beads, and eluted using imidazole. Eluted proteins were bound 
to GST-beads to pull down SUMOylated PIM1, and eluted using reduced glutathione. The 
beads were also boiled post elution to check efficiency and binding of proteins to the beads. 
This experiment was only performed once. 
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Figure 4.6 Purification of SUMOylated PIM1 from in vitro SUMOylation reaction 
(A) Products of the in vitro SUMOylation reactions were divided into two equal fractions. The 
first fraction was bound to GST-beads to pull down all SUMOylated proteins including PIM1. 
The proteins were eluted from the beads using reduced glutathione. The second fraction 
was bound to Ni2+-NTA beads to pull down SUMOylated and unmodified PIM1. The proteins 
were eluted using imidazole. The samples were resolved by SDS-PAGE and stained with 
coomassie. (B) Elutions from GST-beads were bound to Ni2+-NTA beads, and elutions from 
Ni2+-NTA beads were bound to GST-beads to isolate SUMOylated PIM1. The bound proteins 
were eluted as done before, and resolved by SDS-PAGE followed by coomassie staining to 
check purification of SUMOylated PIM1. The data shown here is representative of two 
independent experiments. 
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4.5 SUMOylation of PIM1 increases its kinase activity in vitro 
The main goal of purifying SUMOylated PIM1 was to get rid of the 
relatively large proportion of unmodified PIM1 from the reactions, as it can 
mask the effects of the small proportion of SUMOylated PIM1 in a kinase 
assay. However, this might not be entirely possible as PIM1 interacts with 
itself, so a proportion of SUMOylated PIM1 interacts and co-purifies with 
unmodified PIM1, as evident from GST elution-1 shown in figure 4.6A. 
However, I was able to wash away the majority of unmodified PIM1 through 
the method described above, and increase the ratio of SUMO-modified PIM1 
to unmodified PIM1. Since the GST elution-1 was obtained by affinity 
purification of the in vitro SUMOylation reactions (containing GST-SUMO2, 
6Xhis-PIM1, SAE1/2, IR1+M) using GST beads, it contains a mix of 
SUMOylated PIM1 and SUMO2 itself and some unmodified PIM1. 
For an accurate comparison of relative kinase activity, the same 
amount of unmodified PIM1 and SUMOylated PIM1 was used in each kinase 
assay reaction. This was achieved by first deSUMOylating an equal amount 
of GST elution-1 in vitro using the catalytic domain (amino acids 415-643) of 
the SUMO protease SENP1 (Shen et al., 2006). Histone H3.3 was used as a 
representative substrate in this experiment. Figure 4.7A illustrates the kinase 
assay performed using SUMOylated and deSUMOylated PIM1. The 
procedure has been described in detail in chapter-2 (section 2.6.3). 
As shown in figure 4.7B, SUMOylated PIM1 was found to be more 
active in phosphorylating Histone H3.3 at Ser10 when compared with 
unmodified PIM1 at all the time points. Equal amount of substrate was used 
in these reactions, which was further confirmed by western blotting for total 
Histone H3.3. To rule out that presence of SENP1 catalytic domain affected 
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PIM1 kinase activity, a control kinase assay was set up. Unmodified PIM1 
kinase was incubated with increasing concentrations of SENP1 catalytic 
domain for 1 hour at 30 0C as done previously, followed by the addition of 
kinase assay buffer, ATP and Histone H3.3 substrate for further 30 min at 30 
0C. The reactions were terminated by addition of SDS sample buffer, and ran 
on an SDS-polyacrylamide gel. Coomassie staining of the gel confirmed the 
presence of equal amount of kinase and substrate in each reaction (Fig 
4.7C). Western blotting performed using phospho Ser10 Histone H3.3 
antibody showed no obvious difference in the level of phosphorylation in the 
absence or presence of the SENP1 fragment. These results confirm that, 
under these conditions, SUMOylated PIM1 shows higher kinase activity 
towards Histone H3.3 than unmodified PIM1. 
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Figure 4.7 DeSUMOylation coupled kinase assay 
(A) Schematic outlining the purification of SUMOylated proteins, followed by deSUMOylation 
and kinase assay to measure the activity of SUMOylated PIM1. (B) SUMOylated proteins 
were captured using GST-beads, and eluted in reduced glutathione. The elutions were 
divided into two equal parts. The first part was left untreated, and the second part was 
treated with SENP1 catalytic domain to deconjugate SUMO from proteins. Resulting mix of 
proteins containing SUMOylated PIM1 or (deSUMOylated) unmodified PIM1 was used in a 
kinase assay using Histone H3.3 as a substrate. Samples were collected at the indicated 
time points and terminated by the addition of 2X sample buffer, and resolved by SDS-PAGE.  
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Western blotting was performed using indicated antibodies to measure histone H3.3 
phosphorylation. (C) Purified WT PIM1 was first incubated with or without SENP1 catalytic 
domain fragment for 1 hour at 30 0C, and immediately used in a kinase assay using Histone 
H3.3 as substrate. The reactions were incubated at 30 0C for 30 min and terminated by 
adding 2X sample buffer. The samples were resolved by SDS-PAGE and either stained with 
coomassie to check protein levels. A western blot was also performed to measure histone 
H3.3 phosphorylation using a phospho-specific antibody. The data shown here is 
representative of two independent experiments. 
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4.6 PIM1 protein induction in tetracycline-inducible cell lines 
HeLa and U2OS cells expressing YFP-tagged PIM1 (WT and 
mutants) in a tetracycline-inducible manner were generated to assess PIM1 
function under cellular conditions. The generation of these cell lines has been 
described in chapter-2 (section 2.3.3 and 2.5.10). Once a stable pool of 
colonies was established, the cells were assayed for the expression of YFP-
PIM1 by the addition of doxycycline (a more stable analogue of tetracycline) 
at a concentration of 1 µg/ml for 24 hours, followed by western blotting with 
GFP-tag antibody. Since YFP is a mutant form of GFP, the GFP antibody is 
widely used to detect YFP in western blotting, immunofluorescence, flow-
cytometry and also for immunoprecipitation.  
Figure 4.8A shows that YFP-PIM1 expression is induced in HeLa-FRT 
cells only when doxycycline is added to the cells. The blots also show the 
maximum possible expression levels of WT, K169R, E171A and K67M 
achievable in HeLa-FRT cells upon addition of a saturating concentration of 
doxycycline (1 µg/ml). The main advantage of using these cell lines is that by 
adding varying concentrations of doxycycline to the cells, we can control the 
level of protein expression. In order to find out the concentrations of 
doxycycline at which WT PIM1 and mutants were expressed at comparable 
levels, cells were treated with the indicated concentration of doxycycline for 
48 hours, followed by western blotting with GFP-antibody. The results shown 
in figure 4.8B show that the system works as expected, but it was difficult to 
determine relative concentrations at which WT, K169R, E171A and K67M 
were expressed at exactly equal levels. However, WT PIM1 expression at 10 
ng/ml seemed comparable to the expression of K169R at 20 ng/ml, E171A at 
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10 ng/ml or 12 ng/ml and K67M at 50 ng/ml. The first few experiments such 
as cycloheximide chase assays (described later) were performed with HeLa-
FRT cells. However, over time these cells lost their responsiveness to 
doxycycline, and could not be used any further. Therefore, I also generated 
new PIM1 inducible cell lines in U2OS background. 
Figure 4.9A shows the maximum possible expression levels of WT 
PIM1 and mutants upon addition of 1 µg/ml doxycycline for 24 hours in 
U2OS-FRT cells, which is very similar to the expression levels observed in 
the HeLa-FRT cells. These levels possibly reflect the differences in their 
protein stability (discussed in the next section). A doxycycline titre was also 
performed to identify conditions of similar protein expression levels in the 
different U2OS cell lines. Figure 4.9B shows the increase in levels of protein 
expression in response to increasing doxycycline concentrations. WT PIM1 
expression at 10 ng/ml seemed comparable to that of the expression of 
K169R at 20 ng/ml, E171A at 10 ng/ml and K67M at 50 ng/ml. Cells 
expressing K169R showed some protein expression even in the absence of 
doxycycline. This leakiness is probably because of the presence of 
tetracycline (tet) in the FBS, and can be eliminated by the use of tet-free 
FBS.  
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Figure 4.8 Induction of PIM1 proteins in HeLa-FRT cells following doxycycline addition 
(A) The cells were assayed for the expression of YFP-PIM1 in the presence or absence of 
doxycycline (1 µg/ml) for 24 hours, followed by western blotting with GFP-tag antibody. (B) 
Cells were treated with increasing concentrations of doxycycline for 48 hours, followed by 
western blotting with GFP-antibody. The data shown here is representative of two 
independent experiments. 
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Figure 4.9 Induction of PIM1 proteins in U2OS-FRT cells following doxycycline 
addition (A) Cells were treated with 1 µg/ml doxycycline for 24 hours, followed by western 
blotting using anti-GFP antibody. (B) Cells expressing PIM1 were treated with increasing 
concentrations of doxycycline for 48 hours, followed by western blotting using anti-GFP 
antibody. The data shown here is representative of two independent experiments. 
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4.7 Phosphorylation of endogenous substrates by PIM1 and mutants 
The in vitro kinase assays performed using the K169R and the E171A 
mutants suggested that the SUMOylation might regulate PIM1 substrate 
specificity. To check if these effects could also be observed under cellular 
conditions, I used the U2OS-FRT cells expressing YFP-PIM1 in a tet-
inducible manner. The expression of PIM1 was induced by addition of the 
indicated concentration of doxycycline to the cells for 48 hours (Fig 4.10), 
followed by western blotting for some PIM1 substrates. As shown in the 
figure 4.10, there was a small but clear increase in Histone H3 
phosphorylation at Ser10 in cells expressing WT PIM1. Cells expressing YFP 
alone or the kinase dead K67M PIM1 did not affect Histone H3 
phosphorylation as expected, confirming that YFP-PIM1 was indeed active in 
U2OS cells. The two PIM1 SUMO-mutants, K169R and E171A, although 
expressed at higher levels when compared to WT PIM1, phosphorylated 
Histone H3 to the same extent as the WT PIM1 indicating that these mutants 
were active against Histone H3, as observed previously in the in vitro kinase 
assays. I next checked the phosphorylation of the classical PIM1 substrate, 
BAD. As previously published (Aho et al., 2004), WT PIM1 phosphorylated 
BAD at Ser112, whereas the K67M mutant did not. Interestingly, the PIM1 
SUMO mutants were incapable of phosphorylating BAD and thus, in this 
case, behaved as kinase-dead K67M mutant. Furthermore, a small increase 
in the total levels of c-MYC protein was observed in cells expressing WT 
PIM1 but not K67M, suggesting phosphorylation mediated stabilisation of c-
MYC as previously reported (Zhang et al., 2008). The K169R and the E171A 
mutants were also capable of stabilising c-MYC and phosphorylating c-MYC 
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at Ser62 as the WT PIM1. This is in contrast to the observations from in vitro 
kinase assays performed with c-MYC as a substrate, and could be due to the 
differences in protein folding between bacterial and mammalian cells, or due 
to the different environment of cells. 
PIM kinase inhibitors such as SGI-1776 and AZD1208 have been 
shown to exert anti-tumour effects by inhibiting protein translation via 
decreased phosphorylation of 4E-BP1 and p70 S6K (Yang et al., 2012; 
Keeton et al., 2014). So I wanted to examine if expression of WT PIM1 or 
mutants affected protein translation in U2OS cells by looking at 
phosphorylation of 4E-BP1 at Thr37/46 and p70 S6K at Thr389. However, 
there was no significant increase in phosphorylation of these proteins, 
suggesting that protein translation was not affected in these cells upon PIM1 
expression.  
Additionally, I also looked at signalling pathways activated in response 
to PIM1 activation in U2OS cells. Small molecule inhibition of AKT in prostate 
cancers has been shown to activate PIM kinases, indicating the existence of 
a feedback loop between PIM and AKT kinases (Cen et al., 2013). Therefore, 
I wanted to investigate if expression of PIM1 has any effect on the levels or 
activity of AKT in U2OS cells. Western blotting performed using a pan-AKT 
antibody showed that PIM1 (WT or mutant) does not affect the total levels of 
AKT. However, expression of WT PIM1 significantly reduced basal 
phosphorylation of AKT at Ser473. Since phosphorylation of AKT at Ser473 
is required for maximal activation of kinase activity, these results suggest that 
basal activity of AKT is reduced in these cells. The same downregulation of 
AKT activity was also observed in cells expressing the K169R and the E171A 
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mutants suggesting that PIM1 SUMOylation may not play a role in the PIM1-
AKT feedback mechanism. Also, the K67M mutant did not affect AKT 
phosphorylation or activity suggesting that kinase activity of PIM1 is 
important for the downregulation of AKT activity. These results are also 
supported by a previous study showing that the hearts of PIM1 knock-out 
mice show higher levels of AKT Ser473 phosphorylation when compared 
with wild-type mice (Muraski et al., 2007). 
Furthermore, I looked at ERK1/2 phosphorylation as inhibition of PIM1 
by siRNA or small molecule inhibitors has been shown to decrease ERK1/2 
phosphorylation in prostate and CLL cells (Wang et al., 2012; Decker et al., 
2014). As observed in figure 4.10, expression of PIM1 in U2OS cells 
significantly increased the levels of phospho ERK1/2 at Thr202/Tyr204 
without affecting the total levels of ERK1/2, while the kinase-dead mutant 
K67M did not. Intriguingly, the PIM1 SUMO-mutants did not affect ERK1/2 
phosphorylation in U2OS cells, suggesting that PIM1 SUMOylation regulates 
ERK signalling in cancer cells.  
Overall, the results shown here, using the PIM1 K169R and E171A 
mutants, suggest that PIM1 SUMOylation may regulate substrate specificity, 
and maybe involved in the maintenance of ERK signalling, but not AKT 
pathway. However, further investigation is required in support of this 
hypothesis. 
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Figure 4.10 Phosphorylation of endogenous substrates by WT PIM1 and mutants in 
U2OS-FRT cells U2OS-FRT cells expressing YFP alone, YFP-WT PIM1 and YFP-E171A 
were treated with 10 ng/ml doxycycline; U2OS-FRT expressing YFP-K169R was treated with 
20 ng/ml doxycycline and U2OS-FRT expressing YFP-K67M was treated with 50 ng/ml 
doxycycline for 48 hours, followed by western blotting using indicated antibodies. The data 
shown here is representative of two independent experiments. 
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4.8 SUMOylation of PIM1 regulates protein-protein interactions 
To investigate if PIM1 SUMOylation promotes or inhibits interaction of 
PIM1 with its substrates, co-immunoprecipitation experiments were 
performed using WT PIM1 or mutants. I first tested the interaction of PIM1 
with c-MYC since it is an important PIM1 substrate. To do this, H1299 cells 
were co-transfected with plasmids encoding c-MYC with WT PIM1 or the 
indicated mutants, and immunoprecipitated using two different PIM1 
antibodies as described in chapter-2 (section 2.5.12). The elutions were 
resolved by SDS-PAGE, followed by western blotting with PIM1 and c-MYC 
antibodies. As seen in figure 4.11, immunoprecipitation of PIM1 was 
successful with both antibodies, and no PIM1 was detected when IgG was 
used as negative control. As expected, c-MYC co-immunoprecipitated with 
WT PIM1 as previously reported (Zhang et al., 2008), but not in IgG showing 
specificity of the interaction. c-MYC was also found to co-immunoprecipitate 
with the K169R and E171A mutants, suggesting that the mutation of these 
sites or PIM1 SUMOylation does not affect protein-protein interactions with c-
MYC.  
I also tested PIM1 interaction of another substrate, MDM2, by co-
immunoprecipitation experiment. This was performed in H1299 cells 
transfected with MDM2 and PIM1 plasmids. Since both PIM1 antibodies 
(12H8 and Bethyl) gave same results with c-MYC co-immunoprecipitation, I 
only used 12H8 PIM1 antibody for immunoprecipitation here. As shown in 
figure 4.12A, PIM1 (WT and mutants) were immunoprecipitated efficiently in 
all cases, and no protein was detected in the IgG negative control as desired. 
MDM2 co-immunoprecipitated with WT PIM1 and was absent from IgG 
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samples. A closer look at the immunoprecipitated MDM2 showed two closely 
migrating bands suggestive of some phosphorylated form of MDM2. The 
K169R and the K67M mutants also pulled down the modified and unmodified 
forms of MDM2. Interestingly, the E171A mutant only interacted with the 
higher molecular weight form of MDM2, but not with the lower molecular 
weight band. This suggests that the E171 residue in PIM1 is important for 
interaction with MDM2, or that SUMOylation of PIM1 promotes its interaction 
with MDM2.  
Our lab previously demonstrated that PIM1 increases the stability of 
wild-type MDM2, in a manner that is not dependent on the PIM1 
phosphorylation sites in MDM2 i.e. Ser166 and Ser186 (Hogan et al., 2008), 
suggesting that interaction of MDM2 with PIM1 alone is sufficient for its 
stabilisation, or that a PIM1 substrate indirectly regulates MDM2 levels. 
Therefore, I wanted to investigate if the PIM1 SUMO mutants, K169R and 
E171A could also stabilise MDM2 levels. For this, H1299 cells were 
transfected with plasmids expressing MDM2 alone, or in combination with 
WT PIM1, K169R, E171A or K67M, followed by western blotting for MDM2 
and PIM1. As observed in figure 4.12B, expression of WT PIM1, but not 
K67M, increased the levels of MDM2 when compared with MDM2 alone. The 
K169R mutant also stabilised MDM2, although to a lesser extent than the WT 
PIM1. Surprisingly, the E171A mutant seemed to destabilise MDM2 acting as 
dominant-negative, further suggesting that PIM1 mediated stabilisation of 
MDM2 might be SUMOylation dependent. It should be noted that double 
bands for MDM2 are only visible in hand-made gels but not in precast gels, 
presumably due to the difference in gel composition that can affect protein 
! 196!
mobility and resolution. The samples in figure 4.12B were resolved on a 
precast gel, so the MDM2 doublets are not observed here. Since the exact 
nature and site of MDM2 phosphorylation was unknown, I did not follow up 
on this, but it will be interesting to investigate this aspect in the future. 
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Figure 4.11 Co-immunoprecipitation of PIM1 with its substrate, c-MYC 
H1299 cells were transfected with plasmids expressing c-MYC with either WT PIM1 or the 
mutants. Co-immunoprecipitation was performed using two PIM1 antibodies 12H8 and 
Bethyl or IgG negative control, and immune complexes were captured on Protein-A beads. 
Immunoprecipitated proteins were eluted by boiling the beads in 2X sample buffer, followed 
by western blotting for c-MYC or PIM1. The data shown here is representative of two 
independent experiments. 
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Figure 4.12 Co-immunoprecipitation of PIM1 with its substrate, MDM2 
(A) H1299 cells were transfected with plasmids expressing MDM2 with either WT PIM1 or 
the mutants. Co-immunoprecipitation was performed using 12H8 (PIM1) antibody or IgG 
negative control, and immune complexes were captured on Protein-A beads. 
Immunoprecipitated proteins were eluted by boiling the beads in 2X sample buffer, followed 
by western blotting for MDM2 or PIM1. (B) Equal amount of the indicated PIM1 proteins 
were coexpressed with MDM2 in H1299 cells, and the lysates were subjected to SDS-PAGE 
using precast gels, followed by western blotting using indicated antibodies. The data shown 
here is representative of two independent experiments. 
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4.9 SUMOylation of PIM1 differentially regulates its stability 
To determine whether SUMOylation of PIM1 affects its stability, I 
performed cycloheximide (CHX) chase assays. CHX blocks global protein 
synthesis in eukaryotic cells, and can therefore be used to measure half-life 
or relative protein stability in cells. To perform this assay, I transfected H1299 
cells with plasmids encoding MYC-tagged WT PIM1, K169R, E171A and 
K67M. After 24 hours, cells were untreated or treated with 50 µg/ml CHX, 
and the cells were harvested at 1, 2, 3 or 4 hours post CHX addition. The cell 
extracts were analysed for expression of PIM1 by SDS-PAGE and western 
blotting using 12H8 (PIM1) antibody. The relative levels of protein were also 
quantified using Image Lab software (Biorad). As indicated in figure 4.13, the 
half-life (T1/2) of WT PIM1 was found to be around 120 min in these cells. 
The K67M or kinase-dead PIM1 was relatively unstable with a half-life of 
approximately 70 min, suggesting that kinase activity of PIM1 regulates it 
stability. On the other hand, the K169R mutant was slightly less stable than 
the WT with a half-life of 110 min. Interestingly, the E171A mutant was 
relatively more stable than WT PIM1, K169R and K67M with a half-life of 
over 240 min. The T1/4 (25% protein remaining) for WT, K169R, E171A and 
K67M was >240 min, 180 min, >240 min and 160 min respectively. 
To further confirm these results, and to show that the results were not 
affected by transfection efficiency of the different plasmids in H1299 cells, I 
used HeLa-FRT cells inducibly expressing YFP-PIM1 for the CHX assay. 
HeLa-FRT-PIM1 cells were treated with doxycycline (50 ng/ml) for 24 hours 
prior to the addition of CHX (50 µg/ml). Cells were harvested at the given 
time periods, resolved by SDS-PAGE and western blotting was performed 
using GFP antibody to detect PIM1. The half-life of YFP tagged WT PIM1 
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and the mutants in HeLa cells were qualitatively similar to H1299 cells. 
Contrary to the western blots shown in Fig 4.14 and the results obtained in 
H1299, the quantification data showed that both WT PIM1 and K169R 
mutant have a half-life of 80 min in HeLa-FRT cells. However, the T1/4 (25% 
protein remaining) of WT PIM1 and K169R was 160 min and 135 min 
respectively suggesting that WT PIM1 was indeed slightly more stable than 
K169R. This error can be resolved by obtaining an average of quantification 
data from 2 or 3 independent experiments. As expected, the K67M mutant 
was again relatively unstable than WT PIM1 (half life around 57 min). The 
E171A mutant was most stable with half-life over 360 min (Figure 4.14). The 
T1/4 of E171A was >360 min and that of K67M was 115 min.  
The western blot data and their quantification performed here suggest 
that the relative protein stabilities of WT PIM1 and its mutants are in the 
following order: E171A>WT>K169R>K67M, indicating that SUMOylation 
differentially regulates PIM1 stability in the cells. Since the K169R mutant is 
less stable than the WT, this would suggest that SUMOylation at K169 
stabilises PIM1. On the contrary, PIM1 SUMOylation at K169 and a second 
unknown lysine together might negatively regulate PIM1 stability, as the 
E171A mutant (incapable of SUMOylation at both sites) is more stable than 
WT PIM1.  
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Figure 4.13 Cycloheximide chase of different PIM1 mutants in H1299 cells 
Cells were transiently transfected with plasmids encoding MYC-tagged PIM1 and treated 
with cycloheximide (50 µg/ml) 24 hours post transfection. Cell lysates were harvested 
directly in 2X sample buffer at the indicated time points, followed by western blotting for 
PIM1. Actin was used a loading control. The band intensity in each case was quantified 
relative to the zero time point, which was set as 1, using Biorad ImageLab software, and 
plotted on a graph as percentage of protein remaining. The data shown here is 
representative of two independent experiments. 
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Figure 4.14 Cycloheximide chase of different PIM1 mutants in HeLa-FRT cells 
HeLa-FRT cells stably expressing YFP-PIM1 were treated with 50 ng/ml doxycycline for 24 
hours followed by addition of cycloheximide (50 µg/ml). Cell lysates were harvested directly 
in 2X sample buffer at the indicated time points, followed by western blotting for GFP (PIM1). 
Actin was used a loading control. The band intensity in each case was quantified relative to 
the zero time point, which was set as 1, using Biorad ImageLab software, and plotted on a 
graph as percentage of protein remaining. The data shown here is representative of two 
independent experiments. 
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4.10 SUMOylation of PIM1 promotes its ubiquitination 
As mentioned in chapter-1, SUMOylation has been shown to either 
promote or inhibit ubiquitination of substrates. Since the PIM1 SUMO 
mutants showed a change in protein stability, I wanted to investigate if this 
was due to a change in their ability to undergo ubiquitination in cells. To 
answer this, I performed ubiquitination assays in H1299 cells. Cells were 
transfected with plasmids expressing 6Xhis-tagged ubiquitin with either WT 
PIM1, K169R, E171A or K67M mutants. Ubiquitinated proteins were pulled 
down using Ni2+-NTA beads under denaturing conditions, and the elutions 
were subjected to SDS-PAGE, followed by western blotting for PIM1. As 
shown in figure 4.15, WT PIM1 was ubiquitinated as evidenced by the 
formation of higher molecular weight adducts. Interestingly, the pattern of 
ubiquitination observed was different from that of PIM1 SUMOylation, which 
usually runs as a doublet. Both K169R and K67M mutants were also 
ubiquitinated similar to WT PIM1 suggesting that mutation of these lysines 
does not affect PIM1 ubiquitination. This also indicates that K169 and K67 
are probably not the major sites of ubiquitination. Although it cannot be ruled 
that, like SUMO, the sites of ubiquitination in PIM1 are also promiscuous. 
Conversely, the ubiquitination of the E171A mutant was significantly reduced, 
although not completely abolished, suggesting that SUMOylation of PIM1 
might promote its ubiquitination. So far, mutation of a glutamic acid has not 
been shown to affect ubiquitination independently of SUMOylation, so it is 
plausible that this is a SUMO specific effect. 
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Figure 4.15 Ubiquitination assay of WT PIM1 and mutants 
H1299 cells were transfected with plasmids expressing MYC-tagged WT PIM1, K169R, 
E171A and K67M with 6Xhis-ubiquitin. Forty-eight hours post transfection, ubiquitinated 
proteins were affinity purified under denaturing conditions using Ni2+-NTA beads, as done 
previously for SUMOylation assays. Eluted proteins and whole cell lysate (input) were 
resolved by SDS-PAGE, and western blotting was performed using 12H8 (PIM1) antibody. 
The data shown here is representative of three independent experiments. 
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4.11 RNF4 mediates degradation of SUMOylated PIM1 
Ubiquitination assay performed with the PIM1 SUMO-mutant, E171A, 
suggested that SUMOylation might enhance PIM1 ubiquitination. 
Interestingly, it was shown that polySUMO-modified proteins, such as PML, 
are specifically targeted for degradation by the SUMO-specific E3 ubiquitin 
ligase RNF4 (Tatham et al., 2008). Therefore, I wanted to test if RNF4 could 
also mediate degradation of polySUMOylated PIM1. COS7 cells were 
transfected with plasmids encoding MYC-PIM1 together with or without 
6Xhis-SUMO2 and HA-UBC9, in the presence of absence of WT or mutant 
RNF4. A Ni2+-NTA pull-down experiment was performed as described 
previously, and the lysates were subjected to SDS-PAGE and western 
blotting.  
As shown in figure 4.16, expression of SUMO2 and UBC9 with PIM1 
led to the formation of polySUMOylated PIM1. Addition of RNF4 to the 
reaction caused a decrease in the levels of SUMOylated PIM1. This effect 
was most likely due to selective ubiquitin-mediated degradation of 
SUMOylated PIM1, as a mutant form of RNF4, where the RING domain is 
mutated (mRING), is unable to degrade SUMOylated PIM1. Furthermore, the 
RNF4 mSIM mutant, where the three SUMO interacting motifs were mutated, 
was also incapable of degrading SUMOylated PIM1 suggesting that 
recognition or binding of RNF4 to polySUMO chains on the substrate (PIM1) 
is equally important for its degradation.  
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Figure 4.16 Degradation of SUMOylated PIM1 by RNF4 
COS7 cells were transfected with plasmids expressing MYC-tagged PIM1 alone or with HA-
UBC9 and 6Xhis-SUMO2 to stimulate PIM1 SUMOylation. Cells were additionally 
transfected with plasmids expressing WT RNF4 or RING finger mutant RNF4 (mRING) or 
SUMO-interaction motif mutant RNF4 (mSIM). Cells were lysed under denaturing condition 
after 48 hours, and SUMOylated proteins were captured on Ni2+-NTA beads. Proteins bound 
to Ni2+-NTA beads were resolved by SDS-PAGE followed by western blotting. Western 
blotting was also performed on whole cell lysate (input) to confirm expression of the 
transfected proteins. The data shown here is representative of two independent 
experiments. 
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4.12 Knockdown of UBC9 and RNF4 increase levels of endogenous 
PIM1 
To show that SUMOylation regulates levels of endogenous PIM1 in 
cells, I first performed siRNA knockdown of the SUMO E2 enzyme UBC9 in 
H1299 and HeLa cells using the procedure described in chapter-2 (section 
2.5.9). Cells were also transfected, in parallel, with a pool of non-targeting 
siRNA as a negative control, and harvested at the indicated time points. As 
shown in figure 4.17A, the expression of UBC9 was reduced by 90% in both 
cell lines. Reduction of UBC9 resulted in an increase in the levels of 
unconjugated or free SUMO2 in cells, as expected. Knockdown of UBC9 also 
resulted in an increase in levels of endogenous PIM1 at 48 and 72 hours 
compared to the control (siNS) in both cell lines, suggesting that inhibition of 
SUMOylation stabilises PIM1. However, this effect could also be indirect, as 
UBC9 knockdown will affect SUMOylation of hundreds of proteins 
simultaneously in the cells. Furthermore, to validate that RNF4 can act as an 
E3 ubiquitin ligase for PIM1 in cells, siRNA knockdown for RNF4 was also 
performed in H1299 cells. Figure 4.17B shows that RNF4 was efficiently 
knocked down in cells, which was accompanied with an increase in 
endogenous PIM1 after 72 and 96 hours post siRNA transfection. Taken 
together, these results support the hypothesis that SUMOylation negatively 
regulates PIM1 protein levels in cells. 
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Figure 4.17 Effect of UBC9 and RNF4 siRNA on endogenous PIM1 levels 
(A) H1299 or HeLa cells were transfected with a pool of siRNA targeting UBC9 (siUBC9), or 
non-targeting siRNA pool (siNS) as negative control. Lysates were harvested at the 
indicated time points, and western blotting was performed for endogenous PIM1 (using 12H8 
antibody), SUMO2 and UBC9. (B) H1299 cells were transfected with a pool of siRNA 
targeting RNF4 (siRNF4), or non-targeting siRNA pool (siNS) as negative control. Lysates 
were harvested at the indicated time points, and western blotting was performed for 
endogenous PIM1 (using 12H8 antibody) and RNF4. Actin was used a loading control in 
each case. The data shown here is representative of two independent experiments. 
 
 
 
! 209!
4.13 SUMOylation has no effect on the cellular localisation of PIM1 
PIM1 does not contain any obvious nuclear localisation signal (NLS) 
or nuclear export signal (NES), and has been reported to localise in the 
cytoplasm and the nucleus, depending on the cell type (Ishibashi et al., 2001; 
Ionov et al., 2003; Bachmann et al., 2004). Since SUMOylation has been 
shown to regulate nuclear-cytoplasmic transport and/or sub-cellular 
localisation of various proteins such as RanGAP1 (Joseph et al., 2002), 
KLF5 (Du et al., 2008), PML (Zhong et al., 2000) , TEL (Wood et al., 2003), 
IGF1 receptor (Sehat et al., 2010), I wanted to investigate if SUMOylation of 
PIM1 affects its sub-cellular localisation. To do this, plasmids encoding MYC-
tagged WT PIM1, K169R, E171A or K67M were transiently transfected into 
H1299 cells, and nuclear-cytoplasmic fractionation experiment was 
performed as described in chapter-2 (section 2.5.13).  
Figure 4.18A shows that the fractionation was successful as the 
cytoplasmic protein GAPDH was only detected in the cytoplasmic fraction, 
while the nuclear protein Histone H3 was only detected in the nuclear 
fraction. WT PIM1 localised to both the cytoplasm and the nucleus. No 
differences were observed in the localisation of the K169R, E171A mutants 
indicating that SUMOylation may not be involved in nuclear-cytoplasmic 
shuttling of PIM1. The K67M mutant was also localised in the nucleus and 
the cytoplasm, which also indicates that PIM1 localisation occurs 
independently of its kinase activity.  
PIM1 localisation was also checked in DU145 cells stably expressing 
PIM1. Because of the difference in stability of different PIM1 mutants, the 
cells were treated with the proteasome inhibitor, MG132, prior to fractionation 
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to equalise protein levels. As shown in figure 4.18B, there was no difference 
in the localisation of the WT PIM1, K169R, E171A and K67M mutants. In 
each case, PIM1 was observed both in the cytoplasm and the nucleus, but 
relatively more was observed in the nucleus. Since we obtain 3.5X more 
cytoplasmic extract than the nuclear extract in these experiments (see 
section 2.5.13), the higher levels of PIM1 observed in the nucleus may be 
because of the higher concentration of nuclear extract resolved on the gel. 
This was further confirmed by confocal microscopy of DU145 under the same 
condition. The merged images from different cell lines further indicated that 
PIM1 was predominantly cytoplasmic in these cells with weak PIM1 staining 
in the nucleus (Fig 4.19) as expected. The DNA was stained using DAPI 
(shown in blue) and PIM1 was stained using the 12H8 antibody (shown in 
yellow). 
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Figure 4.18 Nuclear-cytoplasmic fractionation of WT PIM1 and mutants 
(A) H1299 cells were transiently transfected with plasmid expressing MYC-tagged WT PIM1 
or mutants, and a nuclear-cytoplasmic fractionation was performed. Equal concentration of 
the nuclear and cytoplasmic fractions was resolved by SDS-PAGE and western blotting was 
performed using 12H8 (PIM1 antibody) (B) DU-145 cells stably expressing different PIM1 
proteins were treated with MG132 (20 µM for 6 hours) to equalise protein levels, and 
subjected to nuclear-cytoplasmic fractionation. Equal concentration of the nuclear and 
cytoplasmic fractions was resolved by SDS-PAGE and western blotting was performed using 
12H8 (PIM1 antibody). In both experiments, GAPDH was used a cytoplasmic marker and 
Histone H3 as a nuclear marker to check efficiency of fractionation. The data shown here is 
representative of two independent experiments. 
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Figure 4.19 Cellular localisation of WT PIM1 and mutants in DU145 stable cell lines 
DU145 cells stably expressing WT PIM1 or mutants were grown on coverslips, and stained 
with 12H8 (PIM1) antibody (shown in yellow) overnight, followed by incubation with a 
fluorescent-labelled secondary antibody. DAPI was used to stain DNA or nuclear (blue). 
Images were acquired using a 63X oil immersion objective lens of a Leica SP5 confocal 
microscope. Representative images of different fields of view have been shown here. The 
data shown here is representative of one experiment. 
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4.14 Soft agar colony formation assay 
To explore the role of PIM1 in promoting tumorigenesis, I performed 
soft agar colony formation assays in DU145 cells stably expressing WT PIM1 
or mutants. The experimental procedure has been described in chapter-2 
(section 2.5.16). DU145 cells were chosen for this experiment as a previous 
study showed that overexpression of PIM1 in DU145 increased colony 
formation ability of these cells by 6-fold, as well as colony size (Kim, Roh and 
Abdulkadir, 2010). H1299 cells were used as a positive control as they 
readily form colonies in soft-agar within 2 weeks.  
As shown in figure 4.20, H1299 cells formed colonies indicating the 
experimental set up was working as expected. Unfortunately, no colonies 
were formed in any of the DU145 stable cell lines in this assay, even after 6 
weeks of incubation. The very fact that no colonies were observed in cells 
expressing WT PIM1 indicates that maybe higher PIM1 levels are required to 
induce colony formation in these cells. Another explanation is that the genetic 
composition of DU145 cells used by us maybe different from the ones used 
in the previous study. Due to time constraints, I was not able to create stable 
cell lines in other background such as H1299; however, this could be 
performed in the future. 
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Figure 4.20 Soft-agar colony formation in DU145-PIM1 stable cell lines 
DU145 cells stably expressing vector alone or WT PIM1 or PIM1 mutants (K169R, E171A, 
K67M) were grown in soft-agar for 6 weeks to check for their ability to form anchorage-
independent colonies, following which images were acquired using a Motic AE31 inverted 
light microscope at 10X optical resolution. Representative images of different fields of view 
have been shown here. H1299 cells were used as a positive control. The data shown here is 
representative of two independent experiments. 
 
 
 
 
 
! 215!
4.15 Summary and Discussion 
In this chapter, I explored the possible effects of SUMOylation on 
PIM1 activity, stability and localisation. The experiments were performed 
using the PIM1 SUMO mutants containing either a lysine to arginine (K169R) 
or glutamic acid to alanine (E171A) mutation. In the previous chapter, I 
showed that the K169R mutant is only SUMOylated at one site (other than 
K169), whereas the E171A mutant is incapable of undergoing SUMOylation 
at both sites in PIM1.  
The use of single site substitutions, as performed in this study, to 
determine the effects of PTMs on a protein is commonplace in the scientific 
field, and can be very informative. However, the underlying assumption, 
when comparing a wild-type protein against a mutant one, is that 100% of 
wild-type protein is SUMOylated; when in reality only a small percentage of 
the total protein is modified at any given point. Therefore, the results 
obtained using the SUMO site mutants must be interpreted carefully. The 
results presented in this chapter have been summarised in Table. 4.1. 
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Table 4.1 Summary of results 
PARAMETER WT PIM1 K169R E171A K67M 
SUMOylation ++ + - ++ 
Autophosphorylation + - + - 
In vitro Histone H3 
Kinase activity 
++ ++ ++ - 
In vitro c-MYC 
Kinase activity 
++ + + - 
BAD 
phosphorylation 
in U2OS 
+ - - - 
Histone H3 
phosphorylation in 
U2OS 
+ + + - 
Deactivation of AKT 
in U2OS 
+ + + - 
Activation of ERK1/2 
in U2OS 
+ - - - 
Stability ++ + +++ + 
Ubiquitination ++ ++ + ++ 
Localisation No change No change No change No change 
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 Since the activity of many kinases is regulated by 
autophosphorylation, I first looked at autophosphorylation of bacterially 
purified recombinant WT PIM1, and mutants. I demonstrated that WT PIM1 
was capable of undergoing autophosphorylation in vitro, but the kinase-dead 
K67M mutant was not. Surprisingly, only the E171A, but not the K169R, 
mutant could undergo autophosphorylation. The most plausible explanation 
as to why the K67M and K169R mutants are incapable of 
autophosphorylation can be derived from catalysis studies performed with 
other protein kinases such as PKCα (Hanks and Hunter, 1995). It is known 
that the lysine residues equivalent to the conserved PIM1 K67 and K169 in 
other Ser/Thr-kinases are required for efficient ATP binding and transfer of 
phosphate to the substrate. So, the mutation of these core kinase domain 
residues may be expected to negatively affect the kinase activity, and hence 
autophosphorylation. Another explanation is that a lysine to arginine 
substitution might alter the structure of the protein leading to changes in 
activity. It is quite difficult to say if SUMOylation has any effect on the 
autophosphorylation status of PIM1, as the K169 residue might be essential 
for the catalytic activity of the kinase. The E171A mutant, on the other hand, 
is only semi-conserved in protein kinases, and is still capable of tyrosine 
autophosphorylation. This suggests that the E171A mutant might be a better 
indicator of the effect SUMOylation has on PIM1 activity rather than the 
K169R mutant.  
Next, I tested the ability of WT PIM1 and the mutants to phosphorylate 
previously reported PIM1 substrates in an in vitro kinase assay. From 
autophosphorylation studies one would expect the K169R mutant to be 
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catalytically inactive, however, I found that both K169R and E171A mutants 
were active in vitro and phosphorylated Histone H3.3 at Ser10, similar to WT 
PIM1. Intriguingly, both K169R and E171A were able to phosphorylate c-
MYC at Ser62 in vitro, but their kinase activity was significantly reduced 
when compared to the WT. In both cases, the K67M mutant was completely 
inactive in phosphorylating substrates. These results would suggest two 
important things. First, despite the K169R and the E171A mutants displaying 
clear differences in autophosphorylation, their kinase activities seem to be 
unaffected, suggesting that overall autophosphorylation of PIM1 may not be 
required for its basal activity, at least in vitro.  The exact sites of PIM1 
autophosphorylation are unknown, so it was not possible to examine the 
contribution of individual sites towards PIM1 activity. Additionally, I was able 
to show that PIM1, although being a serine/threonine kinase, is also able to 
autophosphorylate on tyrosine residues, which supports a previously 
published study (Palaty et al., 1997). Second, the ability of the PIM1 SUMO 
mutants to phosphorylate some substrate more efficiently than others in vitro 
would suggest that SUMOylation might regulate substrate specificity. Since 
the microenvironment in cells is completely different to that of an in vitro 
kinase assay, I expressed WT PIM1 or mutants in U2OS cells, and looked at 
phosphorylation of endogenous PIM1 substrates such as BAD, c-MYC and 
Histone H3. It was observed that WT PIM1 phosphorylated BAD up to 10 
times higher than the no kinase control, but the SUMO mutants were 
incapable of phosphorylating BAD. Conversely, WT PIM1 and both the 
SUMO mutants were able to phosphorylate H3 and c-MYC. Intriguingly, WT 
PIM1 and both the K169 and the E171A mutants reduced AKT activation in 
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cells, whereas the K67M mutant did not. On the other hand, only WT PIM1 
was able to increase phosphorylation of ERK1/2. These results broadly 
suggest that SUMOylation of PIM1 might promote activation of some 
pathways, or increase their activity towards proteins of a specific pathway. To 
the best of our knowledge, this is the first time the SUMOylation site mutants 
of a kinase have been shown to display differential kinase activity towards 
different substrates, indicating substrate specificity in vitro and in cells. 
Unlike other kinases, PIM1 is constitutively active i.e. it does not have 
an ON or OFF state in cells, so it is unlikely that SUMOylation is required for 
activation of PIM1 kinase activity. Data obtained from in vitro kinase assays 
using the mutants suggest that the mutants are indeed active, but since the 
WT PIM1 used in these assays is not SUMOylated, it is hard to predict its 
exact function. Therefore, I attempted to purify SUMOylated PIM1 from in 
vitro SUMOylation reactions. It was difficult to completely isolate 
SUMOylated PIM1 because of technical reasons, but the kinase assays 
containing a mix of unmodified and SUMO modified PIM1 showed higher 
kinase activity when compared with unmodified PIM1 only. This would 
suggest that SUMO conjugation enhances PIM1 kinase activity, and gives 
rise to two interesting concepts. First, one can speculate that SUMO may 
enhance kinase-substrate interactions, or orient the substrate in a manner 
that increases the rate of reaction. Second, since the fraction of SUMOylated 
PIM1 in the reaction is very small compared to unmodified PIM1, this would 
suggest that SUMOylated PIM1 might form a complex with unmodified PIM1, 
which results in increased kinase activity. 
Furthermore, I showed that both the kinase dead PIM1 K67M and the 
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K169R mutant were less stable than WT PIM1 in cells by cycloheximide 
chase assay, whereas the E171A mutant was considerably more stable than 
WT PIM1. From the kinase assays, we know that both K169R and E171A 
mutants are still active, but the K67M mutant is not. If one considers that 
PIM1 kinase activity and stability are directly related, then K67M should be 
the least stable. However, the K169R mutant is also less stable than WT 
PIM1, which would suggest that the ability to phosphorylate other substrates 
might not contribute to PIM1 stability in cells. Instead, going back to 
autophosphorylation studies, the observation that both K67M and K169R 
cannot autophosphorylate, and are relatively unstable than both WT PIM1 
and E171A (both of which can autophosphorylate) would suggest that PIM1 
autophosphorylation regulates its stability in cells. This is consistent with 
previous studies suggesting that the protein phosphatase PP2A reduces 
PIM1 stability by dephosphorylation (Losman et al., 2003; Ma et al., 2007). 
This also indicates that the change in stability of K169R may not be related to 
SUMOylation at K169, but is due to mutation of an important catalytic site in 
PIM1 that impairs its autophosphorylation. Conversely, mutation of E171 
does not appear to affect its autophosphorylation and activity. So, the 
increase in stability of the E171A mutant would suggest that SUMOylation 
negatively affects PIM1 stability.  
In support of these observations, when SUMOylation was reduced in 
cells by siRNA knockdown of the SUMO E2 enzyme, UBC9, an increase in 
levels of endogenous PIM1 was observed. This is consistent with the idea 
that abolishing SUMOylation would increase PIM1 stability in cells. However, 
it cannot be ruled that these effects are indirect, as knocking down UBC9 
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would have widespread changes in the activity and levels of other 
SUMOylated proteins inside the cell. Ubiquitination assays were also 
performed to investigate any changes in the levels of ubiquitination of the 
PIM1 mutants compared to the WT. Interestingly, while the K67M and the 
K169R mutants could still be efficiently ubiquitinated, ubiquitination of the 
E171A mutant was markedly reduced. This suggests that decreased levels of 
ubiquitination of E171A might contribute, in part, to its enhanced stability 
observed previously in the cycloheximide chase assay. SUMOylation has 
been shown to promote ubiquitin-proteasome mediated of substrates by 
recruiting SUMO-targeted ubiquitin ligases such as RNF4 (Geoffroy and Hay, 
2009). Coexpression of polySUMOylated PIM1 with catalytically active 
RNF4, but not RNF4 mutants, led to proteasomal degradation of the 
SUMOylated pool of PIM1, demonstrating that SUMOylation can promote 
PIM1 ubiquitination via RNF4. Additionally, siRNA knockdown of RNF4 
caused an increase in levels of endogenous PIM1, further suggesting that 
RNF4 might act as an E3 ubiquitin ligase for SUMOylated PIM1 in cells.  
I also looked at the localisation of WT PIM1, the SUMO mutants and 
the kinase dead K67M mutants by ectopic expression or stable expression in 
cell lines. As previously reported, WT PIM1 localised to the nucleus and the 
cytoplasm in the cell lines used (Valdman et al., 2004; Brault et al., 2012). 
However, there was no change in the localisation of the K169R, the E171A 
and the K67M mutant, suggesting that localisation of PIM1 is independent of 
its activity, autophosphorylation status and SUMOylation. Unfortunately, I 
was not able to set up functional assays to study the effects of PIM1 
SUMOylation on cells due to time constraints and technical difficulties. 
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Overall the results presented in this chapter identify SUMO as a novel 
regulator of PIM1 kinase activity and stability in cells. Further opportunities 
and challenges in studying PIM1 SUMOylation are discussed in the next 
chapter. 
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5.1 Challenges in studying PIM1 SUMOylation 
In general, studying protein SUMOylation is challenging, as at a given 
point only a very small proportion of the protein is SUMOylated (Gill, 2004; 
Johnson, 2004). This is because SUMOylated proteins are rapidly 
deconjugated by SUMO proteases. Another possibility is that only a small 
population of a protein that is structurally or functionally different from the 
main pool is SUMO modified in a cell. In case of PIM1, the study was further 
complicated by the lack of antibodies that could immunoprecipitate 
endogenous PIM1, which itself is expressed at low levels. In chapter-3, I 
demonstrated that ectopically expressed 6Xhis-PIM1 could be modified by 
endogenous SUMO2 and ubiquitin. This approach can be extended to 
endogenous PIM1 by the introduction of a 6Xhis tag at the 5’ end of the 
endogenous PIM1 gene locus using CRISPR technology. This should also 
circumvent the need of a PIM1 specific antibody as a His-tag antibody could 
be used instead.  
Another challenge in studying protein SUMOylation is the identification 
of a physiological condition under which the endogenous protein is modified 
by SUMO. A good starting point would be to look at stress responses such 
as heat shock, oxidative stress and hypoxia since these induce global 
changes in protein SUMOylation (Saitoh and Hinchey, 2000; Nguyen et al., 
2006). Interestingly, both heat shock and hypoxia have been shown to 
stabilise PIM1 (Shay et al., 2005; Chen et al., 2009), therefore it would be 
interesting to test endogenous PIM1 SUMOylation under these conditions. A 
recent study showed that metabolic or energy stress can induce 
SUMOylation of LKB1 kinase, which is an upstream kinase of AMPK (Ritho 
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et al., 2015). In addition, SUMOylation of AKT was observed upon insulin 
treatment and heat shock (Li et al., 2013; de la Cruz-Herrera et al., 2014a). 
These examples suggest that SUMOylation of a kinase can occur 
independently of conditions that affect global SUMOylation, and in doing so 
form an integral part of the signalling cascade. However, no such 
mechanisms have been reported for PIM1 in the literature so far. In fact, 
PIM1 kinase activity was shown to remain largely unaffected even when the 
cells were treated with insulin, forskolin, PMA, sorbitol, H2O2 and UV 
radiation (Macdonald et al., 2006). It is currently unknown if cytokines and 
growth factors, that induce expression of PIM1 mRNA, also affect the activity 
of the pre-existing pool of PIM1 protein. If this is the case, then SUMOylation 
might be a mechanism that balances steady state levels of PIM1 in cells.  
One could also expect PIM1 SUMOylation to occur during activation of 
the JAK-STAT signalling, since the E3 SUMO ligases, PIAS1 and PIAS3, are 
also activated under these conditions. As mentioned previously, PIM1 can 
negatively regulate the JAK-STAT pathway by a feedback mechanism that 
involves phosphorylation and activation of SOCS1 and SOCS3 (Peltola et al., 
2004). Activated SOCS bind to and inhibit the transcriptional activity of 
STATs, in a manner that is similar to PIAS1 and PIAS3. So, PIM1 
SUMOylation by PIAS might be another feedback mechanism to control 
PIM1 levels or control the activity of the JAK-STAT pathway in cells, but this 
hypothesis warrants future investigation. Interestingly, both STAT1 and 
STAT3 have also been reported to undergo SUMOylation. Activation of 
STAT1 by IFNγ induces STAT1 SUMOylation at Lys703 by PIAS1, and has 
been suggested to negatively regulate STAT1 mediated target gene 
! 225!
activation (Ungureanu et al., 2003, 2005). More recently, STAT3 was shown 
to be SUMOylated at Lys451, which enhances its interaction with the nuclear 
phosphatase TC45 through a SIM present in TC45 (Zhou et al., 2016). Like 
STAT1, SUMOylation also negatively affects the transcriptional activity of 
STAT3. This would be consistent with the emerging concept of ‘group 
SUMOylation’ where multiple targets involved in the same biological process 
or pathway are SUMOylated simultaneously (Psakhye and Jentsch, 2012).  
 Other instances where proteins can be SUMOylated are during the 
specific stages of the cell cycle. For example, the kinase CDK6 is only 
modified by SUMO2 during the G1 phase and mitosis (Bellail et al., 2014), 
whereas Aurora B SUMOylation is only detected during mitosis (Fernández-
Miranda et al., 2010; Ban et al., 2011). Interestingly, PIM1 was one of the 
hundreds of proteins suggested to be modified by both SUMO and ubiquitin 
during mitosis in a protein microarray screen performed by Merbl and 
colleagues (Merbl et al., 2013). In this study, active mitotic cell extracts from 
HeLa S3 cells were incubated on a protein microarray spotted with >9000 
proteins (including PIM1). The resulting ubiquitin and ubiquitin-like 
modifications occurring on a target protein were then detected individually 
using ubiquitin or SUMO antibody. It should be noted that although the 
enzymes involved in ubiquitin or Ubl modification used in this screen were 
endogenous, the target proteins spotted on the microarray were not. In the 
present study, I did not investigate cell cycle specific changes in PIM1 activity 
and SUMOylation, which is something that can be followed up in the future.  
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5.2 Regulation of kinase activity by SUMO 
Based on the amino acid sequence of PIM1, I identified the presence 
of a consensus SUMO modification site in PIM1 (IK169DE171). Various studies 
have reported the crystal structure of PIM1 in complex with small molecule 
inhibitors. Using these structures, we can visualise the exact position and 
nature of the residues involved in the SUMOylation of PIM1, and at the same 
time predict the outcome of having the SUMO polypeptide conjugated at this 
position. As shown previously in figure 3.1, PIM1 displays the conserved bi-
lobe structure observed in most protein kinases. Here, the ATP-binding site 
is indicated by AMP-PNP (a non-hydrolysable analogue of ATP), while the 
substrate binding site is the indicated by the position of the consensus 
peptide substrate or PIMitide (KRRRHPS*, where * is the phosphorylated 
residue). The residues required for SUMOylation (IKDE) can be mapped 
directly to the substrate binding pocket, which raises two possibilities with 
regards to how SUMO can affect the activity of PIM1. First, the presence of 
SUMO at this position might block access to the substrate, and hence inhibit 
the activity of the kinase. Second, SUMO might act as a tether to bring the 
substrates close to PIM1 promoting protein-protein interaction, and hence 
enhance PIM1 kinase activity. The results presented in this thesis support 
the second hypothesis that PIM1 SUMOylation enhances its activity, and are 
consistent with the published literature on SUMOylation of other kinases.  
SUMOylation of other kinases such as pancreatic Glucokinase 
(Aukrust et al., 2013), AKT (Li et al., 2013; de la Cruz-Herrera et al., 2014a; 
Lin, Liu and Lee, 2016), AMPKβ2 (Rubio, Vernia and Sanz, 2013) and 
Protein kinase R (de la Cruz-Herrera et al., 2014b) has been shown to 
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increase their kinase activity. There are also studies where SUMOylation has 
been shown to inhibit the kinase activity, such as in the case of MEK (Kubota 
et al., 2011) and AMPKα1 (Yan et al., 2015). Of note, most of these kinases 
are SUMOylated at a non-consensus site or outside the kinase domain, with 
the exception of AKT and Aurora B, which are SUMOylated at a conserved 
lysine similar to PIM1 in the kinase domain. Strikingly, K147 in CDK6 (which 
is equivalent to K169 in PIM1) is not a part of a consensus SUMO motif, and 
is ubiquitinated instead (Bellail et al., 2014). More importantly, mutation of 
K147 also abolished CDK6 kinase activity. Unfortunately, a unifying 
mechanism to explain changes in the kinase activity by SUMOylation has not 
be identified so far, and every kinase appears to be affected by SUMO in a 
different way.  
Studying the effect of SUMOylation on a kinase is particularly 
challenging when the modified lysine is present in the kinase domain. In this 
scenario, it becomes difficult to distinguish between the functions of the 
lysine residue associated with the intrinsic activity of the kinase and 
SUMOylation of the substrate.  For example, the human Aurora B SUMO 
mutant, K202R, was found to be kinase dead in a study by Ban and 
colleagues. However, the authors did not observe any change in the kinase 
activity when WT Aurora B was coexpressed with SUMO2 and PIAS3 in the 
presence and absence of SENP2. Therefore, it was suggested that the 
K202R mutant was not appropriate to study effects of SUMOylation on 
Aurora B activity. Unfortunately, the authors did not test the activity of the 
E204A mutant in this study. Furthermore, the AKT SUMOylation mutant 
K276R was also found to be kinase dead, but still capable of 
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autophosphorylation (Li et al., 2013). Similar effects were observed when the 
E278A mutant of AKT was used, which led the authors to conclude that the 
decrease in kinase activity was a SUMO-specific effect. 
 Although the K169R and the E171A SUMO mutant of PIM1 are 
identical in terms of their kinase activity, their ability to undergo SUMOylation 
status is different. To the best of my knowledge, this has not been reported in 
the literature so far. A major difference between the K169R and the E171A 
mutants was in their ability to autophosphorylate. As mentioned before, K169 
is a conserved residue involved in catalysis; therefore the impaired 
autophosphorylation might reflect a change in the intrinsic activity of the 
kinase. On the other hand, the E171A mutant is only semi-conserved in 
protein kinases. It not only retained its ability to autophosphorylate but also 
abolished PIM1 SUMOylation at both sites, which makes its a better mutant 
to study the effect of SUMOylation on PIM1, in my opinion. A sequence 
alignment of this region in other kinases has been shown in figure 5.1.  
One approach used in the literature to overcome the confounding 
effects observed with the Lys to Arg substitution is to fuse the substrate with 
WT UBC9, to mimic a constitutively SUMOylated protein (Jakobs et al., 
2007). The method has been used successfully to study effects of 
SUMOylation on MEK and TBK1 kinases (Kubota et al., 2011; Saul et al., 
2015). Another method of mimicking a SUMOylation defective protein would 
be to fuse the substrate with the catalytic domain of SENP1. However, both 
approaches have limited potential since it involves creation of an artificial 
chimeric protein. Therefore, no single approach can be considered as 
optimal to study effects of SUMOylation on the target protein. 
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AKT         HEKNVVYRDLKLENLMLDKDGHIKIT-DFGLC 
PKA         HSLDLIHRDLKPENLLIDQQGYLQVT-DFGFA 
PLK1        HRNRVIHRDLKLGNLFNEDLEVKIG--DFGLA 
ERK2    HSANVLHRDLKPSNSSLNTTCDLKIC-DFGLA 
PIM1        HNCGVLHRDIKDENILIDLNRGELKLIDFGSG 
PIM2        HSRGVVHRDIKDENILIDLRRGCAKLIDFGSG 
PIM3        HSCGVVHRDIKDENLLVDLRSGELKLIDFGSA 
GSK3        HSFGICHRDIKPQNLLLDPDTAVLKLCDFGSA 
Aurora-B    HGKKVIHRDIKPENLLLGLKGELKIA-DFGWS 
CDK2        HSHRVLHRDLKPQNLLINTEGAIKLA-DFGLA 
p38MAPK     HSAGIIHRDLKPSNVAVNEDCELRIL-DFGLA 
 
c-ABL       EKKNFIHRDLAARNCLVGENHLVKVA-DFGLS  
EGFR        EDRRLVHRDLAARNVLVKTPQHVKIT-DFGLA 
SRC         ERMNYVHRDLRAANILVGENLVCKVA-DFGLA 
 
Figure 5.1 Sequence alignment of the catalytic loop of protein kinases 
Protein sequence alignment showing the conserved residues (red) in the catalytic loop of 
some protein kinases. Note that the lysine residue present within the consensus SUMO motif 
is also conserved in other serine/threonine kinases. Kinases reported to be SUMOylated at 
the conserved lysine are shown in bold. The glutamic acid of PIM1 E171 (green) is also 
aligned with the equivalent residues in other kinases, which shows that E at this position is 
not strictly conserved (Adapted from Hanks and Hunter, 1995).  
 
 
 
 
 
 
 
 
 
Tyr 
kinases 
Ser/Thr 
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5.3 Regulation of kinase stability by SUMO and ubiquitin 
Many activated protein kinases can be degraded by the ubiquitin 
proteasome system (UPS) or through the lysosomal pathway in cells. Many 
factors affect the protein stability of a kinase, but a study performed with 
Protein kinase C suggests that the active conformation of a kinase is 
necessary to elicit its degradation (Lu et al., 1998; Kang et al., 2000). In other 
words, prolonged activation of a kinase can automatically trigger its 
degradation. In another study activation of the receptor tyrosine kinase, 
EGFR, by EGF was shown to not only activate it kinase activity, but also 
trigger its degradation (Galcheva-Gargova et al., 1995; Huang et al., 2006).  
Although PIM1 is constitutively active, the idea that SUMOylation can 
further enhance its activity, and also result in its degradation is analogous to 
the above-mentioned examples. SUMOylation of AKT was also shown to 
increase its kinase activity in three separate studies (Li et al., 2013; de la 
Cruz-Herrera et al., 2014a; Lin, Liu and Lee, 2016). However, there are 
conflicting reports on its stability. Li and colleagues showed that 
SUMOylation does not affect its ubiquitination, whereas Lin and colleagues 
suggest that SUMOylation might stabilise AKT. The discrepancy is due to the 
different experimental techniques used in these studies. Li and colleagues 
used the K276R mutant in their ubiquitination assays with a reported E3 
ligase for AKT called TRAF6. In contrast, Lin and colleagues used 
overexpression of SUMO2, UBC9 and PIAS1 in their cycloheximide assays. 
In the present study, both ubiquitination assay and CHX chase assays were 
performed with the E171A mutant, both of which support our hypothesis that 
SUMOylation destabilises PIM1 by the UPS.  
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Results presented in chapter-3 suggested that both PIAS1 and PIAS3 
might catalyse formation of polySUMO chains on PIM1. Polymeric SUMO 
chains on PIM1 were observed upon proteasome treatment, even in the 
absence of an E3 ligase, suggesting that the UPS also degrades 
SUMOylated PIM1. The addition of an E3 ligase further enhanced this effect, 
notably PIAS1 mediated polySUMOylation was more clear when the cells 
were treated with MG132. It was also observed that PIAS3 was a more 
potent E3 SUMO ligase for PIM1 than PIAS1. Intriguingly, PIAS3 mediated 
SUMOylation seemed to increase the levels of total PIM1 (input). This raised 
the possibility that PIAS3 might stabilise PIM1, whereas PIAS1 might 
destabilise PIM1. However, this could be an artefact of overexpression as 
PIAS3 probably oversaturates the cells with polySUMO chains, leading to 
accumulation of SUMOylated PIM1 that can no longer be degraded, as the 
availability of either the proteasome or the ubiquitin ligases becomes limiting. 
This is also consistent with other studies showing that although PIAS1 
promotes ubiquitination of PML, its expression alone does not lead to 
degradation (Rabellino et al., 2012). A good experiment to do would be to 
measure PIM1 ubiquitination in the absence and presence of PIAS1 or 
PIAS3. Another approach would be to look at PIM1 protein levels following 
knockdown of all PIAS family members simultaneously, as knockdown of 
individual PIAS family members is not effective, most likely due to 
overlapping substrate specificity (Seifert et al., 2015). 
 The SUMO targeted ubiquitin ligase RNF4 plays an important role in 
UPS mediated degradation of SUMOylated proteins. Knockdown of RNF4 
increased endogenous protein levels of PIM1 suggesting that RNF4 can act 
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as an E3 ubiquitin ligase for PIM1. As mentioned before, RNF4 has also 
been shown to control the stability of PML in response to arsenic trioxide 
(Tatham et al., 2008), HIF2α during hypoxia (van Hagen et al., 2009) and 
TRIM28 during DNA damage (Kuo et al., 2014) suggesting that RNF4 has 
specialised functions under stress conditions. However, I was able to 
observe increase in PIM1 protein under unstressed conditions, which raise 
two questions. Is SUMO mediated degradation of PIM1 by RNF4 a general 
housekeeping mechanism to regulate PIM1 levels? Or does RNF4 also 
regulate PIM1 stability upon stress conditions? Finding the answer to these 
questions could also inform us about the physiological relevance of PIM1 
SUMOylation in cells. 
 
5.4 Function of PIM1 SUMOylation  
PIM1 is a weak oncogene, and as such overexpression of PIM1 alone 
is not sufficient to induce cellular transformation or promote proliferation of 
cells (Shirogane et al., 1999; Kim, Roh and Abdulkadir, 2010). Only about 5-
10% of mice overexpressing PIM1 develop lymphomas following a long 
period of latency (7-9 months) (van Lohuizen et al., 1989). It has also been 
suggested that in vivo models are better suited to study the oncogenic 
activity of PIM1, as the same cells used for xenograft experiments show no 
obvious changes in proliferation or survival when grown in plastic dishes 
(Kim et al., 2010). It is also possible that PIM1 overexpression is superfluous 
in most cancer cells as they already express all three PIM kinases, in 
addition to AKT. Therefore, a CRISPR knockout of PIM1 alone might not be 
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sufficient, and would require knocking out PIM2, PIM3 and all the AKT 
isoforms simultaneously. 
 Based on the literature, mouse embryonic fibroblasts (MEF) from PIM 
triple knockout mice (PIM TKO) are probably the best system available to 
study the function of WT PIM1 and mutants. However, the only laboratory 
that still uses these MEF for their own studies was not willing to share them 
with us. Therefore, I created cell lines in HeLa and U2OS expressing PIM1 in 
a tetracycline-inducible manner, to study the effect of WT PIM1 and SUMO 
mutants on the phosphorylation of endogenous PIM1 substrates. The results 
from these cell lines have been discussed in the previous chapter. Although I 
was able to show phosphorylation of known PIM1 targets proteins under 
basal conditions, I was not able to follow up on functional assays due to time 
constraints. Nevertheless, it was surprising to find that the K169R and E171A 
mutants displayed substrate specificity in vitro and in cells, especially in their 
ability to decrease autophosphorylation of AKT at Ser473 similar to WT 
PIM1. This suggests the existence of a possible feedback mechanism 
between PIM and AKT kinases. It is likely that PIM1 indirectly activates a 
negative regulator of AKT, such as Protein kinase C (PKC) or PP2A, which 
decreases phosphorylation at Ser473 (Li et al., 2006). 
Intriguingly, expression of WT PIM1 but not the SUMO mutants 
enhanced phosphorylation of ERK1/2. However, it is unlikely that ERK1/2 is 
a direct target of PIM1, as the phosphorylated residues do not conform to 
PIM1 consensus phosphorylation motif. On that subject, it is worth 
mentioning that a recent study suggested that PIM1 might phosphorylate the 
upstream ERK kinase, MEK1/2 at Ser217/221, to support cell survival 
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(Blanco et al., 2015). There is also evidence in CLL suggesting that PIM1 
indirectly induces the MAPK pathway by phosphorylating the receptor 
tyrosine kinase CXCR4 at Ser339 (Decker et al., 2014). It would be 
interesting to follow up on this aspect, as this would suggest that 
SUMOylation of PIM1 might specifically support activation of the ERK 
pathway. Additional experiments to study phosphorylation of PIM1 substrates 
in the absence and presence of enzymes involved in SUMO modification of 
PIM1 should also be performed. Furthermore, since phospho-BAD was 
increased in the presence of WT PIM, but not the mutants, it might be useful 
to perform apoptosis assays in these cell lines under different stress 
conditions or drug treatments.  
 
5.5 Clinical relevance 
The clinical implications of PIM1 SUMOylation may not be 
immediately apparent at the moment, but it is exciting to think of a drug that 
can induce SUMOylation of PIM1, causing its degradation. Drugs that rely on 
inducing SUMOylation of target proteins are already being used in the clinic.  
For example, Arsenic trioxide, used for the treatment of acute promyelocytic 
leukemia (APL), induces rapid SUMOylation and degradation of the 
oncogenic PML-RARα fusion protein by RNF4 (Lallemand-Breitenbach et al., 
2008). Another example is the anti-diabetic drug Rosiglitazone, which exerts 
its anti-inflammatory effects by inducing SUMOylation of PPARγ (Pascual et 
al., 2005; Lu et al., 2013). 
PIM kinases have been described as one of the potent suppressors of 
MYC-induced apoptosis. The strong synergism between PIM and MYC is 
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evident from PIM1/MYC transgenic mice where 100% mice develop tumours 
in utero (Verbeek et al., 1991). However, MYC has remained a difficult drug 
target, and therefore other approaches to indirectly target MYC activity have 
been proposed, such as inhibition of PIM kinases (Kirschner et al., 2015). 
Interestingly, the SUMO pathway sustains the MYC transcriptional program, 
and inhibition of SAE1/2 was found to be synthetic lethal in breast cancer 
cells exhibiting high MYC activity (Kessler et al., 2012). This is also true in 
case of B-cell lymphomas, where MYC induces a hyper SUMOylation state 
by upregulating gene expression of the components of the SUMO machinery 
(Hoellein et al., 2014). Inhibition of the SUMO pathway resulted in a G2/M 
arrest and subsequent apoptosis of B-cell lymphomas. Knockdown of UBC9 
in the present study caused an increase in PIM1 levels, which would suggest 
that PIM kinase inhibitors might be more effective following inhibition of 
SUMOylation. This hypothesis can be tested easily by treating cells with or 
without UBC9, and measuring their survival following PIM kinase inhibitor 
treatment.  
A recent study identified 1 as a PIM1 target protein. PIM1 mediated 
phosphorylation of NOTCH1 enhances its activity, and the interaction itself 
was suggested to stabilise PIM1 (Santio et al., 2016). NOTCH1 activation in 
breast cancer cells seems to reduce the levels of unconjugated SUMO by an 
undefined mechanism, which makes them highly sensitive to the inhibition of 
UBC9. However, like c-MYC, it is currently not possible to target NOTCH1, 
hence it might be interesting to test PIM inhibitors in NOTCH1 activated cells. 
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5.5 Proposed model 
In brief, the data presented in this thesis identify a novel mechanism of 
regulation of PIM1 kinase activity, and protein levels by SUMO modification. 
There are at least two sites of modification in PIM1, but due to technical 
issues it was not possible to determine the site-specific effects of 
SUMOylation on PIM1. Overall, the results obtained suggest that 
SUMOylation of PIM1 can enhance its kinase activity in vitro, and also 
promote its degradation by the ubiquitin proteasome system. Although the 
exact sequence of events remains unclear, it is tempting to speculate a 
sequential modification model for PIM1 SUMOylation (Figure 5.2). In this 
model, stimuli such as growth factor or cellular stress induce PIM1 
SUMOylation, and enhance its oncogenic potential as a kinase. Once 
phosphorylation of the substrate is achieved, PIM1 can be polySUMOylated 
and targeted for degradation by the E3 ubiquitin ligase RNF4. The 
deregulation of the SUMO pathway in cancers might contribute to the 
increased activity and/or stability of PIM1 observed in cancers. In this sense, 
further analysis of the PIM-SUMO interaction may provide avenues for 
rational co-targeting, which can be exploited therapeutically to improve the 
efficacy of either a SUMO or a PIM kinase inhibitor. 
 
 
 
!
!
!
! 237!
!
Figure 5.2 Model for regulation of PIM1 by SUMOylation 
The bi-lobed structure of PIM1 kinase is shown in blue. The consensus SUMOylated lysine 
residue is located in the substrate binding pocket (K169 in red). For representation sake, the 
non-consensus lysine is shown in blue in the N-terminal domain. Stimulus such as growth 
factors or stress might induce SUMOylation of PIM1 under endogenous conditions. 
SUMOylated PIM1 can bind and phosphorylate substrates. Once this is achieved, a SUMO 
targeted ubiquitin ligase is recruited to polySUMOylated PIM1 leading to attachment of 
polyubiquitin chains on PIM1. The SUMOylated and ubiquitinated PIM1 is then targeted for 
degradation by the proteasome.  
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A1. CXR1002 
CXR1002, an ammonium salt of perfluorooctanoic acid, was identified 
by CXR Biosciences as a potential anti-cancer agent, and tested in Phase I 
clinical trials. It is cytotoxic to cancer cells in culture and in xenograft models. 
Various mechanisms of action of this drug have been proposed. It primarily 
acts as a lipid mimetic, and causes endoplasmic reticulum (ER) stress in 
cells. Additionally, it was also shown to inhibit PIM kinases in a panel of 50 
kinases tested in vitro. The drug is unique in that it is not metabolised at all in 
the human body and gets accumulated to a certain level, following which it is 
excreted intact. Hence, inter-patient variability observed with other drugs, 
due to differences in their ability to metabolise the drug, is thought not to be a 
problem with CXR1002, which makes it an attractive drug.  
The data presented here were performed as a part of validation of 
CXR1002 as a bonafide PIM kinase inhibitor. The main goal of the project 
was to perform a synthetic lethal screen with PIM kinase inhibitors, including 
CXR1002. But soon after the start of this project, a study was published 
identifying PIM1 and PLK1 (Polo-like kinase 1) as synthetic lethal targets in 
prostate cancer (Van Der Meer et al., 2014, advance online publication Jan 
2013). Since various studies in the literature had already tested AKT and 
mTOR inhibitors in combination with PIM1 inhibitors (Blanco-Aparicio and 
Carnero, 2013), we decided to take an alternative approach and focus on 
studying regulation of PIM1. In doing so, I identified SUMOylation as a novel 
mechanism affecting PIM1 function, which could impact PIM kinase inhibitors 
in the future.  
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A2. Experimental methods 
Methods not described previously in Chapter-2 have been included here. 
 
a) Cell lines 
PC3, LNCaP and K562 cells were grown in RPMI1640 media supplemented 
with 10% FBS and 2 mM L-glutamine, in a 37 0C humidified CO2 incubator. 
 
b) Cell viability assay 
Cell viability or cytotoxicity was measured using CellTiter 96 Aqueous One 
Solution Proliferation assay (MTS) kit from Promega. 100 µl of PC3 and 
LNCaP cells were seeded at a density of 10,000 cells per well, and 50 µl of 
K562 at 5000 cells per well in a 96-well plate in triplicate for 24 hours. The 
following day, the media on PC3 and LNCaP was replaced with 100 µl fresh 
media containing 0.1% DMSO as control, or the desired concentrations of 
either SGI-1776 or CXR1002. In the case of K562, 50 µl of fresh media 
containing 2X of final desired drug concentration was added directly to the 
wells, for a final volume of 100 µl and 1X drug concentration. 20 µl of MTS 
reagent was added to the cells after 24 or 72 hours of drug treatment, and 
cell viability was measured by reading absorbance at 490 nm. 
 
c) Kinase assays by western blotting 
PIM1 kinase assays were carried out using purified recombinant GST-PIM1 
with histone H3.3 (NEB, UK) as substrate. Reactions were carried out in a 
total volume of 20 µl containing 50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.2 
mM ATP, 0.5 µg substrate and approximately 0.2 µg PIM1 kinase. 
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Appropriate negative control reactions without any substrate or kinase were 
also set up simultaneously. Reactions were incubated in a 30 0C water bath 
for 30 min, and terminated by addition of 2X SDS sample buffer (with DTT). 
The reactions were boiled for 5 min followed by either coomassie staining of 
the gel or SDS-PAGE and western blotting using a phospho-specific antibody 
against Ser10 of Histone H3.3. 
 
d) Kinase assays using ADP-Glo kinase luminescent assay (Promega) 
Non-radioactive in vitro kinase assays were carried out in 25 µl reaction 
volume containing 200 ng GST-PIM1, 500 ng Histone H3.3 (substrate), 100 
µM ATP (supplied in the Kinase Glo kit), 10 mM MgCl2, 50 mM Tris pH 7.5 
and 100 µM DTT, with or without desired drug concentration in a 96 well 
white-bottom plate. The plate was incubated at 30 0C for 30 min, followed by 
addition of 25 µl ADP-Glo reagent and further incubated for 40 min at RT. 
Next, 50 µl of Kinase detection reagent was added to each well, and 
incubated for 1 hour at RT, following which luminescence was measured 
using Promega GloMax luminometer.  
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A3. Effect of SGI-1776 and CXR1002 on cell viability 
Since PIM kinases are overexpressed in prostate cancer and 
haematological malignancies, I chose two prostate cancer cell lines (PC3 
and LNCaP) and one CML line (K562) to test the efficacy of CXR1002. I also 
used a commercially available inhibitor of SGI-1776 as a control, and for 
comparison with CXR1002. MTS assays were carried out to measure cell 
viability after 24 and 72 hours of drug treatment. The cells were treated with 
increasing doses of either SGI-1776 or CXR1002 to determine half maximal 
inhibitory concentration (IC50). As shown in figure 1 and 2, both SGI-1776 
and CXR1002 decreased cell viability in a dose dependent manner in all 
three cell lines tested at 24 and 72 hours. However, SGI-1776 was clearly 
more potent than CXR-1002, which was used at high micromolar 
concentrations in this assay to observe an effect. The average IC50 values 
for SGI-1776 and CXR1002 in these cell lines was around 7 µM and 350 µM 
respectively.  
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Figure 1 Cell viability following SGI-1776 treatment 
LNCaP, PC3 and K562 cells were plated in 96 well plates for 24 hours prior to addition of the 
indicated drug concentrations for 24 or 72 hours. Cell viability was measured using MTS 
assay kit from Promega as per manufacturer’s instructions. The optical density, which is 
directly proportional to cell viability, was measured at 490 nm and plotted on a graph. 
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Figure 2 Cell viability following CXR1002 treatment 
LNCaP, PC3 and K562 cells were plated in 96 well plates for 24 hours prior to addition of the 
indicated drug concentrations for 24 or 72 hours. Cell viability was measured using MTS 
assay kit from Promega as per manufacturer’s instructions. The optical density, which is 
directly proportional to cell viability, was measured at 490 nm and plotted on a graph. 
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A3. Inhibition of PIM1 kinase in vitro 
As a proof of concept, in vitro kinase assays were performed to test 
direct inhibition of PIM1 by CXR1002 and SGI-1776. Kinase assays were 
carried out using recombinant Histone H3.3 as a substrate, and 
phosphorylation of H3.3 at Ser10 was used as a read-out for PIM1 kinase 
activity by western blotting. Negative control reactions containing no kinase 
or no substrate, and appropriate DMSO controls were also set up. Based on 
the killing curves, I chose two arbitrary concentrations of SGI-1776 and 
CXR1002 in the assay. As shown in figure 3A, Histone H3.3 phosphorylation 
was observed only in the presence of WT PIM1, and not in its absence. SGI-
1776, a known ATP-competitive inhibitor of PIM1, decreased phosphorylation 
of Histone H3.3 at both 10 µM and 20 µM final concentration. 
Phosphorylation was decreased at 320 µM CXR1002, but completely 
abolished at 700 µM.  
Since the assay worked as expected, I adapted it into a more 
quantitative 96-well plate based assay, and measured PIM1 activity in 
response to increasing drug concentrations in vitro. For this I used the ADP-
Glo kinase assay (Promega), which is explained in figure 4. The procedure 
has been described in section A2 experimental methods, and the results are 
shown in figure 3B (SGI-1776) and 3C (CXR-1002). The concentration of 
SGI-1776 used in this assay was in the range of 0.625 µM to 5 µM, and that 
of CXR1002 was in the range of 1.36 µM to 350 µM. Both drugs showed a 
dose dependent decrease in kinase assays. Again, SGI-1776 was 
significantly more potent than CXR1002.  
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Since the ADP-Glo kinase assay is designed to test small molecular 
inhibitors, I wanted to test if CXR1002 affected the components of this assay. 
To do this, different ratios of ATP and ADP (supplied in the kit) were 
incubated with or without 350 µM CXR1002, and the assay was performed 
as described. The results shown in figure 5 indicate that CXR1002 does not 
significantly affect the assay, and therefore the results obtained in figure 3C 
were a true representation of the inhibition of PIM1 by CXR1002.  
The results presented here indicate that while CXR1002 can indeed 
inhibit activity of PIM1 in vitro, the use of such high concentrations of 
CXR1002 even in in vitro assays would suggest that it not a very specific 
inhibitor of PIM kinases. Also, the mode of inhibition may be different to that 
of SGI-1776 (ATP competitive).  
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Figure 3 Inhibition of PIM1 kinase activity  
(A) In vitro kinase assays were carried out using Histone H3.3 as substrate and GST-PIM1, 
in the absence or presence of SGI-1776 and CXR1002. After completion the reactions were 
resolved by SDS-PAGE and western blotting was performed using phospho Ser10 Histone 
H3 antibody as a read out for PIM kinase activity. (B) ADP-Glo kinase assay was performed 
to measure inhibition of PIM1 kinase activity in response to increasing concentrations of 
SGI-1776 or (C) CXR1002. 
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Figure 4 Principle of ADP-Glo kinase assay (Adapted from ADP-Glo kinase assay 
manual, Promega) 
Kinase assays are set up in 96-well white-bottom plates using ATP supplied with the kit. 
After the kinase reaction has occurred, the ADP-Glo reagent is added to terminate the 
reaction, and to deplete the remaining ATP. In the second step, the Kinase detection reagent 
is added to convert the ADP to ATP, and allow the newly synthesises ATP to be measured 
using a luciferase/luciferin reaction. The light generated (in the form of luminescence) 
correlates to the amount to ADP generated in the kinase reaction, which is indicative of 
kinase activity. 
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Figure 5 CXR1002 does not affect the components of the ADP-Glo kinase assay 
ATP and ADP were combined in the indicated ratios at 1, 10 and 100 µM concentrations, 
with or without CXR1002. ADP-Glo kinase assay was performed as per manufacturer’s 
instructions, and luminescence was measured using a luminometer. 
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